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Abstract 
Tuberculosis (TB) disease results in approximately 2 million deaths annually and is the 
leading cause of death due to a single infectious agent. Previous studies have indicated that 
host genetics play an important role in the development of TB. This together with pathogen 
and environmental factors intensifies the complexity of this disease.  
The Major Histocompatibility Complex (MHC) and Leukocyte Receptor Complex (LRC) 
comprise several genes which are known to be important modulators of the host immune 
response. The human leukocyte antigen (HLA) class-I genes of the MHC are involved in the 
presentation of pathogenic antigens on the surfaces of infected cells, while the killer cell 
immunoglobulin-like receptors (KIRs) of the LRC are involved in the recognition of self and 
non-self cells. Natural Killer (NK) cells through their KIRs are thus able to kill non-self cells 
through recognition of the class-I molecules expressed. Additionally, HLAs and KIRs are 
extremely polymorphic and differ markedly across populations of different ethnicities. 
Here we studied these genes and their polymorphisms in the South African Coloured (SAC) 
population to determine their involvement in susceptibility to TB, susceptibility to disease 
caused by specific Mycobacterium tuberculosis subtypes, and understanding their ancestral 
contribution to the SAC with regards to the development of TB. 
We showed that the KIR3DS1 gene and KIR genotypes with five or more activating KIRs, 
and the presence of 3DS1, protected against the development of active TB in the SAC 
population. Several HLA class-I alleles were identified as susceptibility factors for TB 
disease. With regards to genes of the MHC and LRC, several loci were found to alter 
susceptibility to TB in the SAC population, including MDC1, BTNL2, HLA-DOA, HLA-DOB, 
C6orf10, TAP2, LILRA5, NCR1, NLRP7 and the intergenic regions between HLA-C/WASF5P 
and LAIR1/TTYH1. 
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We showed that the Beijing strain occurred more frequently in individuals with multiple 
disease episodes, with the HLA-B27 allele lowering the odds of having an additional episode. 
Associations were identified for specific HLA types and disease caused by the Beijing, Latin 
America-Mediterranean (LAM), Low-Copy Clade (LCC), and Quebec strains. HLA types 
were associated with disease caused by strains from the Euro-American or East Asian 
lineages, and the frequencies of these alleles in their sympatric human populations identified 
potential co-evolutionary events between host and pathogen. 
Finally, we showed that the SAC population is the most diverse SA population with regards 
to HLA alleles and KIR genotypes, as would be expected given the admixture of the SAC. 
Based on the HLA allele class-I profiles across SA populations, we noted that the Ag85B-
ESAT-6, Ag85B-TB10.4 and Mtb72f vaccines currently undergoing clinical trials would 
have low efficacy across most SA populations. We showed that the MHC and LRC regions in 
SAC healthy controls are predominantly of European ancestry, and that SAC TB cases are 
more closely related to Khoisan and black SA population groups. 
Our work highlights the importance of investigating both host and pathogen genetics when 
studying TB disease development and that understanding the genetic ancestral contributions 
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Opsomming 
Tuberkulose (TB) is jaarliks verantwoordelik vir ongeveer 2 miljoen sterftes en is die 
hoofoorsaak van dood as gevolg van „n aansteeklike siekte. Vorige navorsingstudies het 
aangedui dat die genetiese samestelling van die gasheer „n beduidende rol speel in die 
ontwikkeling van TB.  Die kompleksiteit van hierdie siekte word vererger deur die 
betrokkenheid van die gasheer genoom sowel as bakteriële en omgewings faktore.  
Die Major Histocompatibility Complex (MHC) en Leukocyte Receptor Complex (LRC) 
bestaan uit verskeie gene wat die gasheer immuunrespons verstel. Die human leukocyte 
antigen (HLA) klas I gene van die MHC is betrokke by die aanbieding van patogeniese 
antigene op die oppervlak van geïnfekteerde selle, terwyl die killer cell immunoglobulin-like 
receptors (KIRs), geleë in die LRC, betrokke is by die herkenning van eie en vreemde selle.  
NK selle, deur middel van hul KIRs, kan dus vreemde selle uitwis aangesien hulle die 
uitgedrukte klas I molekules kan herken. Beide HLA en KIRs is hoogs polimorfies en verskil 
beduidend tussen etniese groepe. 
In hierdie studie is die bogenoemde gene en hul polimorfismes in die Suid Afrikaanse 
Kleurling bevolking (SAC) ondersoek om vas te stel tot watter mate dit genetiese vatbaarheid 
vir TB, asook vatbaarheid vir TB wat deur spesifieke Mycobacterium tuberculosis subtipes 
veroorsaak word, beïnvloed. Daar is ook gepoog om te verstaan hoe die voorouerlike bydrae 
van hierdie gene die SAC met betrekking tot TB vatbaarheid affekteer. 
Die resultate van die studie het aangedui dat die KIR3DS1 geen en KIR genotipes met vyf of 
meer aktiewe KIRs en die teenwoordigheid van 3DS1, die SAC bevolking beskerm teen die 
ontwikkeling van aktiewe TB. Verskeie HLA klas I allele is geïdentifiseer as 
vatbaarheidsfaktore vir TB. Talle lokusse van die MHC en LRC gene is ook as 
vatbaarheidsfaktore vir TB in die SAC bevolking geïdentifiseer, insluitende MDC1, BTNL2, 
Stellenbosch University  http://scholar.sun.ac.za
HLA-DOA, HLA-DOB, C6orf10, TAP2, LILRA5, NCR1, NLRP7 en die intergeniese areas 
tussen HLA-C/WASF5P en LAIR1/TTYH1. 
Die studie het aangedui dat die Beijing stam meer voorkom in individue wat verskeie kere 
TB gehad het en dat die HLA-B27 alleel die kanse om „n verdere episode te hê, verlaag het.  
Assosiasies is geïdentifiseer tussen spesifieke HLA tipes en siekte veroorsaak deur die 
Beijing, LAM, LCC, en Quebec TB stamme. HLA tipes was geassosieer met siekte 
veroorsaak deur TB stamme van Euro-Amerikaanse en Oos-Asiëse afkoms. Die frekwensies 
van hierdie allele, in hul ooreenstemmende mensbevolkings, dui op „n potensïele ko-
evolusionêre gebeurtenis tussen die gasheer en patogeen. 
Die studie het ook vasgestel dat die SAC populasie die mees diverse SA bevolking is met 
betrekking tot die HLA allele en KIR genotipes, soos verwag sou word gegewe die gemengde 
genetiese herkoms van die SAC. Gebaseer op die HLA allele klas I profiel van verskillende 
SA bevolkings merk ons op dat die Ag85B-ESAT-6, Ag85B-TB10.4 en Mtb72f vaksiene, 
wat huidiglik kliniese toetsing ondergaan, nie so effektief in die meeste SA bevolkings sal 
wees nie.  Die studie het ook bewys dat die MHC en LRC streke in gesonde SAC kontroles, 
grootliks afkomstig was van „n Europese nalatenskap en dat die SAC TB gevalle meer 
verwant is aan die Khoisan en swart SA bevolkings. 
Hierdie studie beklemtoon die noodsaaklikheid om beide gasheer en patogeen genetika te 
bestudeer wanneer die ontwikkeling van TB ondersoek word en dat die verstaan van die 
genetiese voorouerlike bydrae van die SAC bevolking kan bydra tot die identifisering van 
ware en nuwe TB-veroorsakende variante. 
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1.1 Brief History 
 
Tuberculosis (TB) has been a scourge on human health for most of our history with evidence 
of this disease being found in skeletons from the Iron Age (400-230 BC) [1] and exhumed 
Andean [2–4] and Egyptian mummies [5–7]. Throughout the centuries TB has been known 
by numerous names, including phthisis/consumption by the Greeks [8–10]. Hippocrates 
(Book I, Of the Epidemics) described TB as predominantly affecting individuals between the 
ages of 18 and 35 with high mortality for those who contracted the disease [9,11]. During the 
Middle Ages, the disease was known as scrofula, and European monarchs and their subjects 
foolishly believed that the “royal touch” was able to cure all those afflicted with the disease 





centuries also gave rise to the biggest TB epidemic, with the disease famously known as the 
“Great White Plague” which lasted over 200 years [12]. During this time death from the 
disease was considered inevitable, and TB was the leading cause of death in 1650, and 
accounted for more than 30% of all deaths in Europe during the early 1800‟s. It was only in 
1839 that the term Tuberculosis was first devised by Johann Lukas Schönlein to describe 
diseases that were caused by tubercles, based on the theories postulated by Gaspard Laurent 
Bayle. 
One of the earliest descriptions of TB disease was by the Greek physician Clarissimus Galen 
(131 – 201 AD) who described the disease phthisis as an ulceration of the lungs, chest or 
throat which included symptoms of coughing, fever and wasting away of the body; and was 




 centuries, when most of the 
Western World experienced the great TB epidemic that the first significant medical advances 
in understanding the aetiology of the disease were made [12]. Franciscus Sylvius de la Böe, 
in his Opera Medica of 1679, was the first to describe that the tubercles usually seen in 
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consumptive patients as a characteristic of the disease and the formation of ulcers and cavities 
from the lesions of tubercles in progressed forms of the disease; supported by the findings of 
Richard Morton. With regards to disease transmission, both de la Böe and Morton believed it 
to be hereditary; with Morton also considering transmission by intimate contact as a 
possibility. However, it was the work of Gaspard Laurent Bayle which showed that the 
tubercles were the cause, and not a product, of the disease. Thus, the earliest mention of the 
infectious nature of TB disease was published in 1699, in a decree by the Republic of Lucca, 
Italy [14]. 
In 1720, an English physician by the name of Benjamin Marten published “A New Theory of 
Consumptions – More Especially a Phthisis or Consumption of the Lungs” in which he for 
the first time states that the cause of the disease is due to “wonderfully minute living 
creatures” and expresses his theory of “contagium vivium fluidum”, otherwise known as the 
germ theory, implying the transmission of TB from a sick individual to a healthy individual 
through close contact [15]. During the 19
th
 century, several new breakthroughs were made, 
starting with René Laennec‟s invention of the stethoscope allowing for diagnosing TB. He 
explained the disease pathogenesis in his 1819 book D’ Auscultation  Mediate, beginning our 
modern understanding of TB disease [16–19]. In 1865, Jean-Antoine Villemin demonstrated 
the transmissibility of TB between mammalian species (humans-cattle-rabbits), postulating 
that the disease was caused by a specific microorganism [9]. This was supported by the 
findings of an epidemiological study by William Budd [20]. However, the most well-known 
finding of the 19
th
 century occurred in Berlin on 24 March 1882, when Robert Koch in his 
presentation “Die Aetiologie der Tuberculose” describes the identification of the bacterium, 
Mycobacterium tuberculosis (M. tuberculosis), as the causative agent of the disease (Figure 
1) [10,21,22]. In 1890, Koch also announced the identification of a compound – tuberculin – 
that was able to inhibit the growth of M. tuberculosis in guinea pigs [23]. However, after the 
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poor results from clinical trials for the use of tuberculin as a therapeutic vaccine, it was later 
shown to be valuable in the diagnosis of TB, giving rise to the currently used Tuberculin Skin 
Test/Mantoux Test for the diagnosis of latent TB [24–26]. In 1895, Wilhelm Konrad von 















            Figure 1: Timeline for developments in TB disease. [28] 
 
The 20th century saw the fight against TB taken to the next level through the introduction of 
the first, and to date the only, successful vaccine, and chemotherapy. In 1908, Albert 
Calmette and Camille Guérin, through 230 serial passages of the pathogenic Mycobacterium 
bovis (M. bovis) strain; created the first attenuated strain (Bacille Calmette-Guérin or BCG) 
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which was avirulent in cattle, horses, rabbits and guinea pigs [22,29]. The first human 
administration of this vaccine was in 1921 and it was mass administered during 1945-1948 to 
over 8 million children in Europe, in a battle against the post-World War II TB epidemic 
[30]. In 1943, the first anti-TB drug was discovered by Selman Waksman and Albert Shatz 
by isolating streptomycin from Streptomyces griseus [31,32]. This was soon followed in 1947 
with the production of para-aminosalicylic acid (PAS) by Jörgen Lehmann, as the first oral 
therapy against TB [33]. In 1952, the „wonder drug”, isoniazid (INH) was developed by the 
pharmaceutical companies Bayer, Squibb and Hoffman La Roche, and was highly effective 
against M. tuberculosis [32]. For the first time, TB was considered 100% curable in 1960 
through the co-administration of streptomycin, PAS and INH [12]. Unfortunately however, in 
1970 the first outbreak of drug-resistant TB occurred in the United States of America [34], 
leading to one of the major hurdles currently facing medical scientists in eradicating this 
disease [35]. 
1.2 Epidemiology 
1.2.1 Global Epidemic 
 
The World Health Organization (WHO) declared TB a global health problem in 1993 [36], 
with approximately one third (two billion) of the world‟s population being infected with M. 
tuberculosis. In 2011, the WHO estimated 8.7 million new TB cases globally and 1.4 million 
deaths due to the disease. With the global TB incidence steadily declining, 2.2% in the year 
2010-2011, and the mortality rate having been decreased by 41% since 1990, the WHO 
believes that the Millennium Development Goal (MDG) – to halt and reverse the TB 
epidemic by 50% by 2015- has already been achieved (Figure 2). However, this global 
progress conceals regional variations, with African and European countries failing to meet 
the MDG with regards to fighting TB. 
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Figure 2: Global trends in estimated rates of TB incidence, prevalence and mortality. [36] 
Horizontal dashed line represents MDG goal of reducing TB prevalence and mortality by 50% by the year 2015. 
 
The TB burden is highest in the developing world, with Asia and Africa accounting for 40% 
and 24% of the world‟s TB cases, respectively (Figure 3), with India (2 million – 2.5 
million), China (0.9 million – 1 million), South Africa (0.4 million – 0.6 million), Indonesia 
(0.4 million – 0.5 million) and Pakistan (0.3 million – 0.1 million) rated as the five highest-
burden TB countries [36]. Asia accounts for the highest absolute number of TB cases and 
sub-Saharan Africa accounts for the highest rates of active TB per capita. Countries from 
these regions also have approximately 60% of the world‟s drug resistant TB cases (Figure 4) 
[37].  
TB ranks as the second highest cause of death by an infectious agent, after the human 
immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) [36]. While TB 
may be “under control” in developed nations, the disease remains a major health threat in 
third world countries. Due to the immunocompromising effect of HIV in infected individuals, 
an increased risk for reactivation of latent M. tuberculosis infection and rapid disease 
progression has been noted [38–40]. TB-HIV co-infection has also been shown to increase 
the risk of developing TB from 10%-20% in a lifetime to 10% per annum. Thus, TB has 
proven to be difficult to eradicate, primarily due to high HIV infection rates, poor health care, 
poor socio-economic status and the development of drug resistant strains of M. tuberculosis. 
HIV negative TB cases 
HIV positive TB cases 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 6 
 
 
Figure 3: Estimated TB incidence, 2011. [36] 
 
 
Figure 4: Number of MDR-TB cases estimated to occur among notified PTB cases, 2011. [36] 
 
1.2.2 South African Perspective 
 
As previously mentioned South Africa is currently the highest ranked African country with 
regards to TB burden (993 per 100 000 individuals in 2011) [36]. This is mainly due to the 
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high HIV prevalence rate (17.3% in SA adults in 2011) [41] and resulting TB-HIV co-
infections (approximately 50% of new TB cases), complicating the fight for the eradication of 
the disease (Figure 5). South Africa is currently ranked 3
rd
 in the world with regards to TB 
burden, with TB treatment success rates remaining low due to an increase in relapses because 
of poor adherence to treatment therapy and the spread of drug resistant TB [36], resulting in a 
high mortality rate (the leading cause of death in South Africa [42]), However, new 
diagnostic tests for TB have been widely implemented and South Africa is currently one of 
the leading countries in this regard. 
 
Figure 5: Estimated HIV prevalence in new TB cases, 2011. [36] 
 
Of the South African provinces, KwaZulu Natal currently has the highest TB burden in the 
country (30.5%); followed by the Eastern Cape (15.4%), Gauteng (14.2%) and Western Cape 
(12.3%) [43]. Together, these four provinces (out of nine) account for more than 70% of the 
countries TB burden. Important to note is the role of HIV with regards to disease burden, 
where the KwaZulu Natal province currently has the highest HIV prevalence in the country at 
15.8% of its population [44]. 
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1.3 Pathogenesis 
1.3.1 Structure of Mycobacterium tuberculosis 
 
M. tuberculosis organisms are rod-shaped, non-spore forming, aerobic, Gram-positive 
bacteria and approximately 0.5µm x 0.3µm in size (Figure 6) [45]. They are classified as 
acid-fast bacilli due to the difficulty with which the dye is removed using acid-alcohol after 
staining.  The cell wall structure of M. tuberculosis plays an important role in the intracellular 
survival of the bacterium. The mycolic acid (fatty acid) and arabinogalactan (peptidoglycan-
bound polysaccharide) which compose the bacterium cell wall give it an extraordinary lipid 
barrier. This lipid barrier is essentially responsible for M. tuberculosis being able to develop 
resistance and evade the host‟s defence mechanisms. In addition, the presence of 
lipoarabinomannan on the cell wall of the bacterium confers upon it its immunogenic 
properties, allowing the bacterium to survive within macrophages. Thus, the composition and 
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1.3.2 Mycobacterium tuberculosis complex 
 
There are several mycobacterial species that cause TB disease, with M. tuberculosis, M. 
africanum, and M. canetti causing human TB [47] and M. africanum occurring 
predominantly in West Africa [48]. In animals, TB is due to infections by M. bovis (cattle); 
M. caprae (sheep and goats); M. microti (voles); and M. pinnipeddi (seals and sea lions) [49]. 
Collectively, these mycobacterial species are referred to as members of the Mycobacterium 
tuberculosis complex (MTBC) [50]. All members of the MTBC are believed to have shared a 
common African ancestor about 35 000-15 000 years ago [51–53], while all modern strains 
of M. tuberculosis are thought to be descendent from a common ancestor about 20 000-
15 000 years ago [54]. These M. tuberculosis strains can be classified into six major lineages 
and are highly geographically structured (Figure 7) [55], where the East-Asian lineage has 
been shown to be more dominant in many Far East countries, while the Euro-American 
lineage is predominant in Europe and the Americas. 
 
Figure 7: The global population structure and geographical distribution of the six main M. 
tuberculosis lineages. [55] 
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In 1962, Richard Riley demonstrated for the first time that transmission of TB was as a result 
of droplet nuclei (small airborne particles containing viable M. tuberculosis bacteria) [56]. In 
his experiment, he placed guinea pigs in the ventilation chambers above the hospital wards in 
which TB patients were being treated. He noted that only particles small enough to be carried 
to the ventilators reached the guinea pigs, which in turn became infected with the same strain 
as the infected patient, through inhalation of these particles. TB is thus spread through the 
expulsion of these droplet nuclei from infected individuals through coughing, sneezing or 
talking to in close proximity (Figure 8) [57]. However, various factors can influence the 
transmission of M. tuberculosis, including the number of bacilli contained in the droplet 













Figure 8: Mechanisms by which TB is transmitted between individuals. [59] 
 
1.4 Clinical Features 
1.4.1 Symptoms 
 
Classic disease symptoms for pulmonary TB (PTB) include chronic coughing, loss of 
appetite, weight loss, fever, night sweats, and haemoptysis (Figure 9) [60]. Extrapulmonary 
TB (EPTB) can affect any organ of the body and has variable clinical manifestations, 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 11 
 
requiring extreme clinical suspicion [61]. In TB endemic regions, it has been shown that the 
presence of any one of four TB symptoms (cough, fever, night sweats or weight loss) has an 
approximate sensitivity of 80% for identifying patients for further TB diagnostic testing [62]. 
Pre-emptive screening for TB in these regions is also highly recommended to prevent missing 
subclinical TB in patients with HIV co-infections or other non-communicable diseases 
(diabetes and tobacco-related chronic lung disease) [62,63]. 
 
 
                                      Figure 9: Symptoms associated with TB disease. [64] 
 
1.4.2 Host Immune Response 
 
The primary host response to M. tuberculosis infection is cell-mediated immunity [65]. After 
inhalation of droplet nuclei, TB infection begins when the bacteria are phagocytosed by 
alveolar macrophages or dendritic cells [66]. Depending on the host‟s immunity and the 
virulence of the infecting M. tuberculosis strain, the bacterium will either be destroyed or 
survive within the host [65–67]. In most individuals, as a result of a potent immune response 
to the phagocytosed bacteria, the mycobacteria are destroyed and eliminated. However, 
failure to induce a strong enough immune response to the invading pathogen results in the 
formation of granulomas. These structures within the infected lung tissue limits the growth 
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and further spread of the bacilli, and are composed of macrophages; T- and B-lymphocytes; 
and fibroblasts [66]. The T-lymphocytes release various cytokines, including interferon 
gamma (IFN-γ), which promotes killing of the mycobacteria. In some cases, the bacteria are 
not killed but instead enter a phase of dormancy, resulting in a latent infection (a non-
replicative life cycle) and thus control of the disease [66,68]. However, during 
immunosuppression (as with HIV co-infection), the mycobacteria will begin to actively 
replicate, resulting in progression to active TB disease with subsequent spread to other organs 
(EPTB) or to new hosts. 
1.4.3 Clinical Manifestations 
 
TB disease can manifest in several forms; including latent infection, primary disease, active 
disease and EPTB with defined characteristics and is dependent on the immune response 
stimulated at the point of infection [45]. 
TB disease occurs in three forms, namely latent TB, active TB and EPTB disease (Figure 10). 
The latent form of the disease, the most common, occurs in approximately 90% of individuals 
infected with the pathogen [69], and results when the host‟s immune response is unable to 
effectively eliminate the bacterium [45]. During this stage of the disease, growth is limited 
and M. tuberculosis bacilli are contained within granulomas in the lung. These bacteria are 
dormant and are non-infectious and the host does not experience any disease symptoms [70]. 
Active TB disease occurs when, at the point-of-infection, the host immune response elicited 
is not strong enough to prevent the bacterium from actively replicating [45]. TB disease 
occurs in these individuals, who experience TB symptoms (see section 1.4.1) and may result 
in further spread of the disease. At the point where actively replicating bacilli can no longer 
be contained within the granulomatous lung tissue, EPTB occurs through necrosis of these 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 13 
 
structures and the subsequent spread of the bacterium from the lesions into the blood system 
(miliary TB) and the ensuing infection of other body organs [71]. 
 
Figure 10: Clinical manifestations of TB disease. [72] 
 
Most important is the spread of the disease to the central nervous system, causing tuberculous 
meningitis (TBM), which is fatal and occurs predominantly in young children. Individuals 
with EPTB are however less infectious than their PTB counterparts [73]. 
1.5 Diagnosis 
 
TB diagnostics is continuously improving and currently forms a major component of TB 
biomedical research, with different tests available for different forms of the disease. 
Diagnosing latent TB is done by using either the tuberculin skin test (TST) or the interferon-
gamma release assay (IGRA) (Figure 11) [70]. The TST test is predominantly used in low-
income regions, and while it may be as sensitive as the IGRA test, it lacks specificity due to 
high false-negative (immunocompromised and malnourished individuals) and false-positive 
(BCG vaccination) results [74]. This diagnosis is used predominantly in areas where TB is 
endemic and in individuals at risk of disease reactivation (HIV or diabetes co-infections and 
immunosuppressive therapy) [75,76]. 
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Figure 11: Diagnostic tests for latent TB infection. (A) Tuberculin skin test (TST) [77,78] and (B) 
interferon-gamma release assay (IGRA) [79].  
 
 There are currently several diagnostics available for active TB disease, with varying levels of 
sensitivity and specificity [70]. Most commonly used and currently regarded as the “gold 
standard” are sputum microscopy and liquid media culturing, with solid medium culturing 
more commonly used in resource-limited countries. In addition; imaging (X-rays), 
histopathological biopsy examinations and nucleic acid amplification tests are also employed. 
Recently, the Xpert MTB/RIF assay was released as a new diagnostic for TB and drug-
resistance, allowing for rapid MTBC detection (2 hours) with greater sensitivity compared to 
microscopy based tests [80]. The use of this technology, as currently employed in regions of 
high TB prevalence, could drastically lower the disease burden due to better control of the 
disease [36]. 
Drug-resistance in TB, the inability of otherwise effective drugs to kill the bacterium, is 
currently of great concern and a major impediment to the eradication of this disease [81]. 
Current diagnostics for drug-resistant TB allow for the diagnosis of multidrug-resistant 
(MDR)-TB, extensively drug-resistant (XDR)-TB or totally drug-resistant (TDR)-TB, 
depending on the number of drugs to which the bacterium is resistant (see section 1.6) 
[36,82,83]. Currently used diagnostics include the automated liquid culture system (4 -13 
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days); the molecular line-probe assay (24 hours); and the Xpert MTB/RIF assay (2 hours, 
only for Rifampin (RIF) and INH resistant TB) [84–86], with the WHO currently 
recommending that these tests be carried out at the same time as patients are being diagnosed 
for active TB disease [87]. Additional tests for drug-resistant TB include the microscopic-
observation drug-susceptibility assay, the nitrate reductase assay, and colorimetric reductase 
methods [70]. However, these tests are not readily available in highly endemic regions, with 




The treatment of TB has come a long way since the initial description of the disease by 
ancient Greek and Roman physicians who, depending on the time and country, advised 
patients to rest or to exercise, to eat or to abstain from food, to travel to the mountains or to 
live underground [12]. However, the 5
th
 century recommendation of heliotherapy by Caelius 
Aurelianus as a treatment of TB has been shown to be important, where current studies have 
clearly linked Vitamin D deficiency to the development of TB [89,90]. In 1859, the first 
successful sanatorium for the treatment of TB was established by Herman Brehmer in 
Görbersdorf, Germany, and represents the first widely used approach to combat TB disease 
[12]. This treatment was based on good nutrition and exposure to fresh air. 
The use of the BCG vaccine to protect an infant against developing TB in 1921 in Paris, 
France highlights the start of approaches still used today in the fight against TB [22,29]. The 
BCG vaccine is still widely used in infants at birth in TB endemic regions [70]. The vaccine 
has been shown to be highly efficacious in children but not in adults [36] and has a current 
estimated overall efficacy of 50% for the prevention of TB [91]. However, given the poor 
effect in adults and the resultant occurrence of disseminated disease in HIV-infected new-
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borns, there is a major global drive for the development of new and better vaccines, with 
more than 30 vaccines currently in development [36,40,92]. 
The production and use of chemotherapeutic agents since 1940 has drastically altered the 
outcome of active TB disease [93]. Current first-line four drug regimens are able to achieve 
cure rates greater than 95% under trial conditions and greater than 90% under the directly 
observed therapy short course (DOTS) strategy implemented in 1993 by the WHO [36,94]. 
The current first-line drug regimen consists of INH, RIF, pyrazinamide and ethambutol, and 
treatment comprises two phases - a two month intensive phase where all four drugs are 
administered and a four month continuation phase with only INH and RIF - over a six month 
period [70]. In a case where factors for relapse; cavitation, extensive disease, 
immunosuppression, and negative sputum culture conversion at eight weeks present 
themselves then therapy should be extended to nine months. There are however several 
challenges with current treatment plans including poor drug quality, poor drug administration 
and patient compliance and treatment interruptions due to negative side-effects of drugs [95]. 
Current studies are in progress to address some of these issues, with reducing treatment 
periods (four months) and studying the pharmacokinetic effects of multi-drug regimens to 
reduce side-effects [36,70]. 
Long treatment plans and poor treatment adherence has led to the development of drug-
resistant TB [81]. In MDR-TB patients the bacillus is resistant to INH and RIF, and in XDR-
TB patients resistance to INH, RIF, the fluoroquinolone drugs and one of the injectables 
(amikacin, capreomycin and kanamycin) occurs [82,83,96]. TDR-TB, although not currently 
recognized by the WHO, is defined as M. tuberculosis bacteria resistant to all available drugs 
(as per the region where diagnosis occurs) [36]. In the case of drug-resistant TB, drug 
regimens are a combination of first-line and second-line drugs, initially on a standardized or 
empirical basis and then switched to individualized therapy based on the drug-susceptibility 
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results [97,98]. These therapies are usually administered for twenty months (new MDR-TB 
case) or thirty months (previously treated for MDR-TB); with an eight month intensive phase 
[70]. Given the long treatment period, these therapies are often associated with adverse side 
effects and poor treatment adherence, giving rise to XDR-TB and TDR-TB. These forms of 
the disease are extremely hard to diagnose and treat and are associated with high death rates 
[99–102]. There are currently several drugs in the pipeline for drug-resistant TB that have 
shown promise in early trials [103–106]. 
Preventive therapy is currently being recommended for individuals with latent TB and who 
are at a high risk for disease reactivation, especially HIV-infected individuals who reside in 
TB endemic regions [107,108]. There are several treatments recommended for these 
individuals, with regimens consisting of INH and RIF, both individually and together, at 
varying concentrations and therapy periods [109–113]. 
While TB therapy regimens may be generally applicable, treatment modifications should be 
considered in light of TB-HIV co-infections, drug-resistance, pregnancy and the treatment of 
children [36]. To achieve effective TB treatment outcomes, the following goals should be 
strived towards: accurate and efficient diagnosis, limiting relapse and transmission by 
adherence through better administration and supervision, and preventing the development and 
spread of drug-resistance.  
1.7 Other risk factors 
 
TB is an extremely complex disease, and while M. tuberculosis may be necessary, it is not 
sufficient for the development of active TB disease. Therefore, other factors such as 
environment and host also need to be taken into consideration for a complete understanding 
of disease development and progression (Figure 12) [114]. 
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Figure 12: Risk factors for TB. [114] 
 
1.7.1 Environmental Factors 
 
There are several environmental factors that have been shown to affect the outcome of TB 
disease, namely: socio-economic status, nutrition, smoking, and alcohol abuse [114,115]. 
Several studies have linked poor socio-economic status with higher TB incidence rates 
[116,117], with Asia and Africa accounting for more than half of the global TB disease 
burden [36]. Countries within these regions have high levels of poverty and the associated 
overcrowded living conditions [116,117]. Several “high risk environments” for the 
transmission of TB have been reported, including prisons, nursing homes and homeless 
shelters [114,115,118]. In developed countries, there is a higher disease burden in 
marginalized communities, and has been noted that treatment compliance is intrinsically 
linked to economic factors [119]. 
Nutrition has also been shown to play an important role in the development of TB disease, as 
malnutrition results in an altered cell-mediated immune response [120]. Studies conducted in 
the USA during the late 60‟s and early 80‟s have reported increased risk for developing TB, 
with malnourished children being twice as likely [121] and adults who are malnourished 
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having a six- to ten-fold increased risk [122], when compared to their well-nourished 
counterparts. These findings have been confirmed in other human and animal model studies 
[120]. A vitamin D deficiency is usually associated with malnutrition [123,124]. Vitamin D 
has been shown to have an immunoregulatory role and thus deficiencies of this micronutrient 
may lead to impaired host responses to M. tuberculosis [125]. Another result of poor 
nutrition, protein energy malnutrition (PEM), has been shown to have a negative effect on 
host immunity to M. tuberculosis [126]. These negative effects include reduced lymphocyte 
stimulation, low level secretion of the cytokines interleukin-2 (IL-2); IFN-γ; and tumor 
necrosis factor-α (TNF-α) which are important for stimulation of the Th1 response, and 
macrophages with high levels of transforming growth factor β (TGFβ) which suppresses T 
cells and inflammation. 
Exposure to cigarette smoke and the consumption of alcohol have been shown to be strong 
risk factors for TB disease based on meta-analysis and several systematic reviews [127–132]. 
The relative risk (RR) for developing TB disease was higher in smoking individuals (RR = 
2.3-2.7) [129]. Biologically, the exposure to smoke is thought to impair the clearance of 
mucosal secretions; result in alveolar macrophages with reduced phagocytic abilities; and 
result in a diminished immune response due to nicotine [133–135]. In a recent animal study, 
the exposure of mice to cigarette smoke and subsequent infection with M. tuberculosis 
resulted in higher numbers of viable bacilli in the lungs and spleens of these animals [136]. 
The consumption of alcohol was shown, in a meta-analysis, to be a strong risk factor for 
recent TB transmission in both TB endemic and non-endemic regions, with odds ratios (OR) 
of 2.6 and 1.4 respectively [137]. In addition, individuals who consume more than 40mg of 
alcohol per day and/or have alcohol abuse problems, have a considerably higher risk (RR = 
2.94) for developing active TB disease [138]. The (over)consumption of alcohol may result in 
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an altered immune system, specifically the signalling molecules responsible for cytokine 
production [139]. 




 century physicians believed TB disease to be hereditary but with the discovery of the 
causative agent, M. tuberculosis, in 1882 by Koch much of the work done to understand the 
development and progression of the disease focussed solely on the pathogen with host factors 
being largely ignored [12]. However, today there is clear evidence to support the role of host 
genetic factors in TB disease susceptibility. As previously mentioned, some individuals are 
able to eliminate the invading pathogen; while of those individuals who do become infected, 
between 5% and 10% go on to develop active TB disease (see section 1.4.2). This clearly 
demonstrates that host genetics could play a crucial role in disease development and that 
although important; the pathogenic factors of the bacilli, does not in itself define the outcome 
of infection. 
To determine if host genetics plays a role in the outcome of infectious diseases, several twin 
and adoption studies have been conducted, with both providing clear support for the 
importance of host factors in this regard. Twin studies have shown that monozygotic 
(genetically identical) twins have a higher concordance for disease than dizygotic twins 
(Table 1) [140–142]. Adoption studies have provided additional evidence by showing that in 
comparisons of the cause of death between parents and children, adopted children were more 
likely to die from an infectious disease before the age of 40 if their biological parents had 
[143–146]. These studies show that while environmental factors may increase the risk of 
developing TB, host genetic factors are important in the final outcome of the disease. 
Furthermore, a study conducted in a USA nursing home residence showed that staff of 
African-American ancestry were twice as likely to develop TB disease when compared to 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 21 
 
their Caucasian counterparts [147], even though they shared the same environment and were 
of the same socio-economic status. This disparity in infectious disease susceptibility between 
individuals of different ethnicity can also be seen when comparing Europeans and Africans, 
where it appears that Europeans are less susceptible to TB infection than Africans [144]. 
Table 1: Twin studies investigating the heritability of TB. 
Study 
Number of twins Percentage concordance 
Reference 
Monozygotes Dizygotes Monozygotes Dizygotes 
Diehl et al., 1936 80 125 65 25 [148] 
Uehlinger et al., 1938 12 34 58 6 [149] 
Kallmann et al., 1943 78 230 62 18 [141] 
Harvald et al., 1965 135 513 37 15 [150] 
Comstock et al., 1978 54 148 32 14 [140] 
Simonds et al., 2004 55 150 32 14 [142] 
van der Eijik, 2007 54 148 21 19 [151] 
 
This is thought to be due to natural selection. European populations experienced a great TB 
epidemic (The White Plague, 17
th
 century onwards), resulting in a population highly resistant 
to M. tuberculosis infections. While the pathogen may have been present in Africa since the 
Out-of-Africa migrations [152], the disease never reached pandemic proportions until the re-
colonization by European settlers, and there was thus no selection pressure to remove 
causative genes from the African populations. Similarly, in the Qu‟Appelle Indian 
Reservation, initial exposure to the bacterium resulted in a high TB mortality rate (10% per 
annum) [153]. However, after 40 years, the death rate had dropped significantly (to 0.2% per 
annum); highlighting the effect of strong selection pressures in removing disease-causing 
genes from a population. Finally, in 1926 in Lübeck, Germany; 251 new-borns were 
mistakenly vaccinated with a live, virulent M. tuberculosis strain instead of the attenuated 
BCG strain [154]. This unfortunate event resulted in the death of 77 babies from TB, 47 latent 
TB cases, and 127 babies with active TB disease but who later recovered, thus illustrating the 
ability of certain individual‟s immune response to efficiently handle the disease, and clearly 
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demonstrating the importance of host genetic variation in disease outcomes, including 
infectious diseases. 
1.7.2.1 Current approaches in identifying disease causing genes 
 
As highlighted above, TB is an extremely complex disease, with the outcome influenced by 
environmental, pathogenic, and host factors. Identifying the disease causing genes has thus 
far proven to be difficult, and is further exacerbated by the heterogeneity of the underlying 
genetic cause [155]. There are several methodologies currently being used to elucidate the 
genes associated with susceptibility to TB [69]. Even more recent advances in genotyping 
technologies, molecular biology, and bioinformatics have resulted in the introduction of 
powerful high-throughput techniques for the identification of the disease causing genes. 
Current approaches are methodologies that are either hypothesis-driven (candidate gene 
association studies) or exploratory data analysis (genome-wide association studies and next-
generation sequencing). 
1.7.2.1.1 Candidate gene association studies 
 
Candidate gene association studies are still the most commonly used study design for 
identifying disease susceptibility genes [146]. The premise of the candidate gene approach is 
to investigate polymorphisms in a gene of interest and determine if specific alleles of the 
gene occur more (susceptible) or less (protective) frequently in cases (affected individuals) 
and controls (unaffected individuals) [156]. Genes are usually selected based on their 
function – with regard to TB, immunity related and closely associated genes are investigated 
[157]. Studies in animal models have also led to the discovery of potential candidate genes 
[158], where the natural resistance-associated macrophage protein 1 gene (Nramp1) was first 
identified in a mouse model of mycobacterial disease and where its human homologue 
(NRAMP1) was one of the first genes shown to play a role in human TB susceptibility 
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[145,159,160]. Bioinformatics approaches have also identified genes that are highly 
homologous to previously associated disease causing genes [69]. 
If a polymorphism in a candidate gene is significantly associated with an outcome of the 
disease of interest, it may be due to one of three reasons [161]; (1) it is the actual causative 
allele of the disease, (2) it is in linkage disequilibrium (LD) with the causative allele of the 
disease, or (3) it is an artefact of population admixture in populations of mixed ancestry. LD 
is the non-random association of two or more alleles at different loci on the same 
chromosome, where the closer in proximity two alleles are, the less chance there is of them 
being separated by recombination events [162]. This allows for one allele at a given locus to 
predict the allele at a second locus providing that they are in LD [163]. While LD may be 
useful for the identification of novel disease causing variants, it also complicates matters 
when the significantly associated allele is not the causative allele but rather in LD with it 
resulting in false-positive associations. Population stratification may also lead to the 
identification of false-positive and/or false-negative associations through the existence of 
different allele frequencies between subpopulations due to differences in ancestry [164]. This 
is extremely important in highly admixed populations where the contributing populations 
have known differences in disease susceptibility, but it can be overcome by correction [165].  
Population-based case-control association studies are commonly utilized for the identification 
of common variants in disease-causing genes due to their cost-efficiency and high statistical 
power [166]. There are however disadvantages to this approach, including the laborious 
nature given the heterogeneity of TB disease and the low concordance between validation 
studies [165,167]. This low concordance can be mainly attributed to differences in study 
design (definition of TB phenotype, experimental procedure, statistical approaches, and 
power of studies) [168,169]. The selection of controls is extremely important and should be 
matched to cases with regards to age, sex, ethnicity, and social-demographic factors [170]. A 
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number of genes and pathways have been studied to identify the genetic link in TB disease 
susceptibility (Figure 13), with polymorphisms in several genes being found to alter disease 
outcome, albeit with small effect.  
 
Figure 13: Current understanding of genes involved in susceptibility to TB disease. [146] 
 
Some of the major genes identified by this approach and validated in several populations 
include the chemokine (C-C motif) ligand 2 (CCL2), human leukocyte antigen (HLA), 
interferon-γ (IFNG), mannose-binding lectin (MBL), nitric oxide synthase 2, inducible 
(NOS2A), solute carrier family 11A member 1 (SLC11A1), SP110, and the toll-like receptor 
(TLR) genes [69,146].  
1.7.2.1.2 Genome-wide association studies (GWAS) 
 
Recent advances in genotyping technologies and the availability of the human genome 
sequence and the HapMap Project database have allowed researchers to investigate 
polymorphisms across the entire human genome – genome-wide association studies (GWAS) 
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[171–174]. The approach does not depend on known candidate genes, and is therefore free of 
assumptions and allows for the identification of novel genes and pathways. 
While the ability to identify novel variants makes GWAS a highly desirable approach, there 
are several draw-backs to the method. To correct for the large number of tests done and limit 
the likelihood of false-positive discoveries, an extremely high significant cut-off value is 
employed, resulting in the identification of variants which exhibit a large effect and 
discarding any variants of small to moderate effect [69]. This is an extremely contentious 
point regarding the validity of GWAS in infectious diseases, as some researchers believe that 
the “common disease, common variant” hypothesis is not appropriate and that the 
investigation of rare variants would be more informative. GWAS also require extremely large 
study cohorts for adequate power to detect disease causing variants [162]. 
GWAS have been extensively used to identify the underlying genetic variants in common 
diseases, including Crohn‟s disease, rheumatoid arthritis, type-1 and -2 diabetes, macular 
degeneration, inflammatory bowel disease, cardiac diseases and various cancers [175] (Figure 
14). The use of GWAS for infectious diseases have been limited, with published data for 
AIDS [176–178], chronic hepatitis B [179–182] and C [183–185], Kawasaki disease [186–
191], leprosy [192,193], malaria [194,195], meningococcal diseases [196] and TB [197–200], 
with very little to no concordance between studies of the same disease. For TB susceptibility, 
the chromosome 11p13 loci containing the WT1 gene intergenic region was identified as 
playing a role (Table 2) [199]. This region was confirmed in a meta-analysis study of GWAS 
data [201]. While GWAS have been successful in understanding the genetic etiological 
mechanisms for many common diseases (e.g. Crohn‟s disease), the results generated for 
infectious diseases, specifically TB, have left researchers wanting more. 
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Figure 14: Published GWAS loci for 18 trait categories, July 2012. [175] 
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Table 2: GWAS TB susceptibility studies. 
Study Initial sample size Replication sample size Region Genes Strongest risk allele Context P-value OR [95% CI] 
Thye et al., 2010 
[197] 
Ghana:  
cases = 921,  
controls = 1 740 
Gambia: 
cases = 1 316,  
controls = 1 382 
Ghana:  
cases = 1 226,  
controls = 3825, 
parent/child trios and duos = 332. 
Malawi: 
cases = 236, 







 1.19 [1.10-1.30] 
         
Png et al., 2012 
[198] 
Indonesian ancestry: 
cases = 108, 
controls = 115 
Indonesian ancestry: 
cases = 600, 
controls = 540 
European ancestry: 
cases = 1 837, 
controls = 1 779 
NS NS NS NS NS NS 
         
Thye et al., 2012 
[199] 
African ancestry: 
cases = 1 329, 
controls = 1 847 
African ancestry: 
cases = 2 024, 
controls = 5 154 
Indonesian ancestry: 
cases = 1 025, 
controls = 983 
European ancestry: 
cases = 4 441, 
controls = 5 874 
11p13 WT1 rs2057187-A Intergenic 3x10
-11
 1.1 [1.01-1.22] 
 
         
Mahasirimongkol 
et al., 2012 
[200] 
Thai ancestry: 
cases = 433, 
controls = 295 
Japanese ancestry: 
cases = 188, 
controls = 934 
Thai ancestry: 
cases = 369, 
controls = 439 
Japanese ancestry: 
cases = 112, 
controls = 1 089 
NS NS NS NS NS NS 
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1.7.2.1.2 Next-generation sequencing 
 
While GWAS may have allowed for the identification of thousands of statistically significant 
disease susceptibility associations it has failed to explain the full range of genetic 
susceptibility to complex diseases [202]. This can be seen in studies conducted on Crohn‟s 
disease, where more than 70 new loci were identified, but only approximately 23% of the 
disease heritability was described [203]. The ability to compare the entire genome of cases 
and controls for a specific disease/trait is believed to be a better approach for understanding 
the genetic aetiology of the disease/trait. In this regard, the use of next-generation sequencing 
(NGS) technologies has allowed researchers to do just that [202]. 
There are currently two approaches to NGS – exome and whole-genome sequencing [202]. 
Exome sequencing involves targeting all the exomes in the genome. This approach is much 
more cost efficient than whole-genome sequencing, as approximately 2% of the genome is 
coding, but may be more suitable for the study of Mendelian diseases, since most causal 
alleles occur in protein-coding regions (exons) [204]. This method has however been 
successfully employed in some complex diseases, including autism, other 
neurodevelopmental phenotypes, and to find the cause of low HDL-cholesterol [205–207]. 
However, a drawback to employing exome sequencing is that it requires extremely large 
sample sets to identify rare variants (Figure 15) [202].  
On the other hand, whole-genome sequencing allows for the interrogation of all forms of 
DNA variation (single nucleotide polymorphisms (SNPs), single nucleotide variants (SNVs), 
insertion/deletions (indels)) regardless of frequency (rare, low, common) and function 
(coding and non-coding) [202]. This approach may therefore be better suited for complex 
diseases as it has been shown to be due to both coding and non-coding variants. This is 
especially important for TB susceptibility, where all GWAS data to date have identified 
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variants in non-coding regions (Table 2). However, there are substantial challenges that 
accompany this method including an incomplete reference genome [208], complex 
algorithms to identify all forms of variation [209,210], and heavy computational requirements 
[202] (e.g. raw data storage for 800 „Phase I‟ 1000 Genomes Project samples would require 
50 000 Gb for the raw data, compared to 4 GB from GWAS data, and would require 
approximately 20 000 CPU-days of processing time, compared to 715 for GWAS data). 
 
Figure 15: Differential power between GWAS and NGS approaches. [202] 
While the costs associated with NGS approaches are becoming lower and lower as the 
method becomes more widely used due to better technologies and algorithms. There is 
however a greater need for researchers who are computationally and statistically trained and a 
major limitation is the computational power that is required, which many researchers/labs 
currently lack. 
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2.1 The Leukocyte Receptor Complex 
 
The Leukocyte Receptor Complex (LRC) on chromosome 19q13.4 comprises a large cluster 
of cell surface receptors (Figure 16), including the killer cell immunoglobulin (Ig)-like 
receptors (KIRs), leukocyte Ig-like receptors (LILRs), leukocyte-associated Ig-like receptors 
(LAIRs), NKp46 (natural cytotoxicity receptor 1, NCR1) and FCαR1, all of which have been 
shown to regulate the immune system [211]. 
 
Figure 16: Gene organization of the Leukocyte Receptor Complex on chromosome 19. [212] 
 
The KIRs, LILRs, LAIRs and NKp46 belong to the family of Ig-like receptors [212]. This 
family of receptors is characterised by the presence of several conserved extracellular 
domains that consist of 70-110 amino acids which have a sandwich-like structure through the 
formation of two sheets of antiparallel β strands. 
2.1.1 Killer cell immunoglobulin-like receptors 
 
The killer cell immunoglobulin-like receptors (KIRs) are diverse and rapidly evolving 
receptors encoded by sixteen genes (fourteen functional) [213,214]. The KIRs are 
predominantly expressed on the surface of natural killer (NK) cells (Figure 17) but have also 
been shown to be present on a subset of T cells [215,216]. NK cells form part of the innate 
(and adaptive) immune response and have been shown to play a role in infection [217–219]. 
NK cells are able to discriminate between self and non self cells through numerous receptors, 
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with human NK cells utilizing the KIRs [219]. KIRs are thus able to distinguish between 
infected and non-infected cells, resulting in the killing of the former. 
 
 
Figure 17: NK cell regulation dependent upon the expression of KIR receptors and the HLA 
class-I ligands on infected cells. [212] 
 
There are two structural groups into which the KIRs are classified; KIR2D and KIR3D, based 
on the number of Ig-like domains (two: D1-D2 and D0-D2 or three: D0-D1-D2) that they 
have in their extracellular region (Figure 18) [212]. Furthermore, KIRs can be either 
activating (with an immunoreceptor tyrosine-based activation motif (ITAM) –2DS and 3DS) 
or inhibitory (with an immunoreceptor tyrosine-based inhibition motif (ITIM) –2DL and 
3DL). Inhibitory receptors are involved in the recognition of self antigens and induce 
programmed cell death by NK cells in the absence of their HLA class-I ligands (missing self 
hypothesis) [220]. Inhibitory KIRs (iKIRs) have also been shown to have greater affinity for 
ligands than activating KIRs (aKIRs), thus the binding of several aKIRs is required to 
override the response to the binding of a single iKIR [212]. NK cell cytotoxicity is therefore 
controlled by the interplay of these activating and inhibitory signals which are mediated by 
receptors on the cell surface [221,222]. 
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Figure 18: Structural depiction of activating and inhibitory KIRs. Green circles represent the ITAMs 
present in aKIRs, while the red rectangles are ITIMs present in iKIRs. [223] 
 
Expression of the KIR receptors is highly complex and controlled by a stochastic mechanism 
that results in the expression of some receptors and not others on individual cells resulting in 
the ability of NK cell clones to differentially recognize their targets [216,224]. The genomic 
segment where the KIR genes are located has undergone several expansion and contraction 
events over time, resulting in duplication and unequal cross-over in this region [225,226]. 
The KIR genes are highly polymorphic and the KIR gene content (KIR haplotype) usually 
differs among individuals in terms of variation in the number and types of genes present 





D0 D0 D1 D1 D1 D1 
D2 D2 D2 D2 D2 D2 
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four KIR genes (2DL4, 3DP1, 3DL2 and 3DL3) which are present in all haplotypes and are 
referred to as the framework genes [227]. The number of KIR genes in a haplotype usually 
ranges from 7-12 genes, with haplotypes being classified as A or B based on the number of 
aKIR genes present [226]. KIR haplotype A has only one aKIR gene (2DS4) whereas KIR 
haplotype B contains 5 or more aKIR genes (2DS1 - 2DS5 and 3DS1). Furthermore, 
haplotype A has a set number of KIR genes (nine) where haplotype B has a variable number 
of genes. To date, more than 400 KIR genotypes have been identified among unrelated 
individuals [228], and using segregation analyses 40 gene-specific genotypes have been noted 
[229–232]. In addition, KIR genotypes may also show further variability when KIR gene 
alleles are taken into account  [233]. 
Most human KIRs are specific for polymorphic determinants of HLA class-I molecules 
(HLA-A, -B and -C) [212]. To fully understand the role that KIRs play in disease 
susceptibility, the HLA class-I molecules need to be taken into consideration. Briefly, 2DL1 
binds to HLA-C group 2 (C2) alleles, while 2DL2 and 2DL3 bind to HLA-C group 1 (C1) 
alleles [234]. The 2DS genes recognizes the same HLA alleles as their inhibitory counterparts 
(2DS1 binds C2 alleles, etc). 3DL1 and 3DS1 bind to HLA-Bw4 [235–238], while 3DL2 
binds to HLA-A3 and -A11 alleles [234]. 
2.1.2 Leukocyte immunoglobulin-like receptors 
 
The leukocyte immunoglobulin-like receptor (LILR) gene family consists of thirteen genes 
that are believed to have arisen by a large-scale inverted duplication and further gain/loss of 
genes [211,239,240]. There are six activating LILRs, five inhibitory LILRs and two 
pseudogenes [211]. LILRs are ubiquitously expressed by cells of the myeloid lineage and the 
rare plasmacytoid dendritic cells (DCs) [241,242]. LILRB1 is expressed on B cells and there 
is some LILR expression on NK cells, T cells and granulocytes [243]. 
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LILRs are potent modulators of the immune response in that they are able to regulate myeloid 
lineage cells [211]. LILRB2 and LILRB4 expression is associated with induction of a 
tolerogenic phenotype in dendritic cells (DCs), resulting in reduced expression of 
costimulatory molecules and unresponsiveness in CD4
+
 T helper cells to specific antigens 
[244]. Young et al. showed that ligation of LILRB1 on monocyte-derived DCs results in a 
unique DC population that has a distinct morphology and causes down modulation of T cell 
stimulation, independent of secretion of immunosuppressive cytokines [245]. LILRB4 has 
also been shown to modulate T cell responses by inducing helper T cell anergy and 
differentiation of regulatory CD8
+
 T cells [246,247]. Conversely, activation of LILRA2 
resulted in the formation of immature DCs and abrogation of antigen presentation to T cells 
[248]. Furthermore, LILRA2-activated monocytes showed increased cytokine expression 
levels for TNF-α, IL-6, IL-8, IL-10 and IL-12, providing a potential mechanism for down 
regulation of T cell activation of the innate immune response while promoting an 
inflammatory response. 
Similar to KIRs, LILRs are highly polymorphic and some LILRs have known HLA class-I 
ligands [211]. LILRB1 also binds HLA-G, resulting in increased signalling and dominant 
immunosuppressive effects [249,250]. 
2.1.3 Leukocyte-associated immunoglobulin-like receptors 
 
There are two leukocyte-associated immunoglobulin-like receptor (LAIR) genes, LAIR-1 and 
LAIR-2 which are phylogenetically related to many of the immunoreceptors in the LRC but 
differ from one another in having opposite transcriptional orientations [251]. LAIR-2 shares 
84% homology with LAIR-1 but lacks a transmembrane domain and is thus predicted to be a 
soluble receptor. Expression of the LAIR-1 protein occurs on almost all immune cells, 
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including NK cells, B and T lymphocytes, thymocytes, monocytes, DCs, eosinophils, 
basophils, mast cells and C34
+
 hemopoietic progenitors [211]. 
LAIR-1 is a potent inhibitor of the cytotoxic activity of NK cells and T cells [251–256], as 
well as, the differentiation of monocyte-derived DCs [257], and is thus an important negative 
regulator of immune cells [258,259]. LAIR-1 also binds various collagen ligands, including 
glycoprotein VI [260–262]. Collagens are able inhibit primary immune cell activation, 
suggesting that extracellular matrix collagens can regulate the activity of immune cells 
[260,263]. LAIR-2 also binds collagen and could thus act as a negative regulator of LAIR-1 
signalling [264].  
2.1.4 FcαR1 (CD89) 
 
FcαR1 is type I transmembrane receptor for immunoglobulin A (IgA) [265,266] and is 
expressed on myeloid cells [211]. The expression of FcαR1 is up regulated in response to 
formyl-methionyl-leucyl-phenylalanine, TNF-α and IL-8 on neutrophils and 
lipopolysaccharide, TNF-α, IL-1β and granulocyte macrophage colony-stimulating factor on 
monocytes [267,268]. In contrast, TGF-β, IFN-γ, suramin and IgA down regulates FcαR1 
[267,269]. 
IgA is the predominant antibody class present at mucosal surfaces [270] where it functions to 
prevent bacterial adherence, microorganism invasion and neutralizing of bacterial toxins 
[271]. Paradoxically, the absence of antigen results in serum IgA having anti-inflammatory 
properties, promoting down regulation of IgG-mediated phagocytosis, bactericidal activity, 
oxidative respiratory burst and cytokine release [272]. Kanamaru et al. recently showed that 
monomeric FcαR1 targeting induced apoptosis in human monocytes, monocytic cell lines and 
FcαR1 transfected cells [273]. 
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2.1.5 NKp46/Natural Cytotoxicity Receptor 1 (NCR1) 
 
NKp46 engagement has been shown to result in calcium mobilization, cytokine production 
and activation of the cytolytic activity of NK cells [274,275], and is a crucial receptor for the 
recognition and killing of tumor and virus-infected target cells. In the case of influenza virus, 
NKp46 binds hemagglutinin resulting in lysis of the influenza virus-infected cells [276]. 
Studies have also shown that NK cells are able to recognize and kill immature DCs. This 
however is not true for mature DCs which are able to upregulate MHC class-I molecules and 
thus capable of engaging inhibitory NK receptors [277–280]. Based on these findings, 
Moretta proposed a model whereby NK cells regulate antigen presentation by limiting the 
number of DCs migrating to secondary lymphoid organs where they would prime naive T 
cells, thus controlling the amplitude of the subsequent immune response [281]. 
2.2 The Major Histocompatibility Complex 
 
The Major Histocompatibility Complex (MHC) spans chromosome 6p22.1 to 6p21.3 and 
contains over 200 genes, most of which have known immunological functions, amongst 
others [282,283]. Genes in this region are subdivided into three classes: MHC class I, class II 
and class III (Figure 19), with class I and class II genes involved in antigen processing and 
presentation (Figure 20) [284]. 
 
Figure 19: Gene organization of the MHC on chromosome 6. [285] 
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Figure 20: Functions of MHC molecules - antigen processing and presentation. [286] 
 
A characteristic feature of the MHC region is the extent of variation identified to date, with 
class I and class II genes having the greatest amount of variation (Table 3) [283]. This has 
been shown to be important for the ability of the host to respond to several pathogens since 
these polymorphic regions code for the peptide binding grooves [287,288]. This diversity in 
antigen presentation is also facilitated through the expression of MHC gene alleles inherited 
from both parents [289]. These genes are also expressed in co-dominant fashion, where for 
class I genes, any cell will have six different types of class I molecules [290].  
Table 3: Variation identified in HLA class-I and class-II genes. [228] 
HLA class-I molecule Number of alleles Number of proteins 
A 2244 1612 
B 2934 2211 
C 1788 1280 
E 11 3 
F 22 4 
G 50 16 
HLA class-II molecule   
DRA 7 2 
DRB 1418 1051 
DQA1 50 31 
DQB1 323 216 
DPA1 37 19 
DPB1 185 153 
DMA 7 4 
DMB 13 7 
DOA 12 3 
DOB 13 5 
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Due to the extreme variability of the HLAs a systematic nomenclature was developed for the 
sharing of HLA data between laboratories. HLA alleles are named using a unique number 
sequence with up to four sets of digits which are separated by colons (Figure 21) [291]. All 
HLA alleles have a four-digit name, with longer names assigned when necessary, as 
described below. The first set of digits (“Field 1; allele group” in Figure 21) describes the 
type of allele and corresponds to the serological antigen that it presents. The second set of 
digits (after the first colon) lists the subtypes of the allele as a result of one or two nucleotide 
substitutions that result in the change of the amino acid sequence of the protein, where 
numbers are assigned in the order in which the DNA sequence has been identified. The third 
and fourth sets of digits denote alleles that differ by synonymous nucleotide substitutions 
within the coding region of the gene and alleles with polymorphisms in the introns, 5‟ and 3‟ 
untranslated regions of the genes, respectively. Additionally, allele names may include 
suffixes to denote the expression of the allele, where N indicates a null allele (not expressed). 
Other suffixes include: L (low expression), S (soluble secreted molecule), and Q 
(questionable expression).  
Figure 21: HLA nomenclature system. [292] 
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2.2.1 Major Histocompatibility Complex class I genes 
 
The MHC class I genes, also known as the human leukocyte antigen (HLA) class-I genes, can 
be subdivided into classical (HLA-A, -B and -C) and non-classical (HLA-E, -F and -G) 
groups [287]. The HLA class-I molecules are expressed on the cell surface of most nucleated 
cells and function as presenters of intracellular antigens/peptides to cytotoxic T cells [288]. 
Due to the presentation of cytosolic peptides, the pathway associated with HLA class-I 
presentation is usually referred to as the cytosolic or endogenous pathway [293]. However, it 
has been shown that antigens derived from exogenous proteins can be displayed by these 
class-I molecules [294]. This is known as cross-presentation and allows for the presentation 
of HLA class-II antigens by class-I molecules and thus stimulation of cytotoxic CD8
+
 T cells. 
This peptide presentation enables the identification of self and non-self cells, allowing for the 
killing of the latter by cytotoxic T cells (CTLs) by apoptosis through cell-mediated immunity 
[295]. In addition, class-I molecules are known inhibitory ligands of KIRs present on the 
surface of NK cells (Figure 22) and it has also been shown that certain viruses are able to 
down-regulate the expression of these molecules on the surfaces of antigen presenting cells 
(APCs) [287]. In this instance, NK cells through their KIRs are able to mediate cell killing 
through programmed cell death [220,227]. 
 
Figure 22: Known HLA class-I ligands for KIR molecules. [227] 
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Structurally, the HLA class-I molecule consists of an α and a β2-microglobulin (b2m) 
polypeptide chain [288] (Figure 23) which are non-covalently linked through an interaction 
between the α3 and b2m domains [296]. The α domains are encoded by a HLA gene and are 
polymorphic, while the b2m domain is encoded by the b2m gene and is not polymorphic. The 
α1 and α2 domains fold to form the peptide binding groove of the molecule, whereas the α3 
domain interacts with the CD8 co-receptor of CTLs. 
 
 
Figure 23: Structure of HLA class-I molecules. [297] 
 
While the transporter associated with antigen processing (TAP) and TAPBP (TAP-associated 
glycoprotein or tapasin) genes are encoded in the MHC class II region, these genes are 
classified as class I-like. The TAP molecules (TAP-1 and TAP-2) are involved in the 
transport of cytosolic peptides to the endoplasmic reticulum (ER) for their binding to HLA 
class-I molecules [298]. TAP molecules also form part of the peptide-loading complex (PLC) 
(a complex comprising b2m, calreticulin, ERp57, TAP, tapasin, and MHC class I) which 
holds the MHC molecules until they have been fully loaded with peptides [299]. As stated 
previously, tapasin forms part of the PLC, and is involved in the interaction between MHC 
class I molecules and TAP. These genes are thus important for the successful antigen 
processing and presentation capabilities of the HLA class-I molecules (Figure 24).  
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Figure 24: The role of TAP in antigen processing and presentation on MHC class I molecules. 
[300] 
 
2.2.2 Major Histocompatibility Complex class II genes 
 
The MHC class II genes, also known as the HLA class-II genes, can be classified into major 
(HLA-DP, -DQ and -DR) and minor (HLA-DM, -DO) gene groups [287]. These molecules 
are expressed only on APCs and lymphocytes and present peptides derived from extracellular 
proteins [295]. HLA class-II presentation is thus referred to as the endocytic or exogenous 
pathway. The HLA class-II molecules mediate immunization to a specific antigen through 
their expression on professional APCs (macrophages, B cells and DCs) [301,302]. Upon 
infection, these APCs present antigens to CD4 T cells (helper T cells), thus mediating 
immunization to a specific antigen through stimulation of B cells to produce antibodies [303]. 
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Structurally, class-I and class-II molecules are similar in that they are both heterodimers. 
However, the class-II molecules consist of two homogenous peptides, an α and a β chain 
(Figure 25), which are both encoded by the HLA gene [287].  
 
 
Figure 25: Structure of HLA class-II molecules. [304] 
 
2.2.3 Major Histocompatibility Complex class III genes 
 
The MHC class III region is composed of genes encoding the complement system (C2, C4, 
factor B), inflammatory cytokines, TNF and heat shock proteins (HSPs), and has the highest 
gene density in the human genome [305]. Unlike the class I and class II regions, genes in 
class III are not involved in antigen processing and presentation [287]. These genes are also 
not structurally related to the class I and class II genes, with most genes playing a role in the 
immune response but not all. 
Genes of the complement system encode proteins that assist antibodies and phagocytic cells 
in the clearance of pathogens and are thus important in the activation and maintenance of the 
immune response [306]. HSPs are proteins that are activated when cells experience “heat 
shock” and are primarily involved in the folding and unfolding of other proteins [307,308]. 
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Hsp70 is one of the HSPs encoded in the MHC class III region, and is involved in the binding 
and presentation of antigens. The TNF family of proteins play an important role in T cell-
dependent immune responses and induction of the apoptotic pathway [309] and are thus an 
essential component of human disease. 
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3.1 Study Hypothesis 
 
Background: The leukocyte receptor complex comprises a number of genes which have been 
shown to regulate the immune response by various mechanisms. The KIR and LILR gene 
families within the LRC are known to have HLA class-I ligands. These form part of the 
MHC, another region in the genome comprising genes which are highly immune related. 
These regions could thus contain susceptibility factors for TB disease. 
 
1. Genes of the LRC have been shown to play an important role in the control of the 
immune response and as such could alter susceptibility to TB. 
2. Genes of the MHC which are essential to the host immune response could play a role 
in susceptibility to TB. 
3. Given the importance of the HLA class-I genes in immune defence and their 
population specificity, HLA types could interact with M. tuberculosis strain genotypes 
to influence susceptibility to specific strains. 
4. The HLA class-I alleles are highly population specific and could thus help to 
understand the ancestral genetic contributions to the highly admixed South African 
Coloured population and their role in disease susceptibility. 
 
Hypothesis: Genetic variation within the genes of the LRC and MHC complex could play a 
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3.2 Study Objectives 
 
1. To genotype the sixteen KIR genes for absence/presence and their association with 
susceptibility to TB. 
2. To genotype the HLA class-I genes and investigate their association with 
susceptibility to TB. 
3. To investigate the role of KIR/HLA compound genotypes in susceptibility to TB. 
4. To identify genes (polymorphisms) of the MHC and LRC as susceptibility factors for 
TB. 
5. To determine if specific HLA types are associated with susceptibility to specific M. 
tuberculosis strain genotypes. 
6. To identify novel HLA class-I alleles and KIR gene profiles in the South African 
Coloured and San populations. 
7. To study the genetic ancestry contributions to the South African Coloured population 
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Research has established TB as a multifactorial disease with host, pathogen and 
environmental factors all contributing to the development of active TB disease. To date, the 
focus of most research on understanding TB disease aetiology, progression and control has 
been on the pathogen, M. tuberculosis. The widespread use of antibiotics and the current 
failure of these therapeutic agents to halt further spread of the disease suggest that additional 
approaches are required to fight the disease. Only 5-10% of immunocompetent individuals 
develop active TB disease upon exposure to M. tuberculosis which suggests that the host 
immune response plays an important role in the outcome of this disease. In this regard, 
studying how the host genetic make-up differs between individuals who develop active TB 
and those who remain healthy could lead to the identification of genes/variants that could 
help explain this outcome. 
NK cells are known to play an important role in both innate and adaptive immune responses 
[310]. These cells are part of the early defence mechanisms employed when cells are 
experiencing various forms of stress, such as infections and malignant transformations, 
promoting the expression of cytokines and direct cytotoxicity [311] (Figure 26). To carry out 
their function, NK cells have various receptors on their surfaces, which allows for the cells to 
distinguish normal cells from allogeneic and autologous cells. The KIRs have been shown to 
be the primary receptors for this purpose, with LILRs and LAIRs also offering some 
functionality in this regard, as discussed in Chapter 2. As with cytotoxic T cells, NK cells 
mediate programmed cell death through the release of cytotoxic granules which penetrate the 
cell membrane of infected cells. For bacteria, NK cells secrete α-defensins, an antimicrobial 
which disrupts the bacterial cell wall.  
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Figure 26: Signalling pathway of NK cell mediated cytotoxicity, and the involvement of the KIR 
and HLA genes in this process. [312] 
 
T cells are important modulators of the host immune response and play a central role in cell-
mediated immunity, the primary immune response to M. tuberculosis infection [295,313]. T 
cells can be classified into several types; helper, cytotoxic, memory, regulatory and natural 
killer, based on their function [313]. In the context of this study, cytotoxic (CD8
+





 T cells) T cells are of interest, as they are MHC class I and class II 
restricted cell types [295]. CTLs are involved in the killing of infected cells [313], and 
recognise their target cells through antigen presentation of MHC class I molecules [314]. 
Memory T cells on the other hand are a subset of antigen-specific T cells that persist long-
term after an infection has been resolved [313]. Upon re-exposure to the specific antigen, 
these memory T cells expand into a large number of effector T cells, allowing for the immune 
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system to recognise antigens from past infections and facilitating stimulation of a faster 
immune response for subsequent infections. For M. tuberculosis infections, CD4
+
 T cells are 
known to be the main immune response mechanism to overcome the infection [315]. 
However, the role of CD8
+
 T cells in fighting M. tuberculosis infections is also important, 
with these cells having direct microbicidal activity through the expression of granulysin and 
perforin [316–318]. 
Given the importance of genes of the LRC and MHC regions in the host immune response (as 
discussed in Chapter 2), we investigated the relationship between genes and variants of these 
complexes and susceptibility to TB in the SAC population. 
4.2 Materials and Methods 
4.2.1 Study Participants 
4.2.1.1 Case-control samples 
 
The study participants of this study self-classified as being from the South African Coloured 
(SAC) population. This is officially recognized in South Africa as a census term, and used for 
self-classification. This population is highly admixed and has known genetic contributions 
from Black African, European, Khoisan and south and East Asian ancestries [319–321]. The 
mixing of these different ethnicities to form the SAC population could result in population 
substructure which could produce spurious (false positive/negative) association results due to 
different allele levels in the founder populations [164]. 
To test for stratification within the SAC population, 25 unlinked SNP markers were 
genotyped in this population, with no significant stratification detected between cases and 
controls (P = 0.26) [322]. While the use of admixed populations may require additional 
statistical analysis, they also offer the advantage of carrying a greater number of alleles 
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within members of the population, allowing for the investigation of disease markers in a 
single population [323]. 
The samples for this study were collected from the Ravensmead and Uitsig suburbs of the 
Western Cape province of South Africa, where approximately 98% of residents self-identify 
as SAC [320]. These suburbs have a very high TB incidence (1005 per 100 000 in 2007) 
[324] but low HIV prevalence (2%) [325,326], making individuals recruited from these 
suburbs perfect candidates for TB association studies. 
All study participants were unrelated. TB cases were individuals with bacteriologically 
confirmed (smear positive and/or culture positive) pulmonary TB. Controls were healthy 
individuals with no history of TB and who lived in the same community, with a minimum 
age of 17 for inclusion. All study participants were HIV negative. For characteristics of the 
case-control sample set, see Table 4. 
Table 4: Characteristics of the SAC case-control samples for TB association study. 
Characteristic Cases Controls 
Males: n (%) 195 (48%) 77 (22%) 
Females: n (%) 213 (52%) 274 (78%) 
Average age (years ±SD) 35 ±13.1 35 ±12.2 
Total 408 351 
SD – Standard deviation 
4.2.1.2 MHC and LRC data mining, Affymetrix 500K dataset 
4.2.1.2.1 SAC population samples 
 
For a description of the SAC population, see section 4.2.1.1. For characteristics of the SAC 
Affymetrix 500K sample set, see Table 5. 
Table 5: Characteristics of the SAC Affymetrix 500K samples. 
Characteristic Cases Controls 
Males: n (%) 361 (56%) 45 (49%) 
Females: n (%) 281 (44%) 46 (51%) 
Average age (years ±SD) 36.7 ±11.5 31.5 ±4.1 
Total 642 91 
SD – Standard deviation 
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4.2.1.2.2 Wellcome Trust Case Control Consortium (WTCCC) samples 
 
The WTCCC TB samples were collected from the Gambian population [197]. The Gambian 
population also has known population structure, with individuals who belong to this 
population self-identifying as Fula, Jola, Mandinka, Wolloff and Other. 
Gambian pulmonary TB cases were individuals with culture or smear positive TB. Controls 
were recruited from routine births at local health clinics. All individuals included were HIV 
negative. For characteristics of the WTCCC Affymetrix 500K sample set, see Table 6. 
Table 6: Characteristics of the WTCCC Affymetrix 500K samples. 
Characteristic Cases Controls 
Males: n (%) 592 (71%) 492 (48%) 
Females: n (%) 242 (29%) 526 (52%) 
Total 834 1018 
 
4.2.2 DNA extractions 
 
Ethics approval (Health Research Ethics Committee of Stellenbosch University, South 
Africa, Project registration number 95/072) and written informed consent from study 
participants were obtained before the collection of blood samples from individuals residing in 
the Ravensmead and Uitsig suburbs for the extraction of DNA. The DNA was extracted and 
purified using the Nucleon BACC Genomic DNA Extraction Kit (Illustra, Buckinghamshire, 
UK) following the manufacturer‟s instructions. 
After extraction, the NanoDrop
®
 ND-1000 Spectrophotometer and the NanoDrop
®
 v3.0.1 
software (Inqaba Biotechnology, Pretoria, SA) were used to determine the DNA 
concentration and purity. DNA working stock solutions were prepared at a concentration of 
50ng/μl and stored at -20°C. DNA was diluted in TE buffer. 
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4.2.3 KIR Genotyping 
 
The fourteen active KIR genes were genotyped for absence or presence using either the Real-
Time (RT) polymerase chain reaction (PCR) System or the gene-specific PCR-sequence 
specific primers (SSP) method. 
4.2.3.1 RT PCR Protocol 
 
KIR gene primers for this protocol are the proprietary property of the laboratory of Dr. Mary 
Carrington (Laboratory of Experimental Immunology, Frederick National Laboratory for 
Cancer Research, USA), and primer sequences were not shared. 
From 200μM primer stocks, working primer solutions were made in 5ml BD Falcon snap cap 
tubes (BD Biosciences, San Jose, USA) at the following concentrations: KIR3DS1 at 5μM 
per primer, KIR2DS1 at 1.25μM (forward primers) and 2.5μM (reverse primer), and all other 
KIR gene primers were at a final concentration of 2.5μM. 160μl of primer solutions was 
transferred to 96-well plates (Applied Biosystems, Foste City, USA), filling four columns of 
wells. These primer solutions were then transferred to 384-deep-well plates (Applied 
Biosystems), from which 1μl of primer was transferred to 384-well optical plates (Applied 
Biosystems) using the Hydra automated pipetting system (Thermo Fisher Scientific, Hudson, 
USA) (Figure 27). These primer plates were stored at -20°C for later use. 
To do the PCR a master mix for 35 reactions per DNA sample was made by adding 87.5μl 
Platinum SYBR Green qPCR Supermix-UDG with ROX (Invitrogen, Carlsbad, USA), 3.5μl 
of 50ng/μl DNA, and 49μl of water. 4μl of master mix was transferred to each well of the 
384-well primer plates. PCR cycling conditions were: 3 minutes at 94°C, 5 cycles of 15 
seconds at 94°C, 15 seconds at 65°C, 30 seconds at 72°C; followed by 21 cycles of 15 
seconds at 94°C, 15 seconds at 60°C, 30 seconds at 72°C; followed by 4 cycles of 15 seconds 
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at 94°C, 1 minute at 55°C, 2 minutes at 72°C, followed by an extension step of 7 minutes at 
72°C, and stopping the PCR reaction by holding at 4°C. 
 
Figure 27: Schematic representation of plate design for KIR typing. 
 
After completion of the PCR, the 384-well plates were analysed using the ABI 7900HT Fast 
Real-Time PCR System (Applied Biosystems) machine and the SDS v2.3 software (Applied 
Biosystems) package, where the dissociation curve (Figure 28) results were exported and 
saved to the Carrington KIR database. 
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Figure 28: Dissociation curves for KIR typing using Real-Time PCR. [327] 
 
For the KIR2DS4 gene we were not only interested in the absence/presence of the gene, but 
also the size of the gene fragment (197bp and/or 219bp). To determine the size of the 2DS4 
gene fragment the PCR product was not run on the ABI 7900HT Fast Real-Time PCR 
System (Applied Biosystems) machine but instead on the QIAxcel automated gel 
electrophoresis system using the QIAxcel ScreenGel Software (Qiagen, Valencia, USA). This 
automated electrophoresis system is able to accurately analyse fragments with resolutions up 
to 3-5bp and is much more efficient than conventional gel electrophoresis (Figure 29). 
 
Figure 29: Efficiency of QIAxcel system compared to conventional agarose gel electrophoresis. 
[328] 
 
4.2.3.2 Gene-Specific PCR-SSP Protocol 
 
SSP PCR is based on the design of primers which will or will not allow amplification, 
otherwise referred to as the 3‟-mismatch principle [329]. As with the RT PCR protocol 
described above, 384-well primer plates were made by dispensing 1μl (5μM) of a primer pair 
into each well. Each KIR gene had two sets of primers, aligning to two different regions of 
the gene (Table 7), allowing for the genotyping of 12 samples per 384-well plate. In addition, 
primers binding to the intron 3 region of HLA-DRB1 were used as a positive control. 
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Table 7: List of primer sequences used for KIR typing by the PCR-SSP method. 
Name Sequence (5’ – 3’) Exon Size (bp) 
2DL1F1 GTTGGTCAGATGTCATGTTTGAA 4 
146 
2DL1R1 GGTCCCTGCCAGGTCTTGCG 4 
2DL1F2 TGGACCAAGAGTCTGCAGGA 8 
330 
2DL1R2 TGTTGTCTCCCTAGAAGACG 3’UTR 
    
2DL2F1 CTGGCCCACCCAGGTCG 4 
173 
2DL2R1 GGACCGATGGAGAAGTTGGCT 4 
2DL2F2 GAGGGGGAGGCCCATGAAT 5 
151 
2DL2R2 TCGAGTTTGACCACTCGTAT 5 
    
2DL3F1 CTTCATCGCTGGTGCTG 7 
550 
2DL3R1 AGGCTCTTGGTCCATTACAA 8 
2DL3F2 TCCTTCATCGCTGGTGCTG 7 
800 
2DL3R2 GGCAGGAGACAACTTTGGATCA 9 
    
2DL4F1 CAGGACAAGCCCTTCTGC 3 
254 
2DL4R1 CTGGGTGCCGACCACT 3 
2DL4F2 ACCTTCGCTTACAGCCCG 5 
288 
2DL4R2 CCTCACCTGTGACAGAAACAG 5 
    
2DL5F1 GCGCTGTGGTGCCTCG 3 
214 
2DL5R1 GACCACTCAATGGGGGAGC 3 
2DL5F2 TGCAGCTCCAGGAGCTCA 5 
191 
2DL5R2 GGGTCTGACCACTCATAGGGT 5 
    
2DS1F1 CTTCTCCATCAGTCGCATGAA 4 
102 2DS1F2 CTTCTCCATCAGTCGCATGAG 4 
2DS1R1 AGAGGGTCACTGGGAGCTGAC 4 
    
2DS2F1 TTCTGCACAGAGAGGGGAAGTA  4 
175 
2DS2R1 GGGTCACTGGGAGCTGACAA 4 
2DS2F2 CGGGCCCCACGGTTT 5 
240 
2DS2R2 GGTCACTCGAGTTTGACCACTCA 5 
    
2DS3F1 TGGCCCACCCAGGTCG  4 
242 
2DS3R1 TGAAAACTGATAGGGGGAGTGAGG 4 
2DS3F2 CTATGACATGTACCATCTATCCAC 5 
190 
2DS3R2 AAGCAGTGGGTCACTTGAC 5 
    
2DS4F1 CTGGCCCTCCCAGGTCA  4 
204 
2DS4R1 TCTGTAGGTTCCTGCAAGGACAG 4 
2DS4F2 GTTCAGGCAGGAGAGAAT 5 
197/219 
2DS4R2 GTTTGACCACTCGTAGGGAGC 5 
    
2DS5F1 TGATGGGGTCTCCAAGGG 4 
126 
2DS5R1 TCCAGAGGGTCACTGGGC 4 
2DS5F2 ACAGAGAGGGGACGTTTAACC 4 
178 
2DS5R2 ATGTCCAGAGGGTCACTGGG 4 
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Name Sequence (5’ – 3’) Exon Size (bp) 
    
3DL1F1 CGCTGTGGTGCCTCGA  3 
191 
3DL1R1 GGTGTGAACCCCGACATG 3 
3DL1F2 CCCTGGTGAAATCAGGAGAGAG 4 
186 
3DL1R2 TGTAGGTCCCTGCAAGGGCAA 4 
    
3DL2F1 CAAACCCTTCCTGTCTGCCC 3 
211 
3DL2R1 GTGCCGACCACCCAGTGA 3 
3DL2F2 CCCATGAACGTAGGCTCCG 5 
130 
3DL2R2 CACACGCAGGGCAGGG 5 
    
3DL3F1 GTCAGGACAAGCCCTTCCTC 3 
232 
3DL3R1 GAGTGTGGGTGTGAACTGCA 3 
3DL3F2 TTCTGCACAGAGAGGGGATCA 4 
165 
3DL3R2 GAGCCGACAACTCATAGGGTA 4 
    
3DS1F1 AGCCTGCAGGGAACAGAAG 8 
300 
3DS1R1 GCCTGACTGTGGTGCTCG 3’ UTR 
3DS1F2 CCTGGTGAAATCAGGAGAGAG 4 
180 
3DS1R2 GTCCCTGCAAGGGCAC 4 
    
2DP1F1 GTCTGCCTGGCCCAGCT 3 
205 
2DP1R1 GTGTGAACCCCGACATCTGTAC 3 
2DP1F2 CCATCGGTCCCATGATGG 4 
89 
2DP1R2 CACTGGGAGCTGACAACTGATG 4 
    
DRB1F1 TGCCAAGTGGAGCACCCAA Intron3 
796 
DRB1R1 GCATCTTGCTCTGTGCAGAT Intron 3 
bp – base pair 
UTR – untranslated region 
 
 
PCR cocktails were made for each sample in a total volume of 132μl by combining 4μl 
(50ng/μl) of DNA, 16.5μl of 10X PCR Buffer (Invitrogen), 4.95μl of MgCl2 (final 
concentration of 1.5mM) (Invitrogen), 1.32μl of dNTPs (final concentration of 200mM) 
(Bioline, London, UK), 0.825μl of Platinum
®
 Taq polymerase (Invitrogen), and 104.41μl of 
water. 4μl of the PCR cocktail was added to each well for a total PCR volume of 5μl. For 
PCR cycling conditions, see section 4.2.3.1. 
All PCR reactions were electrophoresed on a 3% agarose gel at 100V for 30 minutes, except 
for KIR2DS4 amplicons, which were run at 100V for 1 hour. Gels were stained with 
ethidium bromide (Sigma-Aldrich, Missouri, USA), and 100bp DNA ladder (Promega, 
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Wisconsin, USA) was loaded to confirm the size of the amplified products. DNA ladder and 
PCR amplicons were loaded together with 1X Blue/Orange Loading Dye (Promega). Gel 
visualization and image capturing was done using the G-Box (Syngene, Cambridge, UK). 
4.2.3.3 KIR Haplotypes 
 
The KIR genes present in an individual were grouped together and characterized into a 
genotype (KIR gene profile). These genotypes were then classified into haplotypes based on 
the model of Hsu et al. [229]. Briefly, genotypes were assigned to haplotypes based on the 
following assumptions: 1) all haplotypes contained the 3DL3, 2DL4 and 3DL2 framework 
genes; 2) haplotypes contained either 2DL2 or 2DL3, but not both; 3) haplotypes contained 
either 3DP1 or 3DP1 variant (3DP1v) but not both. Haplotypes were then classified into 
either A or B, where group B haplotypes were defined as having one or more of the following 
genes present: 2DL5, 2DS1, 2DS2, 2DS3, 2DS5, and 3DS1 [330]. Conversely, group A 
haplotypes were defined based on the absence of all group B genes. 
4.2.4 HLA Genotyping 
 
HLA class-I typing was done using the direct-sequencing technique and in the case of 
ambiguous allele calling, the SSP typing protocol was used. All HLA primers used in this 
study are the proprietary property of the lab of Dr. Mary Carrington (Laboratory of 
Experimental Immunology, Frederick National Laboratory for Cancer Research, USA), and 
primer sequences were not shared. 
4.2.4.1 Direct-sequencing protocol 
 
To determine the alleles of the HLA-A, -B and -C genes, exons 2 and 3 of each gene were 
sequenced. Firstly, a PCR reaction was set up by adding 5.7μl of water, 2μl 5X Buffer A 
(Invitrogen), 0.2μl of 10mM dNTPs (Bioline), 0.2μl of 25mM MgCl2 (Invitrogen), 0.2μl of 
10μM forward primer, 0.2μl of 10μM reverse primer, 0.5μl of DMSO, 0.05μl of AmpliTaq 
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Gold (Invitrogen) (HLA-A and -B) / KAPA2G Robust DNA Polymerase (Kapa Biosystems, 
Woburn, USA) (HLA-C), and 1μl of 50ng/μl DNA for a total reaction volume of 10μl. 
Stepdown PCR cycling conditions were used, for HLA-A and -B: 3 minutes at 95°C, 
followed by 5 cycles of 15 seconds at 95°C, 15 seconds at 62°C, 1 minute at 72°C; followed 
by 26 cycles of 15 seconds at 95°C, 15 seconds at 58°C, 1 minute at 72°C; followed by 4 
cycles of 15 seconds at 95°C, 1 minute at 55°C, 2 minutes at 72°C, followed by an extension 
step of 7 minutes at 72°C, and stopping the PCR reaction by holding at 4°C. For HLA-C, the 
cycling conditions were as follows: 3 minutes at 95°C, followed by 5 cycles of 15 seconds at 
95°C, 15 seconds at 70°C, 1 minute at 72°C; followed by 26 cycles of 15 seconds at 95°C, 15 
seconds at 60°C, 1 minute at 72°C; followed by 4 cycles of 15 seconds at 95°C, 1 minute at 
55°C, 2 minutes at 72°C, followed by an extension step of 7 minutes at 72°C, and stopping 
the PCR reaction by holding at 4°C. 
After the PCR, the amplified fragments were electrophoresed on a 2% agarose gel stained 
with GelRed Nucleic Acid stain (Phenix Research Products, Candler, USA). PCR products 
and 100bp ladder (Promega) was loaded into wells with Orange G loading dye (New England 
Biolabs, Ipswich, USA), and allowed to run for 30 minutes at 100V. Gel visualization and 
image capturing were done using the G-Box (Syngene). 
DNA samples that were successfully amplified were subjected to PCR clean-up using the 
Agencourt AMPure XP (Beckman Coulter, Indianapolis, USA) and Biomek® FX P 
laboratory automation workstation (Beckman Coulter) automated PCR purification system. 
After PCR clean-up the DNA samples were set-up for sequencing reactions using primers 
that bind to the intron 2 and 3 regions of each HLA class-I gene to determine the genomic 
sequence of exons 2 and 3 of each gene. For sequencing of these genes the BigDye
®
 
Terminator v3.1 Cycle Sequencing kit (Invitrogen) was used. In a total volume of 10μl the 
following components were added: 5.675μl of water, 1.875μl of 5X BigDye
®
 Buffer 
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(Invitrogen), 0.25μl of BigDye
®
 Ready Reaction Mix (Invitrogen), 0.2μl of 10μM primer, 
and 2μl of DNA (post-PCR cleaned-up). The cycling conditions used for the PCR reaction 
were as follows: 1 minute at 95°C; followed by 25 cycles of 10 seconds at 95°C, 5 seconds at 
50°C, 4 minutes at 60°C; followed by a 4°C holding temperature to stop the reaction.  
 
Following the sequencing reactions the samples were read using the 3730xl DNA Analyzer 
(Applied Biosystems). The Assign
™
 SBT 3.5.1 software package (Conexio Genomics, 
Fremantle, Australia) was used for quality control (QC) and calling of the class-I alleles. 
4.2.4.2 SSP typing protocol 
 
In the event that the sequencing-based typing (SBT) approach resulted in the calling of 
ambiguous and/or uncertain alleles (e.g. the Assign software is unable to call only one type of 
HLA allele for the respective gene or an allele is called that is extremely rare or would not be 
expected in a given population) these samples were re-typed using the PCR-SSP protocol. 
Primers used in this instance were specific to a given allele, for example, the A*68:27 allele 
is extremely rare and to date has only been identified in Black individuals from South Africa. 
To confirm that this allele was indeed present in the SAC population, SSP primers for A*69 
were used to re-type samples called for this allele. Also, in some instances the Assign 
software was unable to distinguish between the A*02:02 and A*02:05 allele, and these 
samples were re-typed using SSP primers for A*02. All ambiguous and uncertain alleles were 
correctly called after SSP typing. 
PCR and sequencing conditions were as described in section 4.2.4.1. 
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4.2.5 Statistical Analysis 
4.2.5.1 KIR and HLA with TB susceptibility analysis 
 
Hardy-Weinberg equilibrium (HWE) was assessed in TB case and control groups for all 
genetic variants using the exact test [331]. Logistic regression model analysis was used to 
compare TB cases and controls by calculating p-values, odds ratios (ORs) and 95% 
confidence intervals (CIs), adjusting for age and sex.  
A result or effect was described as significant if the p-value < 0.05. Bonferroni correction for 
multiple testing was not used, as this method is considered to be over-conservative when 
several genetic associations are tested in the same group of individuals [332], resulting in the 
potential rejection of important findings. Bonferroni correction might also be inappropriate in 
a situation such as this where there is a priori evidence that the genes are associated with TB 
[333], while Bayesian methods for correction rely on knowledge of prior probability of 
involvement, which is currently unknown for most genetic variants [334]. All analyses were 
done in R (freely available from www.r-project.org) using functions from base R and R 
packages genetics and haplo.stats. 
KIR gene and HLA allele and genotype frequencies was calculated by direct counting. 
Associations between KIRs, HLAs and KIR/HLA compound genotypes (based on receptor-
ligand relationships or other functional links) with TB disease were determined. The HLA 
haplotypes were inferred, with their probabilities of being correct, and haplotypes were used 
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4.2.5.2 MHC and LRC data mining analysis 
4.2.5.2.1 Quality Control 
 
The use of microarray data may result in incorrect statistical analysis if low quality data is 
present. In this regard, performing QC parameters on the data to filter out low quality 
samples and SNPs is important. However, the unnecessary removal of data needs to be 
guarded against as it may lead to loss of power. Several checks were performed on the SAC 
and WTCCC 500K Affymetrix data, as recommended [336–339]. These checks were 
performed in a sequential manner; if a sample/SNP was removed then it was not present in 
the dataset for subsequent checks.  Analysis was done using the PLINK open-source whole 
genome association analysis toolset [340]. 
For the SAC and WTCCC datasets the “Calling” and “Frequency Filters” checks were 
applicable. The SNP calling for the SAC data was previously done [320] and resulted in 
several samples and SNPs being discarded. To determine the accuracy of the SNP calling we 
compared the called genotypes of 9 HapMap samples with their known genotypes, the 
accuracy of which was >99%. The SAC dataset also contained 4 duplicate samples, with 
concordance between sample SNP calling >97%. The WTCCC dataset consisted of genotype 
calls for 500 568 SNPs and a probability of correctness for each SNP call. However, since 
Affymetrix CEL files were not provided, we were unable to determine the accuracy of the 
calling using the algorithms described by Ziegler et al. [338]. In this instance, we used the 
probability of correctness scores provided, where PLINK would set the genotype to missing 
if the probability of correctness was <95%. 
Frequency filters allow for the removal of samples and SNPs with high missing rates. This is 
important since a high rate of missing SNP data could be due to genotyping quality problems; 
especially since failure to call a SNP is often non-random [339]. There are several 
recommendations for the missing rate at which samples should be removed, e.g. Laurie et al. 
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recommends a 2% missing rate while Ziegler et al. and the WTCCC recommends a 3% 
missing rate [338,341]. In some instances Ziegler et al. state that the missing rate may be 
raised to 10% before samples are removed [338]. However, in the SAC and WTCCC 
datasets, the 2% and 3% thresholds would be too stringent, resulting in the removal of too 
many samples (SAC: 173 and 99 samples respectively and WTCCC: 1915 and 968 samples 
respectively). A threshold of 5% was therefore set for these sample sets. For SNPs a missing 
rate threshold and minor allele frequency (MAF) of 1-5% are commonly recommended 
[337,339,341]. For the SAC and WTCCC datasets the least stringent thresholds were used, 
SNPs with a missing rate > 5% and a MAF < 1% were removed. HWE p-values should also 
be taken into consideration when filtering SNPs, as any deviations from HWE (in control 
samples) may indicate genotyping errors. There is however no consensus on the HWE p-
value at which SNPs should be removed, with the following recommendations: Laurie et al. 
at P < 1x10
-6
 [339], the WTCCC at P ≤ 5.7x10
-7
 [341], and Miyagawa et al. and Ziegler et al. 
at P < 1x10
-4
 [337,338]. As P < 1x10
-4
 was the most stringent p-value but only resulted in the 
removal of 528 SNPs (0.1%) in the SAC dataset and 15 759 SNPs (3%) in the WTCCC 
dataset, this threshold was used. 
4.2.5.2.2 Association analysis 
 
The Affymetrix 500K MHC and LRC SNP data was analysed using logistic regression with 
an additive genetic model. Models were adjusted for sex and admixture in both population 
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4.3 Results 
4.3.1 KIR and TB case-control associations 
 
The genotyping success rate for the KIR genes and the 2DS4 gene fragment was 99% and 
94%, respectively. Of the 15 KIR genes typed, the frequencies (f) of all genes, except 3DS1, 
were similar between TB cases and controls (Table 8). The 3DS1 gene was found at a higher 
frequency in controls and was significantly associated with protection from TB in the SAC 
population, where the presence of the gene lowered the odds of developing TB (OR = 0.65). 
The 2DS4 gene 22bp deletion was not found to be associated with TB susceptibility in the 
SAC population (Table 9). 
Table 8: Case-control association data for absence/presence of KIR genes and susceptibility to 
TB in the SAC population. 
KIR gene 
TB cases with gene Controls with gene 
Padj
* OR [95% CI]# 
Present (f) Absent (f) Present (f) Absent (f) 
2DL1 390 (0.97) 12 (0.03) 340 (0.98) 7 (0.02) 0.399  
2DL2 281 (0.70) 121 (0.30) 232 (0.67) 115 (0.33) 0.373  
2DL3 302 (0.75) 100 (0.25) 269 (0.78) 78 (0.22) 0.683  
2DL4 400 (0.99) 2 (0.01) 345 (0.99) 2 (0.01) 0.976  
2DL5 280 (0.70) 122 (0.30) 236 (0.68) 111 (0.32) 0.514  
2DS1 138 (0.34) 264 (0.66) 123 (0.35) 224 (0.65) 0.598  
2DS2 274 (0.68) 128 (0.32) 231 (0.67) 116 (0.33) 0.620  
2DS3 111 (0.28) 291 (0.72) 97 (0.28) 250 (0.72) 0.618  
2DS4 386 (0.96) 14 (0.04) 330 (0.95) 17 (0.05) 0.507  
2DS5 219 (0.54) 183 (0.46) 188 (0.54) 159 (0.46) 0.846  
2DP1 385 (0.96) 17 (0.04) 338 (0.97) 9 (0.03) 0.337  
3DL1 388 (0.97) 14 (0.03) 339 (0.98) 8 (0.02) 0.397  
3DL2 402 (1) 0 (0) 347 (1) 0 (0) -  
3DL3 402 (1) 0 (0) 347 (1) 0 (0) -  
3DS1 94 (0.23) 308 (0.77) 105 (0.30) 242 (0.70) 0.014 0.65 [0.46-0.92] 
*P-value adjusted for sex. 
# Odds Ratio [95% Confidence Interval], the odds of having TB vs. no TB, for the absence/presence of the KIR gene. 
 
 
Table 9: Case-control association data for the KIR2DS4 gene fragment and susceptibility to TB 
in the SAC population. 
 
TB cases Controls 
Padj
* 
197/197 (f) 197/219 (f) 219/219 (f) 197/197 (f) 197/219 (f) 219/219 (f) 
2DS4 100 (0.26) 105 (0.27) 181 (0.47) 96 (0.29) 100 (0.30) 134 (0.41) 0.125 
*P-value adjusted for sex. 
#Individuals not heterozygous were classified as homozygous for the size fragment genotyped. 
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For the KIR genotypes (gene profiles), 64 distinct genotypes were identified in the 745 SAC 
individuals (Table 10). Of the 64 KIR genotypes, 36 occurred at a frequency < 0.01 and were 
not analysed, while the A1 genotype was the most common (f = 0.20). Of the remaining 28 
KIR genotypes, most were found at similar frequencies between the two groups and were not 
associated with susceptibility to TB. There were however 2 genotypes, B24 and B57, that 
were significantly associated with susceptibility to TB in the SAC population. The B24 
genotype was present only in TB cases while the B57 genotype was more common in TB 
cases than controls and increased the risk of developing TB with an OR of 2.38. 
Of the 64 KIR genotypes, 3 had group A haplotype-like gene profiles and 61 had group B 
haplotype-like gene profiles, with 20 genotypes (in 33 individuals) not being classified into a 
haplotype group as they failed to meet the assumptions of the Hsu et al. model for haplotype 
classification [229] (Table 10). There were 409 individuals with a haplotype classification 
(frequency > 0.01), 150 with haplotype A and 259 with haplotype B. Both haplotype groups 
occurred at similar frequencies in TB cases and controls (Table 11) and were not associated 
with susceptibility to TB in the SAC population. 
When analysing the KIR genes by number of activating or inhibitory genes present, 
individuals with 5 or more aKIR genes were found to have a lower risk of developing TB, 
with an OR of 0.67 (Table 12). Comparisons for each group type were done by comparing 
individuals who had the group versus those who did not. All other KIR gene categories were 
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 3DL1 2DL1 2DL3 2DS4 2DL2 2DL5 3DS1 2DS1 2DS2 2DS3 2DS5 2DL4 3DL2 3DL3 2DP1 Cases (f) Controls (f) Padj
†
 OR [95% CI]
‡
 
A1 AA                               80 (0.20) 69 (0.20) 0.958   
A2 AA                               1 (0.00) 0 (0.00)     
A3                                 3 (0.01) 4 (0.01) 0.625   
B1 Bx                               0 (0.00) 1 (0.00)     
B2 Bx                               1 (0.00) 1 (0.00)     
B3 Bx                               1 (0.00) 1 (0.00)     
B4 Bx                               3 (0.01) 6 (0.02) 0.399   
B5 Bx                               0 (0.00) 3 (0.01)     
B6 Bx                               1 (0.00) 0 (0.00)     
B7 Bx                               1 (0.00) 1 (0.00)     
B8 Bx                               23 (0.06) 20 (0.06) 0.999   
B9 Bx                               1 (0.00) 0 (0.00)     
B10 Bx                               1 (0.00) 0 (0.00)     
B11 Bx                               1 (0.00) 2 (0.01)     
B12 Bx                               1 (0.00) 4 (0.01) 0.094   
B13 Bx                               4 (0.01) 1 (0.00) 0.478   
B14 Bx                               3 (0.01) 3 (0.01) 0.519   
B15 Bx                               5 (0.01) 2 (0.01) 0.272   
B16 Bx                               0 (0.00) 1 (0.00)     
B17 Bx                               2 (0.01) 0 (0.00)     
B18 Bx                               3 (0.01) 0 (0.00)     
B19 Bx                               0 (0.00) 2 (0.01)     
B20 Bx                               1 (0.00) 0 (0.00)     
B21 Bx                               1 (0.00) 0 (0.00)     
B22 Bx                               1 (0.00) 3 (0.01) 0.165   
B23 Bx                               27 (0.07) 21 (0.06) 0.575   
B24 Bx                               6 (0.02) 0 (0.00) 0.003 Only in cases 
B25 Bx                               0 (0.00) 1 (0.00)     
B26 Bx                               2 (0.01) 4 (0.01) 0.442   
B27 Bx                               0 (0.00) 1 (0.00)     
B28 Bx                               10 (0.03) 8 (0.02) 0.719   
B29 Bx                               1 (0.00) 1 (0.00)     
B30 Bx                               11 (0.03) 11 (0.03) 0.439   
B31 Bx                               6 (0.02) 2 (0.01) 0.207   
B32 Bx                               4 (0.01) 2 (0.01) 0.639   
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 3DL1 2DL1 2DL3 2DS4 2DL2 2DL5 3DS1 2DS1 2DS2 2DS3 2DS5 2DL4 3DL2 3DL3 2DP1 Cases (f) Controls (f) Padj
†
 OR [95% CI]
‡
 
B33 Bx                               1 (0.00) 0 (0.00)     
B34 Bx                               2 (0.01) 1 (0.00)     
B35 Bx                               1 (0.00) 2 (0.01)     
B36 Bx                               9 (0.02) 10 (0.03) 0.303   
B37 Bx                               0 (0.00) 1 (0.00)     
B38                                 0 (0.00) 1 (0.00)     
B39 Bx                               2 (0.01) 1 (0.00)     
B40 Bx                               1 (0.00) 0 (0.00)     
B41                                 4 (0.01) 2 (0.01) 0.639   
B42                                 0 (0.00) 2 (0.01)     
B43                                 0 (0.00) 2 (0.01)     
B44 Bx                               0 (0.00) 2 (0.01)     
B45                                 31 (0.08) 18 (0.05) 0.082   
B46                                 2 (0.01) 2 (0.01) 0.976   
B47 Bx                               0 (0.00) 1 (0.00)     
B48                                 0 (0.00) 1 (0.00)     
B49                                 4 (0.01) 4 (0.01) 0.873   
B50                                 7 (0.02) 8 (0.02) 0.253   
B51                                 1 (0.00) 0 (0.00)     
B52                                 11 (0.03) 17 (0.05) 0.082   
B53 Bx                               1 (0.00) 1 (0.00)     
B54                                 1 (0.00) 0 (0.00)     
B55                                 43 (0.11) 35 (0.10) 0.639   
B56                                 3 (0.01) 1 (0.00) 0.452   
B57                                 26 (0.07) 11 (0.03) 0.017 2.38 [1.16-5.18] 
B58                                 10 (0.03) 15 (0.04) 0.222   
B59                                 1 (0.00) 1 (0.00)     
B60                                 1 (0.00) 0 (0.00)     
B61                                 33 (0.08) 31 (0.09) 0.536   
*Genotypes (gene profiles) are the combination of KIR genes present in an individual. 
#KIR haplotypes, as described by Hsu et al. [229]. 
†P-value adjusted for sex. 
‡ Odds Ratio [95% Confidence Interval], the odds of having TB vs. no TB, for a given KIR genotype.
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Table 11: Case-control association data for KIR haplotypes and susceptibility to TB in the SAC 
population. 
Haplotype No. of TB cases (f) No. of controls (f) Padj
* 
A 81 (0.37) 69 (0.36) 
0.762 
B 138 (0.63) 121 (0.64) 
*P-value adjusted for sex. 
 
 
Table 12: Case-control association data for number of activating/inhibitory KIR genes and 
susceptibility to TB in the SAC population. 
No. of KIR genes No. of TB cases (f) No. of controls (f) Padj
* OR [95% CI]# 
1 activating KIR 84 (0.21) 73 (0.21) 0.991  
2-4 activating KIRs 255 (0.64) 205 (0.60) 0.121  
≥5 activating KIRs 61 (0.15) 67 (0.19) 0.046 0.67 [0.45-0.99] 
≤6 inhibitory KIRs 101 (0.25) 82 (0.24) 0.659  
7 inhibitory KIRs 159 (0.40) 146 (0.42) 0.267  
8 inhibitory KIRs 140 (0.35) 117 (0.34) 0.456  
*P-value adjusted for sex. 
# Odds Ratio [95% Confidence Interval], the odds of having TB vs. no TB, for the number of activating/inhibitory KIR genes. 
 
4.3.2 HLA class-I and TB case-control associations 
 
All alleles were tested for HWE, separately in cases and controls, with no deviation from 
HWE detected (all six HWE p-values = 1). 
In the SAC population, 47 (HLA-A), 77 (HLA-B) and 30 alleles (HLA-C) were detected. 
Analyses were performed only on alleles with a joint frequency > 0.05%. The genotyping 
success rate for HLA-A, -B and -C was 83.2%, 78.6% and 90.4%, respectively. Several 
statistically significant associations were identified with the class-I alleles and susceptibility 
to TB (Table 13). The class-I alleles: A*74:01, B*57:01, B*42:02, B*39:01, C*12:03 and 
C*05:01 were found to be protective against developing TB, lowering the odds of having TB 
with ORs ranging between 0.16 and 0.44. Conversely, the class-I alleles: A*24:07, B*57:03, 
C*18:01 and C*03:02 were found to increase the risk of developing TB with ORs ranging 
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Table 13: Case-control association data for HLA class-I alleles and susceptibility to TB in the 
SAC population. 
HLA Number of TB cases (f) Number of Controls (f) Padj
* OR [95% CI]# 
HLA-A  
A*03:01 53 (0.07) 51 (0.07) 0.946  
A*02:01 46 (0.06) 57 (0.08) 0.596  
A*24:02 44 (0.06) 56 (0.08) 0.124  
A*01:01 44 (0.06) 57 (0.08) 0.274  
A*23:01 48 (0.07) 45 (0.06) 0.630  
A*11:01 44 (0.06) 38 (0.05) 0.357  
A*30:02 38 (0.05) 38 (0.05) 0.948  
A*30:01 40 (0.06) 35 (0.05) 0.421  
A*43:01 35 (0.05) 27 (0.04) 0.291  
A*32:01 31 (0.04) 26 (0.04) 0.414  
A*30:04 32 (0.05) 25 (0.03) 0.260  
A*68:02 28 (0.04) 25 (0.03) 0.824  
A*68:01 21 (0.03) 24 (0.03) 0.699  
A*26:01 16 (0.02) 26 (0.04) 0.077  
A*02:05 22 (0.03) 16 (0.02) 0.287  
A*74:01 10 (0.01) 25 (0.03) 0.013 0.39 (0.17-0.83) 
A*29:01 18 (0.03) 16 (0.02) 0.498  
A*33:03 16 (0.02) 16 (0.02) 0.664  
A*34:02 12 (0.02) 17 (0.02) 0.543  
A*02:02 12 (0.02) 13 (0.02) 0.763  
A*29:02 9 (0.01) 14 (0.02) 0.247  
A*24:07 17 (0.02) 5 (0.01) 0.003 4.27 (1.63-13.29) 
A*66:01 8 (0.01) 9 (0.01) 0.775  
A*01:23 9 (0.01) 8 (0.01) 0.636  
A*02:11 9 (0.01) 7 (0.01) 0.478  
A*31:01 4 (0.01) 8 (0.01) 0.349  
A*02:03 5 (0.01) 7 (0.01) 0.521  
A*68:27 6 (0.01) 4 (0.01) 0.416  
A*36:01 7 (0.01) 2 (0) 0.120  
A*33:01 4 (0.01) 4 (0.01) 0.877  
A*25:01 2 (0) 6 (0.01) 0.097  
A*80:01 2 (0) 3 (0) 0.834  
A*26:12 2 (0) 3 (0) 0.837  
A*02:14 1 (0) 4 (0.01) 0.234  
A*34:01 2 (0) 2 (0) 0.896  
A*24:17 1 (0) 2 (0) 0.836  
A*02:06 1 (0) 3 (0) 0.511  
A*24:03 2 (0) 1 (0) 0.496  
HLA-B  
B*44:03 53 (0.07) 60 (0.09) 0.270  
B*58:02 54 (0.08) 37 (0.06) 0.167  
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 68 
 
HLA Number of TB cases (f) Number of Controls (f) Padj
* OR [95% CI]# 
B*08:01 41 (0.06) 39 (0.06) 0.766  
B*07:02 44 (0.06) 36 (0.05) 0.563  
B*15:03 42 (0.06) 32 (0.05) 0.281  
B*58:01 36 (0.05) 26 (0.04) 0.257  
B*18:01 34 (0.05) 27 (0.04) 0.450  
B*15:10 26 (0.04) 23 (0.03) 0.644  
B*45:01 22 (0.03) 17 (0.03) 0.907  
B*41:01 17 (0.02) 21 (0.03) 0.518  
B*42:01 23 (0.03) 14 (0.02) 0.132  
B*35:01 15 (0.02) 19 (0.03) 0.361  
B*51:01 16 (0.02) 14 (0.02) 0.945  
B*13:02 10 (0.01) 15 (0.02) 0.426  
B*07:05 13 (0.02) 12 (0.02) 0.925  
B*40:01 12 (0.02) 12 (0.02) 0.930  
B*27:05 14 (0.02) 10 (0.02) 0.378  
B*47:01 8 (0.01) 15 (0.02) 0.070  
B*15:01 14 (0.02) 9 (0.01) 0.356  
B*14:01 12 (0.02) 11 (0.02) 0.819  
B*40:06 9 (0.01) 13 (0.02) 0.167  
B*15:02 10 (0.01) 12 (0.02) 0.702  
B*57:03 15 (0.02) 6 (0.01) 0.034 2.75 (1.08-7.93) 
B*52:01 10 (0.01) 10 (0.02) 0.943  
B*35:05 11 (0.02) 9 (0.01) 0.569  
B*14:02 11 (0.02) 9 (0.01) 0.890  
B*57:01 5 (0.01) 14 (0.02) 0.029 0.35 (0.11-0.90) 
B*81:01 12 (0.02) 6 (0.01) 0.338  
B*53:01 11 (0.02) 7 (0.01) 0.271  
B*42:02 3 (0) 15 (0.02) 0.001 0.16 (0.04-0.51) 
B*35:03 5 (0.01) 12 (0.02) 0.078  
B*44:02 4 (0.01) 11 (0.02) 0.109  
B*57:02 7 (0.01) 4 (0.01) 0.913  
B*39:10 8 (0.01) 3 (0) 0.141  
B*41:02 3 (0) 7 (0.01) 0.368  
B*37:01 4 (0.01) 6 (0.01) 0.453  
B*15:21 5 (0.01) 5 (0.01) 0.987  
B*15:13 4 (0.01) 6 (0.01) 0.535  
B*50:01 6 (0.01) 3 (0) 0.321  
B*39:01 2 (0) 7 (0.01) 0.019 0.17 (0.03-0.76) 
B*13:03 4 (0.01) 4 (0.01) 0.777  
B*55:01 4 (0.01) 3 (0) 0.840  
B*40:02 3 (0) 3 (0) 0.845  
B*38:02 2 (0) 4 (0.01) 0.496  
B*27:06 4 (0.01) 2 (0) 0.397  
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HLA Number of TB cases (f) Number of Controls (f) Padj
* OR [95% CI]# 
B*15:16 3 (0) 3 (0) 0.842  
B*38:01 1 (0) 4 (0.01) 0.202  
B*35:02 4 (0.01) 1 (0) 0.273  
HLA-C  
C*06:02 118 (0.16) 135 (0.17) 0.249  
C*04:01 95 (0.13) 106 (0.13) 0.797  
C*07:01 92 (0.12) 93 (0.12) 0.706  
C*17:01 49 (0.06) 65 (0.08) 0.492  
C*07:02 56 (0.07) 47 (0.06) 0.282  
C*02:10 58 (0.08) 44 (0.05) 0.072  
C*03:04 34 (0.05) 29 (0.04) 0.250  
C*16:01 34 (0.05) 26 (0.03) 0.318  
C*18:01 31 (0.04) 19 (0.02) 0.033 1.89 (1.05-3.48) 
C*07:04 20 (0.03) 22 (0.03) 0.643  
C*02:02 20 (0.03) 21 (0.03) 0.838  
C*08:01 13 (0.02) 26 (0.03) 0.154  
C*12:03 12 (0.02) 25 (0.03) 0.021 0.44 (0.20-0.88) 
C*08:02 14 (0.02) 19 (0.02) 0.224  
C*08:04 18 (0.02) 16 (0.02) 0.378  
C*15:02 13 (0.02) 16 (0.02) 0.328  
C*12:02 10 (0.01) 15 (0.02) 0.531  
C*03:02 16 (0.02) 8 (0.01) 0.047 2.38 (1.01-6.04) 
C*14:02 8 (0.01) 14 (0.02) 0.403  
C*15:05 8 (0.01) 11 (0.01) 0.661  
C*01:02 7 (0.01) 12 (0.01) 0.305  
C*05:01 4 (0.01) 14 (0.02) 0.022 0.29 (0.08-0.85) 
C*04:03 8 (0.01) 9 (0.01) 0.847  
C*03:03 9 (0.01) 8 (0.01) 0.850  
C*16:02 2 (0) 4 (0) 0.476  
*P-value adjusted for age and sex. 
#Odds Ratio [95% Confidence Interval], the odds of having TB vs. no TB, for each additional HLA allele carried. 
 
For HLA class-I haplotypes (A-B-C) there was complete data for 499 individuals (242 TB 
cases and 257 controls) for whom haplotype frequencies could be inferred. Individuals with 
missing data were not included in this analysis as they would have too many possible 
haplotypes. In total, 452 possible haplotypes were inferred in the SAC population (see 
Appendix 1), with analyses performed only on haplotypes with a combined frequency ≥ 0.01 
(Table 14). None of the class-I haplotypes was found to be significantly associated with 
susceptibility to TB in the SAC population. 
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Table 14: Case-control association data for HLA class-I haplotypes and susceptibility to TB in 
the SAC population. 
HLA class-I haplotypes No. of TB cases (f) No. of controls (f) Padj
* OR [95% CI]# 
A*0101-B*0801-C*0701† 11 (0.044) 7 (0.027) 
 
1 
A*0301-B*4701-C*0602 6 (0.023) 2 (0.007) 0.314  
A*3001-B*4201-C*1701 2 (0.010) 5 (0.019) 0.072  
A*3002-B*0801-C*0701 5 (0.020) 3 (0.012) 0.932  
A*3004-B*5802-C*0602 2 (0.010) 5 (0.019) 0.220  
A*0201-B*0702-C*0702 3 (0.014) 4 (0.014) 0.754  
A*4301-B*1503-C*1801 2 (0.008) 4 (0.016) 0.075  
A*3001-B*4202-C*1701 4 (0.017) 2 (0.006) 0.182  
A*3002-B*4501-C*1601 3 (0.012) 2 (0.008) 0.967  
A*6601-B*5802-C*0602 2 (0.010) 3 (0.010) 0.626  
*P-value adjusted for age and sex. 
#Odds Ratio [95% Confidence Interval], the odds of having TB vs. no TB, for each additional HLA allele carried. 
†Reference haplotype– the most common (having the highest frequency, so assumed to be the wild type) haplotype in the study 
population. 
 
When analysing the HLA class-I molecules by functional types (Table 15), we found none to 
be significantly associated with susceptibility to TB in the SAC population, as all functional 
genotypes occurred at similar frequencies in TB cases and controls. 
Table 15: Case-control association data for HLA functional types and susceptibility to TB in the 
SAC population. 
Genotype 
TB cases with genotype Controls with genotype 
Padj
* 
Present (f) Absent (f) Present (f) Absent (f) 
Bw4 207 (0.61) 132 (0.39) 172 (0.65) 93 (0.35) 0.338 
Bw480I 143 (0.42) 196 (0.58) 100 (0.38) 165 (0.62) 0.281 
Bw480T 95 (0.28) 244 (0.72) 92 (0.35) 173 (0.65) 0.067 
C1a 80 (0.32) 169 (0.68) 71 (0.32) 150 (0.68) 0.875 
C2b 80 (0.41) 115 (0.59) 71 (0.43) 94 (0.57) 0.873 
C3c 169 (0.60) 115 (0.40) 150 (0.61) 94 (0.39) 0.969 
*P-value adjusted for sex. 
aC1 = C1/C1 genotype. 
bC2 = C1/C2 genotype. 
cC3 = C2/C2 genotype. 
 
4.3.3 KIR_HLA compound genotypes and TB case-control associations 
 
As the KIRs do not act independently but rather interact with HLA class-I molecules to effect 
an immune response, we analysed the KIR genes with their known HLA class-I ligands as 
compound genotypes for susceptibility to TB (Table 16). However, none of the KIR_HLA 
compound genotypes investigated was found to be significantly associated with susceptibility 
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to TB in the SAC population, with all compound genotypes occurring at similar frequencies 
in both groups. 
Table 16: Case-control association data for KIR_HLA compound genotypes and susceptibility 
to TB in the SAC population. 
Genotype 
TB cases with genotype Controls with genotype 
Padj
* 
Present (f) Absent (f) Present (f) Absent (f) 
3DS1_Bw4 53 (0.13) 355 (0.87) 52 (0.15) 299 (0.85) 0.306 
3DS1_Bw480I 36 (0.09) 372 (0.91) 31 (0.09) 320 (0.91) 0.879 
2DL1_C1a or C2b 240 (0.59) 168 (0.41) 215 (0.61) 136 (0.39) 0.624 
2DL1_C2 or C3c 271 (0.66) 137 (0.34) 238 (0.68) 113 (0.32) 0.561 
2DL2_C1 54 (0.13) 354 (0.87) 47 (0.13) 304 (0.87) 0.859 
2DL2_C2 120 (0.29) 288 (0.71) 96 (0.27) 255 (0.73) 0.341 
2DL2_C3 81 (0.20) 327 (0.80) 62 (0.18) 288 (0.82) 0.767 
2DL2_C1 or C2 174 (0.43) 234 (0.57) 143 (0.41) 208 (0.59) 0.454 
2DL3_C1 64 (0.16) 344 (0.84) 55 (0.16) 296 (0.84) 0.965 
2DS1_C2 or C3 94 (0.23) 314 (0.77) 88 (0.25) 263 (0.75) 0.309 
2DS1_C3 37 (0.09) 371 (0.91) 37 (0.11) 314 (0.89) 0.338 
2DS2_C1 54 (0.13) 354 (0.87) 47 (0.13) 304 (0.87) 0.762 
2DS2_C2 118 (0.29) 290 (0.71) 95 (0.27) 256 (0.73) 0.304 
2DS2_C3 75 (0.18) 333 (0.82) 64 (0.18) 287 (0.82) 0.776 
2DS2_C1 or C2 172 (0.42) 236 (0.58) 142 (0.40) 209 (0.60) 0.465 
*P-value adjusted for sex. 
aC1 = C1/C1 genotype. 
bC2 = C1/C2 genotype. 
cC3 = C2/C2 genotype. 
 
4.3.4 MHC and LRC data mining for TB susceptibility variants 
 
To identify additional genes as susceptibility factors for TB we used the Affymetrix 500K 
SNP chip data for the MHC and LRC regions in the SAC and the Gambian (WTCCC) 
populations. For the MHC and LRC regions there were 610 and 78 SNPs respectively, of 
which 598 and 65 SNPs remained after QC analysis in the SAC population and 511 and 51 
SNPs in the Gambian population (see Appendices 2 to 5 for list of all SNPs and their 
associated p-values). 
We identified twenty-eight SNPs in the MHC region that were associated (P < 0.05) with TB 
in the SAC population (Figure 30). Of these, two SNPs were significantly associated with TB 
in both the SAC and the Gambian populations, while twenty-three SNPs showed significant 
association only in the SAC population (Table 17). The remaining three SNPs failed QC 
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analysis in the Gambian dataset and were therefore not analysed. In the Gambian dataset, 
twenty-six SNPs in the MHC region were associated with TB susceptibility (Figure 30 and 
Table 18). The two SNPs associated in both the SAC and WTCCC datasets were in the 
MDC1 gene and the intergenic regions between HLA-C and WASF5P. The MDC1 rs7565 
SNP had opposing effects in the two populations, in that it was found to be protective in the 
SAC population (OR = 0.40) and susceptibility-causing in the Gambian population (OR = 
1.55) (Table 17 and 18). The HLA-C/WASF5P intergenic region, C6orf10, BTNL2, and HLA-
DOA were identified as potential genes/regions of interest, with SNPs associated with these 
regions, although not concordant, identified in both populations. The effect of the BTNL2 
SNPs was an increased risk of TB with ORs of 1.59 and 2.04, whereas the C6orf10 SNPs 
were found to lower the risk of developing TB with ORs ranging between 0.46 and 0.79. The 
HLA-C/WASF5P and HLA-DOA SNPs were found to be either protective or increasing the 
risk of developing TB (Table 17 and 18). 
For the SAC population only, several SNPs in and around the HLA-DOB and TAP2 genes 
were associated with TB (Table 17), where SNPs upstream and in the -DOB gene were found 
to increase the risk of developing TB with ORs ranging between 1.48 and 1.52, while SNPs 
downstream of the -DOB gene and in TAP2 were found to lower the risk of developing TB 
with ORs ranging between 0.37 and 0.68. 
For the Gambian population only, several SNPS associated with HLA-B, -DPA1, MSH5, and 
the intergenic region between TMPOP1 and HLA-E were found to be associated with 
susceptibility to TB (Table 18). The MSH5 and TMPOP1/HLA-E SNPs were all found to 
increase the risk of developing TB with ORs ranging between 1.30 and 2.19 (MSH5) and 1.17 
and 1.25 (TMPOP1\HLA-E), while the HLA-DPA1 SNPs were found to lower the risk of 
developing TB with ORs of 0.35 and 0.40. The HLA-B SNPs were found to be either 
protective (OR = 0.70) or increasing the risk (OR = 1.26) of developing TB. 
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In the LRC region (Figure 31), four SNPs in the SAC (Table 19) and four SNPs in the 
Gambians (Table 20) were associated with TB, with no overlap between the two populations. 
In the SAC population the four potential genes/regions associated with TB included LILRA5 
(OR = 0.41), the intergenic region between LAIR1 and TTYH1 (OR = 1.70), LILRP2 (OR = 
1.56) and NCR1\NLRP7 (OR = 1.99). However, the SNPs in the LILRA5, LAIR1\TTYH1 and 
NCR1\NLRP7 genes all failed QC analysis in the Gambian dataset and were therefore not 
analysed in the population. In the Gambians, the genes LAIR2 (OR = 1.20) and the intergenic 
region between LILRA1 and LILRA2 (OR = 1.22 to 1.40) were associated with TB. 
  
Figure 30: Manhattan plots for SNPs spanning the MHC region on chromosome 6 in the SAC 
and the Gambian populations. The blue line represents P < 0.05 cut-off, with all SNPs above the line 
associated with TB susceptibility in the respective populations. 
 
Table 17: MHC SNPs (Affymetrix 500K SNP chip) associated with TB susceptibility in the SAC 
population. 
SNP Allele Pg_adj* Pa_adj# OR [95% CI]‡ Gene 
rs7565¥ T 0.054 0.020 0.40 [0.20-0.86] MDC1 
rs887466 A 0.022 0.015 1.54 [1.09-2.21] POU5F1 
rs16899203 C 0.008 0.013 2.45 [1.19-5.95] intergenic: HLA-C and WASF5P 
rs3873385 T 0.006 0.002 0.47 [0.30-0.75] intergenic: HLA-C and WASF5P 
rs396038¥ T 0.080 0.026 0.56 [0.35-0.93] intergenic: HLA-C and WASF5P 
rs2523467 T 0.095 0.030 1.41 [1.03-1.93] MICA 
rs11965547 A 0.050 0.018 0.54 [0.33-0.90] SLC44A4 
rs12524063 A 0.024 0.017 0.46 [0.25-0.87] C6orf10 
rs9268302 T 0.046 0.017 0.67 [0.48-0.93] C6orf10 
rs6907322¤ A 0.039 0.011 0.65 [0.46-0.90] C6orf10 
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SNP Allele Pg_adj* Pa_adj# OR [95% CI]‡ Gene 
rs3763308 A 0.044 0.022 2.04 [1.10-4.22] BTNL2 
rs4530903 T 0.030 0.030 0.48 [0.26-0.93] intergenic: DRB1 and DQB1 
rs9272723¤ T 0.003 0.013 1.48 [1.09-2.02] DQA1 
rs2647046 A 0.015 0.008 1.60 [1.13-2.28] intergenic: DQB1 and DQA2 
rs9275572 A 0.021 0.006 0.64 [0.46-0.88] 
intergenic: 
DQB1/DQA2/MTCO3P1 
rs2621382 G 0.040 0.015 1.48 [1.08-2.04] intergenic: DQB2 and DOB 
rs2157082 G 0.036 0.013 1.49 [1.09-2.06] intergenic: DOB/DQB2/DQA2 
rs2857136 A 0.040 0.011 1.51 [1.10-2.09] DOB 
rs2857129 A 0.037 0.010 1.52 [1.10-2.10] DOB 
rs1894407 A 0.074 0.023 0.68 [0.49-0.95] DOB and TAP2 
rs9784858 C 0.009 0.005 0.54 [0.36-0.83] DOB and TAP2 
rs10484565 A 0.007 0.007 0.37 [0.19-0.75] TAP2 
rs3101942 G 0.001 0.001 0.55 [0.39-0.79] uncharacterized LOC100294145 
rs3129304 C 0.020 0.022 0.58 [0.37-0.92] DOA 
rs3129303 C 0.034 0.031 0.60 [0.39-0.95] DOA 
rs429916 A 0.001 0.000 2.35 [1.45-4.01] DOA 
rs3130014 G 0.044 0.016 1.66 [1.10-2.63] intergenic: tapasin 
rs2747476¤ C 0.057 0.018 2.67 [1.17-7.73] KIFC1 
¥SNPs associated with susceptibility to TB in the SAC and the Gambian populations. 
¤SNP failed QC analysis in the Gambian population dataset. 
*Genotype P-value adjusted for sex. 
#Allele P-value adjusted for sex. 
‡ Odds Ratio [95% Confidence Interval], the odds of having TB vs. no TB, for each SNP. 
 
Table 18: MHC SNPs (Affymetrix 500K SNP chip) associated with TB susceptibility in the 
Gambian population (WTCCC). 
SNP Allele Pg_adj* Pa_adj# OR [95% CI]‡ Gene 
rs9295873 G 0.036 0.010 1.24 [1.05-1.46] intergenic: TMPOP1 and HLA-E 
rs9461607 A 0.034 0.010 1.24 [1.05-1.47] intergenic: TMPOP1 and HLA-E 
rs9295878 A 0.061 0.023 1.17 [1.02-1.34] intergenic: TMPOP1 and HLA-E 
rs9295881 T 0.070 0.025 1.17 [1.02-1.34] intergenic: TMPOP1 and HLA-E 
rs9295888 A 0.031 0.009 1.25 [1.06-1.48] intergenic: TMPOP1 and HLA-E 
rs17477480 G 0.047 0.014 1.23 [1.04-1.45] intergenic: TMPOP1 and HLA-E 
rs7565¥ T 0.029 0.015 1.55 [1.09-2.22] MDC1 
rs3095340 C 0.052 0.018 0.82 [0.71-0.97] 
intergenic: 
FLOT1/TUBB/IER3/MDC1 
rs1265052 C 0.009 0.010 0.84 [0.73-0.96] C6orf15 
rs239467 A 0.044 0.017 1.30 [1.05-1.61] intergenic: HLA-C andWASF5P 
rs4523128 C 0.044 0.017 1.30 [1.05-1.61] MSH5 
rs396038¥ T 0.032 0.032 0.71 [0.51-0.97] intergenic: HLA-C and WASF5P 
rs9295984 A 0.070 0.024 1.26 [1.03-1.54] HLA-B 
rs2523575 G 0.012 0.020 0.70 [0.51-0.95] HLA-B 
rs3130484 C 0.012 0.004 2.19 [1.27-3.89] MSH5 
rs3131379 A 0.048 0.025 1.83 [1.08-3.16] MSH5 
rs17201431 C 0.027 0.027 0.52 [0.27-0.93] CFB 
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SNP Allele Pg_adj* Pa_adj# OR [95% CI]‡ Gene 
rs3134926 G 0.055 0.017 1.18 [1.03-1.35] NOTCH4 
rs9267954 T 0.015 0.012 0.76 [0.61-0.94] 
intergenic: NOTCH4 and 
C6orf10 
rs12528797 G 0.095 0.038 0.79 [0.63-0.99] C6orf10 
rs3135376 G 0.025 0.025 1.59 [1.06-2.40] intergenic: BTNL2/DRA 
rs12199692 G 0.113 0.037 1.19 [1.01-1.41] DOA 
rs6936620 A 0.079 0.024 1.28 [1.03-1.59] DOA 
rs3077 A 0.116 0.040 1.16 [1.01-1.33] DPA1 
rs9348904 A 0.103 0.035 1.16 [1.01-1.33] DPA1 
rs3135021 A 0.029 0.016 1.19 [1.03-1.36] DPB1 
¥SNPs associated with susceptibility to TB in the SAC and the Gambian populations. 
*Genotype P-value adjusted for sex. 
#Allele P-value adjusted for sex. 
‡ Odds Ratio [95% Confidence Interval], the odds of having TB vs. no TB, for each SNP. 
 
  
Figure 31: Manhattan plots for SNPs spanning the LRC region on chromosome 19 in the SAC 
and the Gambian populations. The blue line represents P < 0.05 cut-off, with all SNPs above the line 
associated with TB susceptibility in the respective populations. 
 
 
Table 19: LRC SNPs (Affymetrix 500K SNP chip) associated with TB susceptibility in the SAC 
population. 
SNP Allele Pg_adj* Pa_adj# OR [95% CI]† Gene 
rs1761450¤ A 0.006 0.003 0.41 [0.23-0.72] LILRA5 
rs8109349¤ G 0.025 0.009 1.70 [1.14-2.63] intergenic: LAIR1 and TTYH1 
rs8104498 C 0.007 0.035 1.56 [1.03-2.44] LILRP2 
rs16986092¤ T 0.018 0.01 1.99 [1.17-3.69] NLRP7/NCR1 
¤SNP failed QC analysis in the Gambian population dataset. 
*Genotype P-value adjusted for sex. 
#Allele P-value adjusted for sex. 
† Odds Ratio [95% Confidence Interval], the odds of having TB vs. no TB, for each SNP. 
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Table 20: LRC SNPs (Affymetrix 500K SNP chip) associated with TB susceptibility in the 
Gambian population (WTCCC). 
SNP Allele Pg_adj* Pa_adj# OR [95% CI]† Gene 
rs6509880 T 0.033 0.009 1.20 [1.05-1.37] LAIR2 
rs2555685 G 0.002 0.002 1.40 [1.13-1.73] intergenic: LILRA1 and LILRA2 
rs2555687 A 0.033 0.009 1.31 [1.07-1.60] intergenic: LILRA1 and LILRA2 
rs16985743 T 0.046 0.019 1.22 [1.03-1.44] intergenic: LILRA1 and LILRA2 
*Genotype P-value adjusted for sex. 
#Allele P-value adjusted for sex. 
† Odds Ratio [95% Confidence Interval], the odds of having TB vs. no TB, for each SNP. 
4.4 Discussion 
 
Given that only 10% of immunocompetent individuals will develop active TB disease, 
understanding the host genetic contribution to this phenomenon will enable us to comprehend 
the disease aetiology and progression better. Since the genes of the MHC and LRC, 
specifically the HLAs and KIRs, are known to have important immune functions, we 
proposed to study these genes and their variants with respect to susceptibility to TB. For the 
KIR genes, a significant association was identified for the 3DS1 gene (OR = 0.65) which was 
shown to lower the odds of developing TB in the SAC population by 35%. This gene has 
been previously associated with TB susceptibility in the Lur population from Iran [342] and 
the Chinese Han population [343], with ORs of 0.39 and 2.12 respectively. The effect of this 
gene with regards to TB susceptibility has thus been found to differ between populations, 
with 3DS1 having a protective role in the SAC and Iranian population but increasing the risk 
of developing TB in the Chinese Han population. However, in a study in the Tehran, Iran 
population, the 3DS1 KIR gene was not found to be associated with TB [344]. This study 
however had a small sample size. To date, several studies have identified associations with 
the 3DS1 gene and disease susceptibility [345], predominantly HIV-1 infections [238,346]. 
Most studies have found the 3DS1_HLA-Bw4-I80 compound genotype to be associated with 
lower viral loads, slower decline of CD4
+
 T cell counts and delayed progression to AIDS 
[346–348]. However, this compound KIR_HLA genotype was not associated with TB 
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susceptibility in the SAC population. In this regard, Barbour et al. showed that the 3DS1 gene 
and the Bw4-I80 allele act independently in their protective role in HIV-1 disease 
progression, where 3DS1 was found to increase the CD4
+
 T cell count and the HLA-B allele 
was associated with lower viral loads [349]. To understand the functional mechanisms of 
3DS1 in HIV-1 infections, Alter et al. showed expansion of 3DS1
+
 NK cells during acute 
HIV-1 infections in the presence of Bw4-I80 [350,351] and Long et al. showed increased 
IFN-γ and CD107a levels from 3DS1
+
 NK cells in individuals with early HIV-1 infections 
that were independent of the presence of the Bw4-I80 allele [352]. For HIV-1 exposed 
seronegative (HESN) subjects conflicting reports have been published, with Boulet et al. and 
Tomescu et al. reporting a protective role for 3DS1 and disease susceptibility [353,354], 
while Tomescu et al. and O‟Connell et al. reported no enrichment for the KIR3DS1 gene in 
HESN individuals for HIV-1 acquisition [355,356]. All these studies raise the question 
whether the protective effect is due to the presence of 3DS1 or any of the other genes in LD 
with it. For other infectious diseases, the 3DS1 gene has been found to result in severe 
pandemic influenza (H1N1) 2009 infections [357] and spontaneous recovery from hepatitis B 
infection in individuals with increased frequency of 3DS1 [358]. 
Additional KIR associations identified with TB include two genotypes (B24 and B57) and 
individuals with five or more aKIR genes. The two genotypes were found to increase the risk 
of developing TB, with B24 occurring only in TB cases in our study cohort. The Bx 
genotypes are designated as such since they contain mostly aKIRs. The 3DS1 gene, found to 
lower the risk of developing TB, is one of these aKIRs but was not present in any of the KIR 
genotypes associated with increased risk of disease. In addition, both KIR genotypes had only 
four aKIRs present, while we found individuals with five or more aKIRs being protected 
against developing TB.  In a previous study on nasopharyngeal carcinoma, the authors 
reported an increased risk (3.4 fold) among Epstein-Barr virus (EBV)-seropositive 
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individuals and carriers of five or more aKIRs [359]. As our study indicated that individuals 
with the aKIR gene 3DS1 and with 5 or more aKIRs, were protected against TB, we show an 
imbalance towards aKIRs in protection against TB, which could be as a result of increased 
cytolysis of M. tuberculosis infected cells by NK cells.  
Our investigation of HLA class-I alleles identified several significant associations with 
susceptibility to TB in the SAC population. To date, most HLA associations have been 
identified between the class-II alleles and susceptibility to TB [360]. Most studies on HLA 
class-I to date have focussed on supertypes and TB susceptibility. In a meta-analysis of HLAs 
and susceptibility to TB, the only class-I supertype associated with TB was HLA-B*13, and 
none of the class-I alleles found to be associated in this study belonged to this supertype 
group. In studies subsequent to the HLA and TB meta-analysis, associations were identified 
between the HLA-B*51 and -B*52 supertypes and susceptibility to TB in an Indian cohort, 
where B*51 was found to increase the risk of TB (OR = 18.53) and B*52 lowered the risk of 
developing TB (OR 0.0) [361]. In a study conducted in a Brazilian population, the HLA-
A*02 and -B*18 allelic supertypes were found to be associated with TB susceptibility, with 
both alleles lowering the risk of developing TB (OR = 0.64 and 0.37, respectively) [362]. 
Again, none of the alleles associated in this study belonged to these supertype groups. The 
data therefore suggests great variability in the HLA alleles involved in TB susceptibility in 
different populations. 
In 2011, Alter et al. identified associations between SNPs in the HLA class-I region and 
susceptibility to leprosy, caused by M. leprae, in a Vietnamese and Indian population [155]. 
Of the twelve SNPs associated with leprosy, eleven occurred in the centromeric end of the 
class-I region, of which one (rs16899203) was present in the SNP set (500K Affymetrix 
SNP-chip) analysed in our study. This SNP was also found to be associated with 
susceptibility to TB in the present study, and maps to the 5‟ UTR region of the HLA-C gene. 
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In total, four 5‟ UTR HLA-C SNPs were identified as susceptibility factors in the SAC and 
the Gambian populations, with one SNP (rs396038) associated in both populations. Taken 
together, this data strongly suggests that the HLA-C gene plays an important role in 
mycobacterial disease susceptibility. Another SNP identified by Alter et al. mapped to the 
MICA gene. Although this SNP was not present in our Affy 500K SNP set, we identified 
another SNP in the MICA gene (rs2523467) to be associated with TB susceptibility. 
However, in the study by Souza et al., none of the MICA alleles investigated was found to be 
associated with TB in a Brazilian population [362]. 
Since most studies of genes of the MHC and LRC and susceptibility to TB have focussed on 
the HLA class-I, class-II and KIR genes, we sought to identify other genes within these 
complexes that may play a role in TB susceptibility given the functional relevance of most of 
these genes. To do this we used Affymetrix 500K SNP chip data for the SAC and the 
Gambian (WTCCC) populations, with the latter serving as a validation cohort. Unfortunately 
the concordance of associated SNPs between the two populations was low, in part due to QC 
processes. There were however several overlapping MHC genes between the two 
populations, including chromosome 6 open reading frame 10 (C6orf10), butyrophilin-like 2 
gene (BTNL2), HLA-DOA and TAP2. The C6orf10 gene is an uncharacterized gene located in 
the MHC class II region which has previously been found to be associated with psoriasis in a 
Chinese population [363]. This gene could play an important role in TB since it has been 
shown to be a downstream effector of TNF-α, a pro-inflammatory cytokine known to play an 
important role in the development of active TB disease [364], and is produced by 
macrophages, CD4
+
 T cells and NK cells. Previous work from our lab investigated BTNL2 
SNPs and TB susceptibility, with no significant associations identified [365]. However, the 
SNP found to be associated with TB in this study was not included in the study by Möller et 
al. In a subsequent study of BTNL2 SNPs in a Chinese Han population, three SNPs were 
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significantly associated with TB disease [366]. Several studies have also identified an 
association between SNPs of BTNL2 and sarcoidosis [367–369], a disease with similar 
clinical and pathophysiological factors as TB. Expression of BTNL2 is increased in human 
monocyte-derived macrophages upon exposure to M. tuberculosis and lipopolysaccharides 
[367] and inhibits T cell activation in a murine model [370]. Several SNPs in the HLA-DOA 
and -DOB genes were also identified as susceptibility factors for TB in the SAC population. 
These two class-II genes combine to form a heterodimer, HLA-DO, which is found in B cell 
lysosomes and regulates the peptide loading of HLA-DM-derived antigens on HLA class-II 
molecules [371]. Fallas et al. showed that increased levels of HLA-DO resulted in lower 
levels of class-II peptides in B cells and a significant inhibition in the presentation of some 
exogenous antigens to T cells [372]. In essence, high levels of HLA-DO resulted in down 
modulation of class-II antigen processing and presentation, which negatively impacts the 
CD4
+
 T cell response to M. tuberculosis infections. The final MHC gene for which 
significant association with TB susceptibility was detected is TAP2. The transporter 
associated with antigen processing (TAP) molecules, composed of two subunits TAP1 and 
TAP2, is involved in the translocation of peptides from the cytosol to the class-I molecules in 
the endoplasmic reticulum [373,374], where Kartunnen et al. showed that TAP2, but not 
TAP1, processing is critical for peptide translocation and binding [373]. Taken with our 
findings of HLA class-I molecules altering susceptibility to TB and the importance of CD8
+
 
T cells in overcoming M. tuberculosis infections [375], this suggests that the TAP2 gene 
could play an important role in susceptibility to TB. 
In the LRC complex, SNPs associated with LILRA5, LILRP2, NCR1/NLRP7and the 
intergenic region between LAIR1/TTHYH1 were found to be associated with TB in the SAC 
population, with no overlap in genes between the SAC and the Gambians. LILRA5 and 
LILRP2 are members of the LILR gene family, where LILRP2 is a pseudogene and overlaps 
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the LILRA5 gene. LILRA5 plays an important role in the initiation of the innate immune 
response through the induction of several proinflammatory cytokines [376]. Significantly, 
LILRA5 is not involved in the recognition of class I molecules but instead binds to non-MHC 
class I ligands on target cells, providing a novel immune regulatory mechanism [377]. The 
LAIR1 gene is an inhibitory leukocyte-associated immunoglobulin-like receptor that is 
structurally related to the KIRs but regulates NK cell activity independently of class-I 
molecules [251]. LAIR1 is present on peripheral mononuclear cells, including NK cells, T 
cells and B cells and regulates the immune response through inhibition of NK cell-mediated 
cytotoxicity of self cells and limiting dendritic cell differentiation through binding to its 
ligands [251,378]. Lastly, the NCR1 (NKp46) and NLRP7 genes found to be associated with 
TB are important immune response modulators. NCR1 is involved in cytokine production 
and regulates the activation of the cytolytic activity of NK cells [379]. Furthermore, defective 
expression of NCR1 in HIV-1 patients has been noted, resulting in impaired NK cell function 
and progression of the disease [380]. With regard to TB disease, Vankayalapati et al. showed 
that NK cells use the NCR1 receptor on their surface to lyse M. tuberculosis H37Ra infected 
monocytes [381,382] in response to vimentin, a 57-kDa molecule that is highly expressed on 
the surface of infected monocytes, compared to uninfected cells [383]. The NLRP7 gene 
belongs to the nucleotide-binding and leucine-rich repeat-activating gene family (NLRs) that 
is involved in pattern recognition [384]. NLRP7 is involved in the formation of 
inflammasomes in human macrophages, in response to microbial acylated lipopeptides [385]. 
Furthermore, NLRP7 activation resulted in the stimulation of ASC-dependent caspase-1, IL-
1β, IL-18 maturation and the restriction of intracellular bacterial replication, but not caspase-
1-independent secretion of the proinflammatory cytokines IL-6 and TNF-α. 
Our study has resulted in several interesting and novel findings with regards to susceptibility 
to TB in the SAC population, but further work is required to understand the biological 
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relevance of these findings. With regards to the association of aKIRs (3DS1 and ≥5) and TB 
susceptibility, functional work would help to determine how these genes alter TB 
susceptibility. For example, flow cytometry experiments could be used to determine the 
expression and number of KIR receptors on M. tuberculosis infected CD56
dim/bright
 cells. 
Furthermore, the cytotoxicity levels of these cells can be investigated using biological assays 
for apoptosis, etc. The true ligand for KIR3DS1 has yet to be elucidated, with HLA-Bw4-I80 
regarded as its ligand due to the 85% homology which 3DS1 has with the 3DL1 gene, where 
Bw4-I80 is the confirmed ligand [345]. Further studies are thus required to identify the 
putative ligand of the 3DS1 gene. With regards to the MHC and LRC genes identified, these 
variants would have to be validated in other populations, the genes could be sequenced to 
find the causal variant, and functional characterization of the SNPs should be conducted to 
understand how they may alter TB disease progression. Experiments to do this may include 
quantitative RT-PCR (qPCRs), western blotting and functional bio-assays. 
The NK cells are important modulators of host immunity to infections [345], with NK cell 
activity and cytokine production largely regulated by the KIRs and their HLA ligands, of 
which HLA-C is the dominant KIR ligand [227]. Our study shows that aKIRs may play an 
important role in TB, and together with a previous study on leprosy susceptibility [155], that 
HLA class-I molecules are also important in disease pathogenesis of mycobacterial 
infections. 
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The work presented in this chapter has been published in The Journal of Infectious Disease, 
see Appendix 6 for a copy of the article “Associations between Human Leukocyte Antigen 
Class I Variants and the Mycobacterium tuberculosis Subtypes Causing Disease”. 
5.1 Introduction 
 
The HLAs represent an unsurpassed example of polymorphism and it is believed that this 
extreme diversity has occurred through selection events, allowing for the identification of 
peptide antigens from various pathogens and stimulation of an effective immune response by 
up-regulation of the Th1 pathway [386–388]. HLA data for various populations demonstrates 
significant differences in allele frequencies between different geographical populations, with 
some HLA alleles completely absent from certain populations (Figure 32) [319,389]. HLA-
B*73 for example, is absent in Khoisan-speaking and pygmy populations but common in 
Asian populations [228,390]. Recent archaeological and molecular studies have also 
indicated that KIRs and certain HLA alleles have been introduced into the non-African 
human population after the “Out-of-Africa” migration possibly by interbreeding with archaic 
humans [389]. These alleles would be maintained in the population if they were advantageous 
to the immune response. The HLA genes were the first to be associated with susceptibility to 




Figure 32: Differences in global allele frequencies for HLA alleles. [391] 
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The present-day population structure of several pathogens, including M. leprae and M. 
tuberculosis, can be attributed to ancient human migrations (Figure 33) [152,392,393]. Such 
long standing host-pathogen interactions could lead to adaptive genetic changes in both the 
host and pathogen populations [55]. Evidence of this can be seen from studies which have 
shown that M. tuberculosis lineages have adapted to specific human populations [55,394,395] 
and the selection of strains from a distinct sub-lineage by a human population in a defined 
geographical setting [396]. In cosmopolitan settings the association between particular 
MTBC lineages and their human hosts have remained even though some degree of 
intermingling of the different human populations has occurred (Figure 34) [55,394,395]. 
 
 
Figure 33: Diagrammatic representation of the “Out-of-and-Back-to-Africa” theory for the 
host-pathogen co-adaptation of MTBC. [152] (a) Hypothesized migration of MTBC lineages out of 
Africa. (b) Recent human migration, trade and conquest pattern. 
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Figure 34: Preferential transmission of MTBC lineages in sympatric populations in a 
cosmopolitan setting. [55] Colour of bars represents MTBC lineage as per Gagneux et al. [55]. 
 
M. tuberculosis strains of the Beijing lineage are probably the most well characterised and are 
associated with increased virulence and transmission [397]. They are the most dominant 
strain lineage globally and have been reported in many Asian countries; and are emerging as 
the dominant strain in several other countries, including South Africa [398], Argentina, Cuba, 
Malawi, Vietnam, countries of the former Soviet Union (USSR) and parts of Western Europe 
[399]. In the USA, strains from the Beijing lineage were responsible for a MDR TB outbreak 
[400,401] and they are the main MDR strains in South Africa [402]. Different M. 
tuberculosis strains induce different patterns of host immune response [403–405] as well as 
resulting in different disease phenotypes [406–408]. Beijing strains are also thought to be 
able to evade the protective effect of the BCG vaccine [409] and have evolved properties 
which allow them to cause disease more frequently than non-Beijing strains [54]. This could 
be due to their ability to modulate the host immunity towards a Th2 instead of a Th1 response 
[410] or their inhibition of TNF-α release as demonstrated in activated THP-1 macrophages 
[411]. Another potentially virulent property of the Beijing strain is its intact pks1-15 gene, 
which is responsible for the production of phenolic glycolipids (PGLs) [412]. These PGLs 
have been shown to attenuate the early host immune response to infection and inhibit the 
release of pro-inflammatory cytokines.  
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Within the Cape Town metropole in South Africa, infections caused by the Beijing strains 
were found to be rising exponentially over a decade while infections caused by non-Beijing 
strains have remained constant [398]. Furthermore, Hanekom et al. showed that the Beijing 
sub-lineage 7 strains were able to transmit and cause disease more frequently than strains 
from sub-lineages 2 to 6 in urban and rural populations of the Western Cape [396]. It appears 
that this is due to evolutionary selection in local populations for this sub-lineage instead of a 
founder effect. 
In this study we investigate the relationship between HLA class-I molecules and disease 
caused by specific M. tuberculosis lineages, specifically those lineages occurring in the 
Western Cape, South Africa.  
5.2 Materials and Methods 
5.2.1 Study Participants 
 
For a description of the study population refer to section 4.2.1.  
Three-hundred TB cases with bacteriologically confirmed pulmonary TB were included in 
this study (age in years = 34.8 ± 12.6, males = 53%).  
5.2.2 HLA Genotyping 
 
For a description of the HLA class-I genotyping refer to section 4.2.2.  
The extreme variability in the MHC molecules has resulted in the description of over a 
thousand alleles for the HLA-A and –B loci [288]. While this extensive polymorphism has 
resulted in the ability of each variant to bind a unique repertoire of peptide ligands, they have 
also been shown to largely overlap in their peptide binding specificity allowing for clustering 
of these variants into supertypes. A supertype therefore comprises a supermotif which reflects 
the broad main anchor motif for all the alleles belonging to that supertype. The A2-supertype 
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for example, shares specificity for peptides containing an aliphatic hydrophobic residue in 
position 2 and the C-terminus; whereas the A3-supertype recognizes peptides with small or 
aliphatic residues in position 2 and basic residues at the C-terminus of the class-I molecules. 
There are currently twelve supertype descriptions for over 750 HLA-A (Figure 35) and –B 
alleles (Figure 36). 
There are however no supertype classifications as yet for the HLA-C alleles. These alleles 
were thus defined based on their KIR2DL1 and KIR2DL2 binding [413] as previously done 
by Balamurugan et al. [414]. Individuals who had alleles that could not be classified into a 
supertype were labelled as “unclassified”. 
 
Figure 35: HLA-A supertype classifications and their associated alleles. [288] Under each supertype, 
alleles are grouped by colour on the basis of the stringency of selection: experimentally established motif (i.e., 
reference panel) (green), exact match(es) in the B and F pockets (white), one exact and one key residue pocket 
match (yellow), key residue match(es) at B and F pockets (grey). Alleles with no match at one or both pockets 
are listed with red font. 
Stellenbosch University  http://scholar.sun.ac.za




Figure 36: HLA-B supertype classifications and their associated alleles. [288] Under each supertype, 
alleles are grouped by colour on the basis of the stringency of selection: experimentally established motif (i.e., 
reference panel) (green), exact match(es) in the B and F pockets (white), one exact and one key residue pocket 
match (yellow), key residue match(es) at B and F pockets (grey). Alleles with no match at one or both pockets 
are listed with red font 
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5.2.3 HLA allele frequencies for geographical populations 
 
HLA class-I allele frequency data for white (Table 21) and East Asian (Table 22) populations 
were obtained from the online allelefrequencies.net database (AFND) 
(www.allelefrequencies.net) [228] (Figure 37). This database is dedicated to the storage of 
allele, genotype and haplotype frequencies of various immune related genes in different 
populations. The database currently houses data of more than 600 000 individuals (from 
1 133 human populations) for frequencies of genetic variants in the HLAs, KIRs, MHC class-
I chain-related genes, and cytokine genes. This online repository was developed due to the 
extensive variability within these genes; and their importance in disease association studies, 
population diversity studies and transplantation [415]. 
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A*23:01 A*74:01 B*07:05 B*14:01 B*14:02 B*35:01 B*58:02 C*08:01 C*16:01 
Australia New South Wales 
Caucasian 
134 0.019 - 0.004 0.011 0.011 0.045 - - 0.020 
Austria  200 0.020 - - 0.005 0.022 0.068 - - - 
Azores Central Islands 59 0.071 - - 0.018 0.054 0.071 - - - 
Azores Santa Maria and Sao 
Miguel 
43 0.026 - - 0.013 0.051 0.090 - - - 
Azores Terceira Island 130 0.031 - 0.004 0.016 0.051 0.058 - - 0.027 
Belgium  99 0.016 - - 0.005 0.010 - - - - 
Brazil Belo Horizonte Caucasian 95 0.053 - - 0.005 0.053 0.042 0.005 - - 
Bulgaria  55 0.055 - 0.009 - 0.009 - - - - 
Croatia  150 0.023 - - 0.003 0.020 0.064 - - - 
Cuba Caucasian 70 0.079 - - 0.029 0.057 0.029 - - - 
Czech 
Republic 
 106 0.019 - - - 0.014 0.061 - - - 
England North West 298 0.018 - 0.003 0.010 - 0.032 - - - 
Finland  91 0.006 - - - - 0.117 - - 0.006 
France Corsica Island 100 0.01 - - - - - - - 0.035 
France Reims 102 - - - 0.005 0.044 - - - - 
France  Rennes Population 3 200 0.02 - - - - - - - - 
France Southeast 130 0.012 - 0.004 0.012 0.035 0.047 - - 0.051 
Georgia Saventi Region Svan 80 - - - - 0.019 0.100 - - - 
Georgia Tibilisi 109 0.019 - 0.005 - 0.014 0.083 - 0.005 0.019 
Germany Essen 174 - - - 0.003 0.014 - - 0.012 0.006 
Germany Population 6 8862 0.022 - 0.002 0.005 0.018 0.061 - - 0.022 
Ireland Northern 1000 0.014 - 0.001 0.022 0.036 0.055 - 0.001 0.050 
Ireland South 250 0.008 - - 0.024 0.024 0.036 - - 0.040 
Italy Bergamo 101 0.011 - - - - - - - 0.030 
Italy North 279 - - - - - - - - 0.043 
Italy North Population 3 97 0.058 - - - 0.067 0.133 - - 0.034 
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Italy North Pavia 81 0.012 - - - 0.031 - - - 0.019 
Italy South 141 - - - - - - - - 0.018 
Macedonia Population 4 216 - - - 0.002 0.007 - - - - 
Madeira  185 0.062 - - 0.027 0.049 - 0.003 - - 
Morocco Settat Chaouya 98 0.074 0.007 - 0.007 0.041 - - - 0.071 
Poland  200 0.03 - 0.008 0.005 0.018 0.043 - - 0.008 
Poland DKMS 20653 0.023 - 0.003 0.003 0.014 0.053 -  0.014 
Portugal Center 50 0.01 - 0.010 - 0.040 0.050 - - - 
Portugal Center Population 2 562 - - - - - - - - 0.037 
Portugal North 46 0.109 - - - 0.065 0.065 - - - 
Portugal South 49 0.061 - - 0.020 0.031 0.133 - - - 
Romania  348 0.025  0.007 0.006 0.017 0.101 - - - 
Serbia Population 2 102 - - 0.005 0.010 0.044 0.088 - - - 
Spain Andalusia 99 - - - - - - 0.006 - 0.067 
Spain Andalusia Gypsy 99 0.006 - 0.005 - 0.035 0.035 - - 0.051 
Spain Catalonia Girona 88 0.046 - - - - - - - 0.098 
Spain Gipuzkoa Basque 100 0.020 - - - - - - - 0.166 
Spain Majorca and Minorca 90 0.050 - - - - - - - 0.071 
Sweden Northern Sami 154 - - - - - 0.035 - - - 
Sweden Southern Sami 130 - - - 0.008 - 0.081 - - - 
Switzerland Geneva 80 - - - - - - - - 0.027 
Turkey Population 5 142 - - - - - - - - 0.004 
United 
Kingdom 
Population 3 604 - - - - - - - - 0.041 
USA Caucasian Bethesda 307 0.018 0.011 0.004 - 0.043 0.070 0.004 - 0.030 
USA Caucasian Population 2 265 0.013 - 0.002 0.004 0.034 0.068 - - 0.025 
USA Caucasian Population 3 88 0.023 - - - - - - - - 
USA Caucasian Population 4 1070 0.013 0.001 0.002 0.008 0.034 0.072 - 0.001 0.044 
USA Eastern European 558 0.017 0.001 0.005 0.004 0.030 - 0.001 0.002 0.028 
USA European American 
Population 2 
1245 - - 0.002 0.013 0.023 0.046 - - - 
USA Philadelphia Caucasian 141 0.033 - 0.011 - 0.022 0.056 0.004 - 0.031 
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USA San Antonio Caucasian 222 0.006 - - 0.006 0.045 0.075 - 0.003 0.067 
Venezuela Colonia Tovar 86 0.047 0.012 - - - - 0.006 - - 
 





A*23:01 A*74:01 B*07:05 B*14:01 B*14:02 B*35:01 B*58:02 C*08:01 C*16:01 
China  Beijing 67 0.075 - 0 - - 0.053 - 0.114 0.008 
China  Beijing Shijiazhuang Tianjian Han 618 0.004 0.002 0.004 0.001 - 0.03 0.002 - - 
China  Canton Han 264 0.006 0.006 0.017 0.002 - 0.019 - 0.133 - 
China  Guangxi Region Maonan 108 - - - - - 0.005 - - - 
China  Guangzhou 102 - - 0.02 - - 0.025 - 0.158 0 
China  Guizhou Province Bouyei 109 - - - - - 0 - 0.177 - 
China  Guizhou Province Miao Population 2 85 - - - - - 0.042 - 0.059 - 
China  Guizhou Province Shui 153 - - - - - 0.015 - 0.206 - 
China  Inner Mongolia Region 102 0.015 - 0.005 - 0 0.039 - - - 
China  North Han 105 0 0 0 0 0.005 0 0 - - 
China  North Han Population 2 567 - - - - - - - 0.089 0.001 
China  Qinghai Province Hui 110 0.009 - 0 - 0.009 0.068 - - 0.005 
China  South Han 284 0.005 0.005 0.016 0.002 - 0.018 - 0.126 - 
China  South Han Population 2 1098 - - - - - - - 0.099 0 
China  Southwest Dai 124 0.004 - 0.004 - - 0.008 - 0.081 - 
China  Yunnan Province Bulang 116 - - 0.03 - - - - 0.366 - 
China  Yunnan Province Han 101 - - 0.015 - - 0.03 - 0.149 - 
China  Yunnan Province Hani Population 2 150 - - - - - 0.053 - 0.153 - 
China  Yunnan Province Jinuo 109 - - 0.005 - - - - - - 
China  Yunnan Province Wa 119 - - 0.021 - - - - - - 
Hong Kong  Chinese 569 0 - 0.014 0 0 0.016 0 - - 
Japan  Central 371 - - - - - 0.076 - 0.074 - 
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Japan  Hokkaido Ainu 50 - - - - - 0.11 - - - 
Japan  Kyoto and Osaka 165 - - - - - - - 0.079 - 
Japan  Population 3 1018 - - - - - 0.078 - 0.082 - 
Japan Population 5 117 - - - - - 0.078 - 0.109 - 
Mongolia  Buryat 141 0.014 - - - - - - - - 
South Korea Population 1 324 - - - - - - - 0.099 - 
South Korea Population 3 485 0 0 0.008 0.021 0 0.057 0 0.074 0 
Taiwan  Ami 98 - - - - - - - 0.26 0 
Taiwan  Atayal 106 - - - - - - - 0.184 0 
Taiwan  Bunun 101 - - - - - - - 0.089 0 
Taiwan  Hakka 55 0 0 0.027 0 0 0.009 - 0.073 0 
Taiwan  Han Chinese 504 - 0.002 0.004 - - 0.02 - 0.081 - 
Taiwan  Minnan Population 1 102 0 0 0.005 0 0 0.01 - 0.108 0 
Taiwan  Paiwan 51 0 0 0 0 0 0.01 - - - 
Taiwan  Pazeh 55 0 0 0 0 0 0.018 - 0.136 0 
Taiwan  Population 2 364 0.001 - 0.001 - - 0.017 - 0.097 - 
Taiwan Population 3 212 - - - - - 0.031 - - - 
Taiwan Saisiat 51 - - - - - - - 0.049 0 
Taiwan  Siraya 51 0 0 0 0 0 0.029 - 0.108 0.01 
Taiwan  Taroko 55 - - - - - - - 0.191 0 
Taiwan  Thao 30 - - - - - - - 0.083 0 
Taiwan  Tsou 51 - - - - - - - 0.098 0 
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5.2.4 Bacterial Isolates and Genotyping 
 
Sputum samples were previously collected for culture at diagnosis from all new and 
retreatment TB patients who attended primary health-care clinics and who were resident in an 
epidemiological field site in Cape Town, South Africa during the period January 1993 to 
December 2004. This study forms part of a larger, long-term molecular epidemiological 
project which was approved by the Health Research Ethics Committee of Stellenbosch 
University, South Africa (2003/022/N). 
M. tuberculosis isolates were classified by culturing the sputum on MGIT and/or Löwenstein-
Jensen media. DNA was extracted as previously described [416]. Isolates were classified by 
IS6110 restriction fragment length polymorphism (RFLP) genotyping [417] and 
spoligotyping [418] using internationally standardized protocols. Strains were identified 
according to distinct IS6110 banding patterns using Gelcompar II (Applied Maths, Sint-
Martens-Latem, Belgium) as previously described [419] and were subsequently grouped into 
evolutionary clades which were classified based on their spoligotype signatures [420,421]. 
Strains having less than six IS6110 bands (low-copy clade) comprise a single lineage as 
defined by IS6110 (as previously described [420]) and were therefore regarded as a single 
clade. Sub-lineages of the Beijing clade were identified as previously described [396]. M. 
tuberculosis lineages were classified into East-Asian [422] or Euro-American [54,423,424] 
MTBC lineages and inferred from Gagneux et al. [55]. 
5.2.5 Statistical Analysis 
 
Logistic regression models were used to analyse the likelihood of TB cases having a specific 
strain, compared to having any other strain, because they enable us to adjust for other 
variables such as age and sex by including them in the models as covariates.  All p-values, 
ORs and their CIs were derived from these models. Genetic association with susceptibility to 
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different strains was tested using each of the following as predictors in the models: 
genotypes, additive allelic and additive haplotypes.  The haplotypes were inferred, with their 
probabilities of being correct, and haplotypes were used as predictors in logistic regression 
models, with their probabilities as weights as previously described [335]. We tested for 
Hardy-Weinberg Equilibrium using the exact test [331]. All analysis were done in R (freely 
available from www.r-project.org) using functions from the base R and R packages genetics 
and haplo.stats. 
See section 4.2.5.1 for discussion on correcting for multiple testing. 
5.3 Results  
5.3.1 Host genotype and multiplicity of infections 
 
MTBC lineage, strain and sub-lineage frequencies in this study cohort are listed in Table 23 
and the frequencies of the HLA class-I supertypes in the SAC study population are listed in 
Table 24. Most TB cases (90%) had only one episode of disease with infection caused by one 
strain, but 27 (9%) and 3 individuals (1%) had disease episodes caused by two and three 
different strains, respectively. Of the 30 individuals with more than one disease episode, 19 
(63%) had one infection with the Beijing strain, and other episodes with another strain, 
whereas less than 5% of those with a non-Beijing strain had an additional episode with 
another strain. Figure 38 shows that of the 70 individuals with a Beijing strain, 19 (27%) had 
more than one episode with different strains. Of the 19 individuals who had 2 or more 
infections of which one was Beijing, Beijing was the first infection in 6 cases, and a 
subsequent infection in 13 cases. Having the HLA-B*27 allele was found to be significantly 
associated (P = 0.006) with having fewer strains, with each B*27 allele lowering the odds of 
having an additional infection with a different strain (Table 25). 
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Table 23: M. tuberculosis strain frequencies in the SAC population of the Western Cape. 
MTBC lineage Frequency Strain Frequency Sub-lineage Frequency 
Euro-American 0.79     
  LAM 0.32   
  LCC 0.19   
  Quebec 0.11   
  Haarlem 0.10   
  HaarlemLike 0.02   
East Asian 0.21     
  CAS1 0.02   
  Beijing 0.23   
  Beijing  Sub-lineage 2-6 0.26 
  Beijing  Sub-lineage 7 0.74 
      
  Other 0.11   
MTBC - M. tuberculosis complex. 
 
 
Table 24: HLA class-I supertype allele, genotype and haplotype frequencies in the SAC 
population of the Western Cape. 
Allele Frequency (n) Genotype Frequency (n) Haplotype
†
 Frequency 
HLA-A A*01-B*07-C2 0.03 
A*01 0.33 (167) A*01/A*01 0.13 (33) A*01-B*08-C2 0.05  
A*02 0.19 (98) A*01/A*02 0.11 (27) A*01-B*27-C1 0.03 
A*03 0.24 (120) A*01/A*03 0.16 (40) A*01-B*44-X 0.03 
A*24 0.15 (78) A*01/A*24 0.10 (25) A*01-B*58-C1 0.07 
X
#
 0.08 (41) A*01/X 0.04 (9) A*01-B*58-C2 0.03 
  A*02/A*02 0.02 (5) A*02-B*07-C2 0.05 
  A*02/A*03 0.10 (24) A*02-B*27-X 0.03 
  A*02/A*24 0.10 (24) A*02-B*44-C2 0.03 
  A*02/X 0.05 (13) A*03-B*07-C1 0.04 
  A*03/A*03 0.07 (17) A*03-B*27-C1 0.03 
  A*03/A*24 0.06 (14) A*03-B*44-C2 0.03 
  A*03/X 0.03 (8) A*03-B*58-C1 0.03 
  A*24/A*24 0.02 (4) A*24-B*07-C1 0.03 
  A*24/X 0.03 (7) A*24-B*44-C1 0.03 
  X/X 0.01 (2) X-B*27-C1 0.03 
HLA-B   
B*07 0.25 (123) B*07/B*07 0.06 (15)   
B*08 0.06 (31) B*07/B*08 0.04 (10)   
B*27 0.17 (84) B*07/B*27 0.09 (21)   
B*44 0.23 (114) B*07/ B*44 0.09 (23)   
B*58 0.17 (86) B*07/ B*58 0.09 (22)   
B*62 0.06 (30) B*07/ B*62 0.04 (10)   
X 0.05 (24) B*07/ X 0.03 (7)   
  B*08/ B*27 0.02 (6)   
  B*08/ B*44 0.03 (7)   
  B*08/ B*58 0.02 (5)   
  B*08/ B*62 0.01 (3)   
  B*27/ B*27 0.04 (9)   
  B*27/ B*44 0.08 (20)   
  B*27/ B*58 0.03 (8)   
  B*27/ B*62 0.04 (9)   
  B*27/ X 0.01 (2)   
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  B*44/ B*44 0.05 (12)   
  B*44/ B*58 0.13 (33)   
  B*44/ B*62 0.01 (3)   
  B*44/ X 0.02 (4)   
  B*58/ B*58 0.01 (3)   
  B*58/ B*62 0.02 (5)   
  B*58/ X 0.03 (7)   
  X/X 0.01 (2)   
HLA-C   
C1 0.45 (243) C1/C1 0.23 (62)   
C2 0.32 (171) C1/C2 0.24 (65)   
X 0.23 (122) C1/X 0.20 (54)   
  C2/C2 0.12 (32)   
  C2/X 0.16 (42)   
  X/X 0.05 (13)   
#X = Unclassified. 
†Only haplotypes with frequencies greater than 3% were considered and haplotypes were inferred. 
 
 
Figure 38: Presence of Beijing strain in individuals according to number of disease episodes. 
Individuals with a Beijing strain of infection were more likely to have subsequent infections (P < 0.001). Of the 
19 individuals who had 2 or more infections, one of which was Beijing, Beijing was the first infection in 6 
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Table 25: Associations of HLA class-I genotypes with number of disease episodes. 
HLA genotype Padj
*
 OR [95% CI]
#
 
A*01 0.806  
A*02 0.589  
A*03 0.236  
A*24 0.963  
B*07 0.379  
B*08 0.542  
B*27 0.006 0.21 [0.03-0.68] 
B*44 0.878  
B*58 0.417  
B*62 0.158  
C1 0.701  
C2 0.577  
*P-value adjusted for age and sex. 
# Odds Ratio [95% Confidence Interval], the odds of having a one disease episode vs. more than one disease episode, for each extra HLA 
allele carried. 
Individuals with one disease episodes (n = 270) vs. individuals with more than one disease episode (n = 30). 
5.3.2 Relationship between host and bacterial genotype in TB disease 
 
All genotype distributions were in HWE. 
The allele, genotype and haplotype distributions for HLA-A, -B and -C were significantly 
associated with the genotype of the M. tuberculosis strain causing disease in the host.  The 
Beijing strain was significantly associated with each class of variation of the HLA class-I 
genes, with the A*01, B*08 and C2 alleles increasing the odds of having disease with a 
Beijing strain (Table 26) with ORs ranging between 1.58 and 2.32, while conversely, each 
B*27 and C1 allele lowered the odds of having disease with a Beijing strain with ORs of 0.35 
and 0.60, respectively. Disease with a Beijing strain was also influenced by HLA-B and -C 
genotypes, as well as three class-I haplotypes (Table 27). However, due to the small sample 
sizes and the resulting large CIs these results are imprecise.  
TB caused by LAM genotype strains was found to be significantly associated with the A*03 
allele (Table 26), where each additional allele increased the risk with an OR of 1.65. Two 
HLA-A genotypes were also associated with a LAM infection (Table 27). For the LCC strain, 
each B*44 allele increased the risk of disease with an OR of 2.07 whereas the presence of the 
B*07 allele lowered the chances of disease with a LCC strain by OR of 0.49 (Table 26). The 
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odds of disease with a Quebec strain was increased by the presence of the B*58 allele with 
OR of 2.69 (Table 26). 
Table 26: Associations of HLA class-I alleles and M. tuberculosis lineages in the SAC 
population of the Western Cape. 
HLA allele Strain Padj
*




LAM 0.163  
Beijing 0.031 1.58 [1.04-2.40] 
LCC 0.288  
Quebec 0.676  
Haarlem 0.780  
HaarlemLike 0.419  
CAS1 0.198  
    
A*02 
LAM 0.328  
Beijing 0.391  
LCC 0.846  
Quebec 0.601  
Haarlem 0.744  
HaarlemLike 0.592  
CAS1 0.023 Allele and strain did not 
occur together. 
    
A*03 
LAM 0.022 1.65 [1.08-2.54] 
Beijing 0.068  
LCC 0.906  
Quebec 0.672  
Haarlem 0.840  
HaarlemLike 0.655  
CAS1 0.489  
    
A*24 
LAM 0.355  
Beijing 0.925  
LCC 0.386  
Quebec 0.558  
Haarlem 0.459  
HaarlemLike 0.024 Allele and strain did not 
occur together. 
CAS1 0.401  
    
B*07 
LAM 0.861  
Beijing 0.144  
LCC 0.019 0.49 [0.25-0.89] 
Quebec 0.668  
Haarlem 0.293  
HaarlemLike 0.312  
CAS1 0.408  
    
B*08 
LAM 0.103  
Beijing 0.045 2.32 [1.02-5.13] 
LCC 0.772  
Quebec 0.111  
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Haarlem 0.083  
HaarlemLike 0.345  
CAS1 0.326  
    
B*27 
LAM 0.606  
Beijing 0.002 0.35 [0.16-0.68] 
LCC 0.653  
Quebec 0.546  
Haarlem 0.504  
HaarlemLike 0.272  
CAS1 0.587  
    
B*44 
LAM 0.085  
Beijing 0.238  
LCC 0.007 2.07 [1.22-3.52] 
Quebec 0.979  
Haarlem 0.959  
HaarlemLike 0.208  
CAS1 0.779  
    
B*58 
LAM 0.098  
Beijing 0.118  
LCC 0.810  
Quebec 0.009 2.69 [1.27-5.75] 
Haarlem 0.282  
HaarlemLike 0.540  
CAS1 0.238  
    
B*62 
LAM 0.579  
Beijing 0.597  
LCC 0.776  
Quebec 0.005 Allele and strain did not 
occur together. 
Haarlem 0.488  
HaarlemLike 0.205  
CAS1 0.186  
    
C1 
LAM 0.247  
Beijing 0.011 0.60 [0.40-0.89] 
LCC 0.832  
Quebec 0.295  
Haarlem 0.515  
HaarlemLike 0.351  
CAS1 0.799  
    
C2 
LAM 0.085  
Beijing <0.001 2.03 [1.35-3.08] 
LCC 0.398  
Quebec 0.899  
Haarlem 0.521  
HaarlemLike 0.681  
CAS1 0.961  
    
*P-value adjusted for age and sex. 
#Odds Ratio [95% Confidence Interval], the odds of having a specific lineage, versus any other lineage, for each extra HLA allele carried. 
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Table 27: Associations of HLA class-I genotypes and haplotypes with M. tuberculosis lineages in 




 HLA genotype/haplotype 




HLA-A HLA-B HLA-C Haplotype 






A*01/A*02 3.89 [1.37-11.04] 
A*03/Undefined 6.33 [1.19-33.67] 










C1/C2 3.61 [1.39-9.33] 
C2/C2 4.39 [1.49-12.97] 




A*01-B*08-C2 7.8 [1.2-50.0] 
A*02-B*07-C2 8.3 [1.5-45.6] 
A*01-B*44-Undefined 7.6 [1.2 50.30 
LCC 0.812 0.125 0.137 0.715   
Quebec 0.454 0.164 0.517 0.094   
Haarlem 0.783 0.184 0.952 0.091   
HaarlemLike 0.768 0.905 0.095 0.466   
CAS1 0.734 0.874 0.643 0.696   
†P-value adjusted for age and sex. 
¥Odds Ratio [95% Confidence Interval], the odds of having a specific lineage and genotype or haplotype, versus any other lineage, 
compared to the reference genotype/haplotype (OR = 1). 95% CI could not be calculated for HLA-B genotypes due to their very low 
frequencies in patients whose infections were not Beijing. 
#No HLA-C genotypes ORs of having a LAM strain were significant when compared to the reference genotype.  
$Reference genotype – the most common (having the highest frequency, so assumed to be the wild type) genotype/haplotype in the study 
population. 
 
As Beijing sub-lineage 7 is the most frequent sub-lineage in the Western Cape but not the rest 
of South Africa, we tested whether this could be attributed to the HLAs in the human host. 
We identified two significant associations; where the A*30:02 allele occurred only in 
individuals with TB due to a Beijing sub-lineage 7 strain (P = 0.02) and is thus a potential 
risk factor; and with A*02:02 having a protective role against disease with Beijing sub-
lineage 7 strain (P = 0.012, OR = 0.04 [95% CI: 0.0-0.51] (Table 28). However, it should be 
noted that these Beijing sub-lineage 7 results are preliminary due to the small number of 
individuals (53 individuals with a sub-lineage 7 infection and 19 individuals with a sub-
lineage 2-6 infection) that could be included in this analysis. 
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Table 28: Associations of HLA class-I alleles with Beijing sub-lineages in the SAC population of 







 OR [95% CI]
¥
 
A*01 0.42 0.163  
A*03 0.17 0.156  
A*02 0.22 0.674  
A*24 0.16 0.570  
   
 
B*07 0.30 0.282  
B*44 0.27 0.627  
B*58 0.13 0.265  
B*27 0.08 0.945  
B*08 0.11 0.573  
B*62 0.07 0.836  
   
 
C1 0.35 0.436  
C2 0.45 0.969  
   
 
A*03:01 0.05 0.079  
A*02:01 0.08 0.843  
A*24:02 0.04 0.364  
A*01:01 0.09 0.787  
A*23:01 0.10 0.202  
A*11:01 0.03 0.221 
 A*30:02 0.09 0.020 only occurred in individuals with Beijing sub-lineage 7 
A*30:01 0.04 0.970  
A*43:01 0.02 0.409  
A*32:01 0.08 0.494  
A*30:04 0.04 0.993  
A*68:02 0.03 0.138  
A*68:01 0.03 0.699  
A*26:01 0.02 0.385  
A*02:05 0.04 0.969  
A*74:01 0.01 0.069  
A*29:01 0.03 0.265  
A*33:03 0.03 0.221  
A*34:02 0.01 0.429 
 A*02:02 0.03 0.012 0.04 [0.00-0.51] 
A*29:02 0.02 0.390  
   
 
B*44:03 0.11 0.987  
B*58:02 0.04 0.345  
B*08:01 0.11 0.573  
B*07:02 0.09 0.259  
B*15:03 0.04 0.941  
B*58:01 0.02 0.362  
B*18:01 0.04 0.890  
B*15:10 0.03 0.686  
B*45:01 0.03 0.106  
B*41:01 0.04 0.889  
B*42:01 0.04 0.304  
   
 
Cw*06:02 0.11 0.287  
Cw*04:01 0.08 0.738  
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 OR [95% CI]
¥
 
Cw*07:01 0.17 0.940  
Cw*17:01 0.10 0.432  
Cw*07:02 0.11 0.353  
Cw*02:10 0.09 0.510  
Cw*03:04 0.02 0.210  
Cw*16:01 0.08 0.054  
Cw*18:01 0.04 0.088  
Cw*07:04 0.03 0.236  
Cw*02:02 0.02 0.196  
Cw*08:01 0.04 0.879  
    
!HLA supertypes and 4-digit alleles were investigated. 
#Frequency of alleles in individuals included in the Beijing sub-lineage analysis. 
†P-value adjust for age and sex. 
¥ Odds Ratio [95% Confidence Interval], the odds of having sub-lineage 7, versus any other sub-lineage, for each extra HLA allele carried. 
 
5.3.3 Relationship between M. tuberculosis phylogenetic lineages and HLA 
class-I allele frequencies in specific geographical populations 
 
Table 29 contains a summary of associations between MTBC lineages and HLA types in the 
SAC population, as well as the bacterial “footprint” of these MTBC lineages in various 
regions globally. M. tuberculosis strains in our study group were separated into Euro-
American or East-Asian, the two MTBC lineages most prevalent in the Western Cape. HLA 
class-I allele frequencies of the ancestral populations were derived from AFND. In our SAC 
sample set there were 199 individuals with Euro-American MTBC lineage only, 57 with East 
Asian MTBC lineage only, 18 with both MTBC lineages and 26 with neither. Several 
significant associations were identified, with the following alleles associated with both 
MTBC lineages: A*23:01, B*14:01, B*14:02 and C*16:01 (Table 29). The A*23:01 and 
C*16:01 alleles were found to be less prevalent in those individuals with a Euro-American 
MTBC of infection while increasing the risk of having an infection caused by an East Asian 
MTBC. However, the HLA allele frequencies in the white and East Asian human populations 
do not correlate with this as these alleles were found to be more prevalent in white 
populations than East Asian populations. The opposite effect was seen for the B*14:01 and 
B*14:02 alleles, with all individuals carrying these alleles having a Euro-American MTBC. 
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In this instance, the HLA population data for B*14:02 was in line with this finding as the 
allele occurs more frequently in white populations than East Asian populations.  
Individuals with Euro-American MTBC infections were less likely to have the C*08:01 allele 
and more likely to have the A*74:01 and B*58:02 alleles. At the population level, alleles 
A*74:01 and B*58:02 occurred at the same frequency in both human populations whereas 
allele C*08:01 was found at an extremely low frequency in the white population and at a very 
high frequency in the East Asian population, providing an inconsistent correlation between 
risk in the population of specific strains and frequency of HLA alleles.  
Statistically significant associations with the East Asian MTBC only were seen for the 
B*07:05 and B*35:01 alleles, with the former increasing the risk of having this strain and the 
latter reducing the chance (to zero in this study). These findings largely concur with the 
population data where the B*07:05 allele is found more frequently in East Asian populations 
than white populations and the B*35:01 allele occurring more frequently in white populations 
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Table 29: Associations between M. tuberculosis phylogenetic strains and HLA class-I alleles in geographic populations. 
 MTBC phylogenetic lineages Allele frequency per human population
‡
 
 HLA Allele 
Euro American East Asian 
SAC
*
 White East Asian 
Padj
†




 OR [95% CI]
#
 
A*03:01 0.741 1.14 (0.54-2.56) 0.320 0.66 (0.25-1.47)    
A*24:02 0.631 1.21 (0.58-2.79) 0.078 0.45 (0.15-1.08)    
A*01:01 0.350 0.69 (0.32-1.53) 0.309 1.52 (0.67-3.29)    
A*23:01 0.026 0.43 (0.20-0.90) 0.043 2.24 (1.03-4.84) 0.065 0.023 0.008 
A*02:01 0.093 0.53 (0.25-1.12) 0.736 1.15 (0.50-2.44)    
A*11:01 0.074 2.38 (0.93-8.07) 0.078 0.39 (0.09-1.10)    
A*30:02 0.562 0.79 (0.36-1.84) 0.090 1.98 (0.89-4.32)    
A*43:01 0.208 1.88 (0.72-5.91) 0.081 0.37 (0.08-1.12)    
A*32:01 0.388 0.67 (0.28-1.69) 0.086 2.18 (0.89-5.14)    
A*30:04 0.475 1.45 (0.54-4.59) 0.701 0.82 (0.26-2.17)    
A*30:01 0.281 0.59 (0.23-1.58) 0.712 1.21 (0.41-3.16)    
A*68:02 0.289 1.80 (0.63-6.54) 0.470 0.67 (0.18-1.91)    
A*02:05 0.130 0.43 (0.15-1.29) 0.547 1.42 (0.42-4.14)    
A*68:01 0.199 2.43 (0.66-16.13) 0.769 0.83 (0.19-2.57)    
A*29:01 0.560 1.47 (0.43-6.77) 0.749 0.81 (0.18-2.72)    
A*02:02 0.360 1.99 (0.49-13.49) 0.538 1.49 (0.38-5.00)    
A*33:03 0.086 4.56 (0.83-86.93) 0.369 1.83 (0.46-6.39)    
A*26:01 0.503 1.68 (0.40-11.63) 0.659 0.70 (0.10-2.97)    
A*34:02 0.720 1.31 (0.35-8.54) 0.871 0.89 (0.14-3.30)    
A*24:07 0.756 0.79 (0.19-4.01) 0.313 0.38 (0.02-2.16)    
A*74:01 0.016 All are EuroAm 0.338 0.39 (0.02-2.31) 0.016 0.003 0.003 
A*29:02 0.063 0.20 (0.03-1.09) 0.168 3.28 (0.58-18.60)    
A*66:01 0.402 2.38 (0.36-48.04) 0.667 0.63 (0.03-4.12)    
A*68:27 0.598 1.75 (0.27-35.28) 0.645 0.61 (0.03-4.02)    
A*02:03 0.199 0.30 (0.04-1.93) 0.799 0.75 (0.04-5.35)    
        
B*58:02 0.001 4.64 (1.73-16.48) 0.140 0.53 (0.20-1.21) 0.087 0.003 0.002 
B*44:03 0.781 0.90 (0.43-1.99) 0.133 1.78 (0.83-3.67)    
B*07:02 0.983 0.99 (0.47-2.27) 0.582 1.25 (0.55-2.66)    
B*08:01 0.059 0.46 (0.21-1.03) 0.071 2.13 (0.94-4.72)    
B*15:03 0.675 1.20 (0.52-3.12) 0.103 0.44 (0.12-1.16)    
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B*18:01 0.950 0.97 (0.39-2.79) 0.679 1.23 (0.43-3.07)    
B*15:10 0.942 0.97 (0.40-2.79) 0.817 0.89 (0.27-2.22)    
B*58:01 0.816 0.88 (0.33-2.76) 0.184 0.41 (0.06-1.44)    
B*42:01 0.417 0.66 (0.24-1.90) 0.274 1.77 (0.61-4.81)    
B*41:01 0.951 0.96 (0.31-3.65) 0.895 1.08 (0.29-3.36)    
B*57:03 0.674 0.76 (0.23-2.97) 0.283 1.94 (0.56-6.16)    
B*45:01 0.801 1.19 (0.33-5.64) 0.505 1.55 (0.39-5.24)    
B*27:05 0.062 5.11 (0.93-98.32) 0.146 0.27 (0.01-1.46)    
B*35:01 0.129 3.93 (0.72-75.44) 0.009 None are EastAsian 0.022 0.057 0.039 
B*51:01 0.265 0.49 (0.14-1.78) 0.362 1.85 (0.46-6.52)    
B*15:01 0.896 1.10 (0.30-5.23) 0.611 0.67 (0.10-2.75)    
B*14:01 0.018 All are Euro-Am 0.019 None are EastAsian 0.018 0.005 0.008 
B*52:01 0.670 1.42 (0.32-10.17) 0.306 0.37 (0.02-2.14)    
B*53:01 0.708 1.35 (0.31-9.48) 0.859 0.87 (0.12-3.75)    
B*07:05 0.051 0.23 (0.05-1.01) 0.020 5.66 (1.32-29.02) 0.016 0.003 0.009 
B*14:02 0.024 All are Euro-Am 0.028 None are EastAsian 0.016 0.019 0.007 
B*47:01 0.951 1.05 (0.26-6.54) 0.556 0.58 (0.03-2.85)    
B*40:06 0.974 1.03 (0.21-7.53) 0.499 0.50 (0.03-3.08)    
B*35:05 0.942 0.94 (0.19-6.94) 0.497 0.50 (0.03-3.07)    
B*13:02 0.481 2.08 (0.32-41.72) 0.063 None are  EastAsian    
B*40:01 0.170 0.30 (0.05-1.74) 0.662 1.49 (0.20-8.08)    
B*15:02 0.111 0.23 (0.03-1.44) 0.463 2.03 (0.26-12.75)    
B*81:01 0.524 0.54 (0.09-4.31) 0.097 4.68 (0.74-37.04)    
B*57:02 0.690 0.68 (0.11-5.49) 0.416 2.21 (0.28-14.25)    
        
Cw*06:02 0.064 1.66 (0.97-2.98) 0.103 0.63 (0.34-1.09)    
Cw*07:01 0.272 0.74 (0.44-1.27) 0.182 1.45 (0.84-2.46)    
Cw*04:01 0.261 1.42 (0.78-2.74) 0.075 0.55 (0.26-1.06)    
Cw*02:10 0.387 0.74 (0.39-1.48) 0.962 0.98 (0.47-1.95)    
Cw*07:02 0.090 0.56 (0.29-1.10) 0.057 1.93 (0.98-3.76)    
Cw*17:01 0.474 0.78 (0.40-1.57) 0.110 1.73 (0.88-3.33)    
Cw*16:01 0.028 0.35 (0.14-0.89) 0.002 4.48 (1.78-11.69) 0.039 0.021 0.005 
Cw*18:01 0.628 1.29 (0.48-4.14) 0.765 1.17 (0.40-3.03)    
Cw*02:02 0.165 2.39 (0.72-11.15) 0.444 0.61 (0.14-2.00)    
Cw*03:04 0.783 1.18 (0.39-4.40) 0.490 0.64 (0.14-2.10)    
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Cw*07:04 0.374 1.78 (0.53-8.30) 0.894 1.09 (0.29-3.36)    
Cw*08:04 0.355 2.00 (0.50-13.60) 0.129 0.26 (0.01-1.39)    
Cw*08:02 0.123 4.01 (0.73-76.98) 0.137 0.26 (0.01-1.43)    
Cw*15:02 0.939 1.06 (0.28-5.16) 0.195 0.30 (0.02-1.68)    
Cw*03:02 0.161 3.65 (0.65-71.76) 0.215 0.32 (0.02-1.75)    
Cw*08:01 0.021 0.20 (0.04-0.78) 0.054 3.83 (0.97-16.10) 0.017 0.002 0.107 
Cw*12:03 0.263 0.43 (0.10-1.94) 0.933 0.93 (0.13-4.27)    
Cw*12:02 0.715 1.36 (0.29-9.96) 0.369 0.41 (0.02-2.42)    
Cw*14:02 0.753 0.75 (0.14-5.66) 0.696 1.42 (0.19-7.58)    
Cw*04:03 0.519 1.96 (0.30-39.41) 0.056 None are East Asian    
Cw*03:03 0.498 2.03 (0.31-40.70) 0.564 0.55 (0.03-3.54)    
†P-value adjusted for age and sex. 
‡Allele frequencies provided for significant associations only.  
#Odds Ratio [95% Confidence Interval], the odds of having a specific MTBC phylogenetic lineage, versus the other MTBC phylogenetic lineage. 
*Frequency in the South African Coloured (SAC) population. 
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5.4 Discussion  
 
We report for the first time a number of associations between human HLA class-I types and 
specific M. tuberculosis strains. The role of the co-evolution of host and pathogen in disease 
development has been difficult to study in humans, with most of the proof of concept to date 
provided by studies of pathogen [55,394–396] and animal models [425,426]. We postulated a 
natural experiment in co-evolution taking place in the Cape Town area, which has 
experienced a multiplicity of human visitors and their mycobacterial strains over the past 350 
years. The resident population is extremely diverse [320] with inputs from Khoisan, Bantu, 
European and Asian people and could therefore be assumed to have HLA types from all these 
ancestral populations. The M. tuberculosis strains present can be expected to have 
experienced intense competition and as the incidence of TB is one of the highest in the world 
(1005 per 100 000 in 2007 [43]), we were able to investigate correlations between bacterial 
strain and HLA type in adequate numbers of patients. In this study we identified associations 
between HLA class-I gene variants with certain strain genotypes; excluding Haarlem, 
Haarlem-like and CAS1 strains, which occurred at very low frequencies within our study 
cohort. The strongest associations were identified for disease with Beijing genotype strains, 
which was found to be associated with several alleles, genotypes and haplotypes of the HLA 
class-I genes in the SAC population. Specific allelic associations were also identified for the 
LAM, LCC and Quebec genotype strains. We showed that the Beijing genotype strains 
occurred more frequently in individuals with multiple disease episodes (P < 0.001) compared 
to infections by non-Beijing genotype strains. 
The B*27 supertype reduced the odds of having multiple disease episodes, as well as having a 
Beijing strain. This supertype allele is found frequently in individuals who are able to control 
their HIV infections without any antiretroviral treatment [427] and with slow disease 
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progression [428,429]. This is thought to be due to an increased CD8
+
 T cell response in 
individuals with this allele and induction of the apoptotic pathway through the increased 
presence of cytotoxic proteins [430–434]. The B*27 supertype has not previously been shown 
to be associated with susceptibility to TB [360]. 
Even though CD4
+
 T cells (HLA class-II restricted) represent the predominant immune 
response mechanism against M. tuberculosis infection [68], there is growing evidence that 
suggests an important role for CD8
+
 T cells (HLA class-I restricted) in protection against M. 
tuberculosis infection [295,316,435–438]. Studies in animals and humans have shown that M. 
tuberculosis is capable of stimulating MHC class-I restricted CD8
+
 T cells and the 
involvement of several different pathways for class-I presentation of mycobacterial antigens 
via cross-presentation [294], where HLA class-I recognition of mycobacterial antigens 
includes ESAT-6 (HLA-B*52), 19kDa lipoprotein (HLA-A*02:01) and Ag85B (HLA-
A*02:01) [436,439,440]. CD8
+
 T cells also have direct microbicidal activity and kill M. 
tuberculosis through the expression of granulysin and perforin [318,441–443]. HLA class-I 
alleles have been associated with leprosy susceptibility [155], providing further support for 
the role of class-I genes in immunity against mycobacterial infections. It is however possible 
that the strong LD between genes within the MHC complex [444] could mean that the 
associations found here reflect the involvement of the class-II genes which remain to be 
genotyped in this population. 
To date, variants in the TLR2 [61], IRGM [445] and SLC11A1 (NRAMP1) [446] genes have 
shown a correlation between human and bacterial genotype. Variants in SLC11A1 and TLR2 
were found to be associated with an increased risk of having TB with a Beijing strain in 
Asian populations, while in Ghana, the IRGM polymorphism was found to protect against 
infections caused by the Euro-American lineage. The phenotype of TB disease may be 
affected by the bacterial strain, as strains of the Euro-American lineage appear to be less 
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likely to cause extra-pulmonary disease [61], while strains of the Beijing and S genotypes 
were associated with an increased risk of extra-thoracic disease [447]. In Vietnam, the relapse 
rate was significantly increased in TB cases caused by Beijing strains, and this probably 
contributes to the successful spread of this strain family [448]. It is therefore evident that the 
outcome of exposure to M. tuberculosis depends on both the human and bacterial genotypes, 
and Alter et al. [155] speculated that genetic heterogeneity in common infectious diseases 
could be at least partially explained by the pathogen strain differences, and patient strain 
types should therefore be incorporated into the analysis to overcome genetic heterogeneity. 
Both MTBC lineages and HLA allele frequencies are found in specific geographical settings, 
e.g. lineages of an East Asian origin occur more frequently in human populations from the 
same region [55]. HLA allele frequencies are hugely dissimilar between different ethnic 
groups, with certain alleles completely absent in some populations [319,389]. We therefore 
investigated the frequencies of HLA class-I alleles associated with the Euro-American and 
East Asian M. tuberculosis lineages, in their sympatric populations. We postulated that an 
allele more frequent in individuals with a Euro-American strain would also occur more 
frequently in white populations, whereas an allele that lowered the risk of having a Euro-
American strain-infection would occur at an extremely low frequency or be absent in white 
populations. The same rationale would apply to East Asian M. tuberculosis strains and human 
populations from East Asia. However, although results fitting the postulate were found in 
several cases, there was no fit in an equivalent number. This could be explained by the use of 
allele frequency averages across a number of populations listed in the databases. The 
A*23:01 allele for example, occurs between allele frequencies of 0.075 in the Beijing Han 
population (AFND), and 0.004 in the Shijiazhuang Tianjian Han, highlighting the enormous 
discrepancies between allele frequencies in populations of the same geographical region. 
Secondly, HLA genes are involved in several biological processes [296] and some may thus 
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be under balancing selective pressures [386] which could have led to the discrepant findings. 
In spite of the limitations of this broad categorisation of populations, we did find several 
cases where the predominant MTBC lineage and the HLA class-I allele frequency fitted the 
hypothesis of the co-evolution of M. tuberculosis strains with the HLA class-I genes. We now 
show that specific strains are associated with HLA types of the host, thus providing a 
molecular genetic explanation for the previous observation by Gagneux et al., who correlated 
M. tuberculosis strain lineages with geography [55]. 
The evolutionary forces on HLA have been extremely complex [386], including many 
bacterial and viral infections. We could thus be seeing the remaining association due to co-
evolution with M. tuberculosis and/or other diseases with similar clinical pathologies. 
Hershberg et al. has postulated an Out-of-and-back-to-Africa migration of MTBC which 
coincided with the Out-of-Africa human migration pattern and the subsequent global human 
exploration quests [152]. Considering this hypothesis, the bottleneck events which 
accompanied the out-of-Africa migration, and the expansion of disease-causing variants 
within the last 5 000 years [449], it is quite likely that co-evolution between MTBC and their 
human hosts could have occurred.  
In summary, this study highlights the role of HLA class-I molecules in infection with M. 
tuberculosis strains and emphasizes the importance of considering both host and pathogen 
genotype in understanding TB disease development and vaccine efficacy. Host-pathogen co-
evolution has significant biomedical and epidemiological implications and by identifying the 
genes involved in this interaction, the adaptation mechanisms of host and pathogen can be 
understood, as well as the limitations which they impose upon each other. It is also likely that 
the complexity of HLA types within any given population and the possible balancing effects 
of increased susceptibility to TB versus other pathogens or conditions, will prevent any 
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simple correlations being seen between the predominant HLA type in a population and the 
strain of M. tuberculosis in that area. 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 6:  
Population Genetics 
Stellenbosch University  http://scholar.sun.ac.za




The HLA class-I and KIR genes reside on different chromosomes and probably represent the 
most polymorphic loci in the human genome [450]. These genes are important in the host 
immune response to disease (infectious, autoimmune, and cancers) and reproduction, two 
biological processes essential for the maintenance of the human population [234,389]. These 
loci are thus undergoing rapid evolution and balancing selection, as maintaining a variety of 
class-I proteins may be critical for the long-term survival of the human population [391]. 
Some studies have also provided strong evidence for co-evolution between the HLA and 
KIRs [451,452]. Approximately 7000 class-I alleles and more than 400 different KIR profiles 
have been identified to date [228]. However, given that populations from different 
geographical regions are under different selective pressures, the frequencies of these loci 
(alleles and haplotypes) have been shown to differ between populations, with several studies 
highlighting a correlation between KIR and HLA frequencies and ethnicity, migration routes 
out of Africa, and relative population isolation [227,453,454]. 
South Africa is home to several population groups including African, white and mixed 
ancestry giving rise to a highly cosmopolitan population, which is mainly due to its 
geographical position and turbulent history [455]. The African population comprises several 
groups including the Pedi, Tswana, Xhosa, Zulu and the Khoisan, with the latter group 
believed to be the indigenous people of the country [456–458]. The white South African 
population is descended from several European countries (Britain, France, Germany and The 
Netherlands) as a result of the initial colonization of the Cape Town area by the Dutch East 
India Company (VOC) in 1652 [455]. White South Africans today are broadly grouped 
according to language (English or Afrikaans). The two admixed populations of South Africa 
include the Indian and the SAC populations. The South African Indian population is thought 
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to be a hybrid population from various regions of the Indian subcontinent [459], whereas the 
SAC represents a population with a unique genetic composition with influences from 
African, Asian and European populations [320,321,459–461].  
The SAC population is thought to stem from the indigenous Khoisan who occupied the Cape 
of Good Hope at the time of colonization by the VOC, which resulted in the introduction of 
not only the European settlers but also political exiles from Indonesia and Malaysia, and 
slaves from the Indian subcontinent, Madagascar, Indonesia and other areas along the African 
East coast [455,459,462]. The Cape thus served as a melting pot of individuals from various 
continents, and given the acceptance of mixed marriages in early Cape society, often between 
European men and women who were either Khoisan, freed slaves or of mixed parentage and 
between Khoisan and slaves, this resulted in the SAC population of today. In the Western 
Cape Province, the Coloured population accounts for 48.8.1% of the population according to 
the South African National Census data of 2011, and 8.9% of the national population 
(http://www.statssa.gov.za). Furthermore, the SAC population of the Western Cape is 
predominantly Afrikaans speaking (35.7%), while in the Ravensmead/Uitsig suburbs (our 
study site), 90.1% of the self-identified Coloured individuals are Afrikaans-speaking. It is 
also important to note that the SAC population as denoted in this study do not include the 
Cape Malays (Muslims), a minority population group (10.3% of the Western Cape 
population) believed to be genetically distinct and that has not been incorporated into the core 
structure of the SAC people [459]. 
Understanding the evolutionary history and genetic underpinnings of human populations, 
specifically admixed populations, affords us the opportunity to better understand patterns of 
variation across distinct global populations and to identify specific disease-causing genes. A 
previous study using the frequencies of HLA class-II alleles highlighted the genetic diversity 
between the various South African population groups [319], and a genome-wide investigation 
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showed that the genetic composition of the SAC population is predominantly Khoisan (32% - 
43%), Bantu-speaking African (20% - 36%), and European (21% - 28%), with a smaller 
Asian contribution (9% - 11%) [320]. This has been predominantly confirmed in a study done 
by Chimusa et al., who used additional publically available data sets to determine the best 
ancestral populations for the SAC population [321]. As previously described, the HLA class-I 
alleles and KIR gene frequencies show huge variation across distinct global population 
groups [389], and in some instances have been used to classify populations. This, together 
with differences in disease susceptibility, drug-, and vaccine efficacy between individuals of 
different ethnicities, highlights the importance of understanding the genetic profiles of 
distinct populations. 
In this study we use the KIR gene and HLA class-I allele frequencies of the various SA 
population groups to understand the genetic relationships between these groups, and their 
influence on susceptibility to TB in the SAC population. 
6.2 Materials and Methods 
6.2.1 Study Populations  
6.2.1.1 South African Coloured 
 
For a description of the study population refer to section 4.2.1.  
Four-hundred and forty-three healthy controls from the Ravensmead/Uitsig suburbs were 
included in this study. 
6.2.1.2 Khoisan 
 
The Khoisan individuals in this study belong to a ‡Khomani San community from the 
Upington and Andriesvale regions of the Northern Cape. In a previous study by Chimusa et 
al. to identify the best Khoisan (‡Khomani, Ju|'hoan, Bushman, or SAN) proxy ancestral 
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population for the SAC, the ‡Khomani San were shown to be the best fit [321]. DNA samples 
were collected from 75 ‡Khomani San individuals (2011 to 2012, in collaboration with Dr. 
Brenna M. Henn, Stanford University) with written informed consent and approval from the 
Health Research Ethics Committee of Stellenbosch University, project registration number 
N11/07/210. From this sample set, 61 Khoisan individuals with HLA class-I allele data were 
included in this study. 
6.2.1.3 South African: Black and White 
 
HLA class-I data for the Black and White South African population groups was provided by 
Maria Paximadis, NHLS and the University of Witwatersrand, and described in Paximadis et 
al. 2012 [463]. Briefly, 302 unrelated individuals (200 Black South African and 102 White 
South African) were randomly selected from the ESKOM cohort, representing a cross-section 
of the Black (Ndebele, Pedi, South Sotho, Swati, Tsonga, Tswana, Venda, Xhosa, and Zulu) 
and White (Afrikaans and English) subgroups of the South African population. Individuals 
were recruited countrywide at ESKOM working sites. 
6.2.1.4 South African populations from allelefrequencies.net database 
 
Allelefrequencies.net is an online database for allele frequencies of immune related genes in 
different populations [228], predominantly focussing on the KIR and HLA genes. See Table 
30 for a list of South African populations for which allele frequencies were derived from this 
database. 
 
Table 30: HLA class-I and KIR frequency data for South African population groups from the 
allelefrequencies.net online database. [228] 
Population Loci typed Sample size Method Reference 
Natal Tamil A, B, C 51 SSOP 
MG Hammond. Proceedings of the 13
th
 
International Histocompatibility Workshop, 2006 
San KIRs 91 SSOP Derek Middleton 2006 
Xhosa KIRs 50 SSOP 
Williams et al., 2004. Human Immunology 
65:1084-85 
SSOP – sequence specific oligonucleotide polymerization 
 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 117 
 
6.2.2 HLA and KIR typing 
6.2.2.1 South African Coloured 
 
For a description of the KIR and HLA typing methods employed in the SAC population refer 
to sections 4.2.3 and 4.2.4 respectively. 
6.2.2.2 Khoisan 
 
DNA was collected from saliva samples using Oragene
®
 kits, following the manufacturer‟s 
instructions. 
For the class-I alleles, calling was done using bead-based sequence specific oligonucleotide 
probe hybridization [464] and whole-exome sequencing data. Briefly, library preparation and 
exome enrichment was done as described in the Agilent SureSelect
XT
 Target Enrichment 
System (Agilent, Santa Clara, USA) for Illumina Paired-End Sequencing Library, version 
1.1.1, January 2011. QC analysis of the sequencing libraries was done using the Bioanlyzer 
High Sensitivity DNA Kit (Agilent). Samples were then sequenced using the Illumina 
HiSeq2000 platform (Illumina) using standard protocols. The read-pairs generated were 
mapped to the HG19 reference build, chr6:28702021-33392022, and extracted using 
SAMtools 0.1.18 [465] and split into separate fastq files for each individual. Bowtie (version 
0.12.7) [466] was used to pull read-pairs with low-stringency to a given HLA locus (positive 
filter), and pairs that mapped to any pseudo- or homologous gene were also removed 
(positive filter). Reads that passed these filters were then aligned to a final reference 
sequence, ImmunoPolymorphism Database [467], and SNP calling was done using 
SAMtools/bcf. HLA class-I alleles were called based on the variation of exons 2 and 3 of 
each gene, and to account for the high divergence of these exons, final alignments were made 
to reference sequences matching individuals‟ class-I types. To attribute phase for the local 
alignments the –phase function of SAMtools was used; this was done due to the close 
proximity and/or presence of highly heterozygous sequences. To confirm individual SNP 
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genotypes we used the independent alignments of filtered reads from MIRA 3 [468]. Finally, 
new variants were confirmed for sequence and phase using Sanger sequencing and one or 
more of the following: pyrosequencing, DNA cloning or segregation in families. 
6.2.2.3 South African: Black and White 
 
To type the HLA class-I alleles in these South African populations two methods were 
employed as described in Paximadis et al. [463]. Briefly, HLA-A and -B were typed using 
the Applied Biosystems SBT kits on the ABI PRISM 3100 GENETIC ANALYZER (Applied 
Biosystems). A 2-kB PCR amplicon was generated (exons 1-5) and subjected to direct 
sequencing of exons 2-4. Allele calling was done using the MatchMaker Allele Identification 
Software (Applied Biosystems). 
High-resolution typing of the HLA-C alleles was done using the PEL-FREEZ SSP UniTray 
PCR-based method (DYNAL Invitrogen Corporation) and the SBTexcellerator HLA-C Core 
kit (Qiagen, Hilden, Germany). As with HLA-A and -B direct sequencing of exons 2-4 was 
done to determine the class-I alleles. 
6.2.2.4 South African populations from allelefrequencies.net database 
 
For method used to type KIR and HLAs see Table 30. 
6.2.3 Data Analysis 
6.2.3.1 Allele and genotype frequencies across South African populations 
 
Allele frequencies for the SAC and Khoisan populations were determined by direct counting. 
We used this approach due to the limitation of current computer programs requiring allele 
calls for all loci typed, where individuals missing alleles at one locus will be removed from 
the sample set when determining the allelic frequencies of the population. The frequencies of 
two- and three-locus haplotypes were estimated using the expectation maximization (EM) 
algorithm [469,470] as employed in PyPop version 0.70 software program [471]. Allele and 
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haplotype frequencies for the South African black and white populations were obtained from 
Paximadis et al. [463] and the Natal Tamil population from AFND [228]. 
Tests for HWE, LD and neutrality were done in PyPop version 0.70 [471]. Deviations from 
HW proportions were tested using an exact Monte-Carlo Markov chain test [472]. Overall 
LD measures were estimated using two approaches, the D‟ [473] and Wn [474]statistics, 
where D‟ weights the contribution to LD of specific allele pairs by the product of their allele 
frequencies (D‟ij = Dij / Dmax) and Wn (Cramer‟s V Statistic) is a re-expression of the Chi-
square statistic, XLD
2
, normalized to be between 0 and 1. A P-value < 0.05 represents 
significant overall LD. For neutrality, the Ewens-Watterson homozygosity test [475,476] 
with Slatkin‟s Monte-Carlo implementation [477,478] was done for each locus, where the 
normalized deviate of homozygosity (Fnd) is the difference between the observed and 
expected homozygosity divided by the square root of the variance of the expected 
homozygosity. A significant (P < 0.05) negative Fnd implies balancing selection whereas a 
significant positive Fnd implies directional selection. 
6.2.3.2 Genetic relationships between South African populations 
 
Principal Coordinate (PCO) plots were constructed using the Multi-Variate Statistical 
Package (MVSP) version 3 (Kovach Computing Services; http://www.kovcomp.co.uk/mvsp) 
to understand the genetic relationships between the South African populations with regards to 
their HLA class-I composition. PCO analysis is a more general form of principal component 
analysis (PCA) and is able to use a variety of different measures of distance/similarity. PCO 
is also better for analysis where there are more variables than cases, as in this case, and where 
PCA is not recommended. The PCO is calculated as a Q-mode eigenanalysis and gives 
eigenvectors but not scores. We used Euclidean distance (Ed),  
Edij = √∑            
 
   , 
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to measure the relation between populations, where i and j represent two rows (cases) of the 
data matrix, k represents the column (variable), and n equals the total number of variables. 
Important to note, a PCO of Ed will give the same result as a Q-mode PCA. 
6.2.3.3 Contributions of MHC and LRC from ancestral populations to the SAC  
6.2.3.3.1 Population Structure 
 
DNA samples from the SAC and Khoisan individuals were genotyped using the Illumina 
OmniExpress (700K) platform (Illumina, San Diego, USA). SNPs with a missing threshold 
of 5% and a MAF of 0.5% were removed from the dataset. SNP data for additional 
populations were obtained from public data sources: The International HapMap Project [479] 
and the Human Genome Diversity Project (HGDP) [480]. Populations selected from these 
public data repositories represented putative ancestral populations (Table 31) for the SAC 
population from four major population groups: European, non-Khoisan African, Khoisan, and 
Asian. 
Table 31: Putative ancestral populations to determine the Structure of the South African 
Coloured (SAC) and Khoisan (SAN) populations. 
Population Description n Source 
French European 28 HGDP 
Pathan Iranian ethnic group belonging to Afghanistan and Pakistan 22 HGDP 
Cambodian Southeast Asian 10 HGDP 
Mozabite Northern Africa (Berber ethnic group) 29 HGDP 
Bantu_S African Bantu 8 HGDP 
BantuKenya African Bantu 10 HGDP 
Maasai Bantu from Kinyawe, Kenya 30 HapMap 
Hadza  17  
Sandawe  23  
San African San 6 HGDP 
San_NB_Schuster Namibian San 12 Schuster 
SAN South African San 35 Henn 
 
 
To determine the genetic contributions to the SAC and SAN populations we used 
STRUCTURE [481,482]. SNPs were selected that were at least 1 MB apart and LD as 
detected in unrelated individuals was taken into account. Admixture proportions for the SAC 
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and SAN individuals was estimated by 50 independent runs in 6 groups of unrelated 
individuals for each K between 1 and 10. K, the number of populations, was estimated as the 
number of populations that maximized the probability of the data, and minimized the 
variance in this probability over successive runs [481]. 
6.2.3.3.2 Local Ancestry in adMixed Populations (LAMP-LD) 
 
To infer the locus-specific ancestry of the MHC and LRC regions in the SAC population we 
used the LAMP-LD software package (http://lamp.icsi.berkeley.edu/lamp/lampld/) [483], 
which employs a hierarchal Hidden Markov Chain Model. Using the genotypes of admixed 
individuals (SAC) and reference haplotype panels of ancestral populations, LAMP-LD 
estimates the number of alleles from each ancestry at each locus for each individual.  
We used three “mixing” populations: European (French), Bantu, and Khoisan (with ≥ 75% 
San ancestry) to determine the allelic contribution to the MHC and LRC regions in the SAC 
population. 
6.3 Results 
6.3.1 HLA class-I allele frequencies across South African populations 
 
The allele frequencies of HLA-A, -B and -C observed in the fourteen SA populations are 
listed in Tables 32 to 34, respectively. In all instances the SAC population showed the 
greatest diversity with regards to number of alleles present (A = 41, B = 67, C = 28), 
followed by the Khoisan population for HLA-A (30) and -B (31) and the English for HLA-C 
(22). In total, 53 HLA-A, 83 HLA-B, and 47 HLA-C alleles were observed across the SA 
populations, with the SAC population carrying 77%, 81% and 60% of these alleles, 
respectively. In tables 32 to 34, highlighted frequencies denote alleles that occurred in only 
one SA population, while those frequencies in bold are alleles that occur only in the SAC and 
one other SA population. 
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The A*02:01 allele was the most common allele in the white population occurring in 26% of 
both English and Afrikaans individuals. This allele was also one of the most common alleles 
in the SAC population, present in approximately 8% of the population. While this allele 
occurred at a high frequency (f = 0.071 – 0.119, avg. f = 0.083) in several black populations 
(Xhosa, Swati, South Sotho, Ndebele and Venda), it was not among the top 3 alleles 
occurring in the SA black, Khoisan and Natal Tamil populations. The A*01:01 allele also 
occurred in approximately 8% of the SAC population, the highest frequency of any of the 
HLA-A alleles in the SACs, and was also the second most common allele in the white and 
Natal Tamil populations, occurring at very high frequencies of 0.20 and 0.17, respectively. 
This allele was absent from most black populations, and present in only 2 (f = 0.016) Khoisan 
and 8 black (f = 0.02) individuals. For the Khoisan population, A*23:01 was the most 
common allele present in 13% of the population, followed by A*03:01 in 11% of the 
population. The A*23:01 allele was also found to be the most common allele in several black 
populations, with frequencies ranging between 0.095 and 0.20, but occurred at low 
frequencies in the white population (f = 0.015) and was absent in the Natal Tamil population. 
The A*03:01 allele on the other hand was absent in most black populations and common in 
the white (f = 0.120) and SAC (f = 0.07) populations. For the SA black populations, the most 
common alleles were A*30:01 (f = 0.106) and A*30:02 (f = 0.101). These alleles were found 
at moderate frequencies in the SAC and Khoisan populations, but low frequencies in the 
white populations, with A*30:01 absent in Afrikaans individuals and A*30:02 absent in 
English individuals. For the Natal Tamils, the most frequent allele was A*11:01 (f = 0.180), 
which was moderate to common in the white (f = 0.06) and SAC (f = 0.05) populations. 
For HLA-B, the most common alleles for the white population were B*07:02 (f = 0.149) and 
B*08:01 (f = 0.133). The B*07:02 allele was also the most common allele in the Khoisan 
population (f = 0.115), occurring at modest frequency in the SAC (f = 0.054) and black (f = 
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0.046) population and absent in the Natal Tamils. The B*08:01 allele occurred at frequencies 
of 0.059 (SAC), 0.064 (black) and 0.071 (Natal Tamil) and was absent in the Khoisan 
population. For the SAC, the most common allele was B*44:03 (f = 0.090), an allele common 
in the white (f = 0.072), Khoisan (f = 0.098), black (f = 0.059) and Natal Tamil (f = 0.051) 
populations. The two most common alleles in the SA black populations were B*58:02 (f = 
0.094) and B*42:01 (f = 0.089), with both alleles absent in the Natal Tamils, occurring at a 
very low frequency (fB*58:02 = 0.005) or absent (fB*42:01 = NP) in SA whites, and at low to 
moderate frequencies in the SAC (fB*58:02  = 0.056, fB*42:01 = 0.021) and Khoisan (fB*58:02  = 
0.082, fB*42:01 = 0.025) populations. In Natal Tamils, the two most common alleles were 
B*40:06 (f = 0.143) and B*57:01 (f = 0.102), where B*40:06 was only present in the 
Afrikaans (f = 0.011) and SAC (f = 0.020) populations and B*57:01 in the white (f = 0.041) 
and SAC (f = 0.021) at moderate frequency and very rare in the Khoisan population (f = 
0.008). 
HLA-C showed much less differentiation between the SA populations in terms of allele 
frequencies. C*04:01 occurred at a very high frequency in the white (f = 0.088), Coloured (f 
= 0.131), Khoisan (f = 0.262), and black (f = 0.119) populations and at a moderate frequency 
in the Natal Tamils (f = 0.042). The C*06:02 allele occurred at a very high frequency in all 
SA populations and was the most common allele in the SAC (f = 0.167), blacks (f = 0.149) 
and the Natal Tamils (f = 0.177). Finally, C*07:01 (f = 0.172) and C*07:02 (f = 0.137) were 
the two most common alleles in the SA white population, and occurred at moderate to high 
frequency (f = 0.058 to 0.135) in all other SA populations. 
Analysis of the HLA class-I data showed that the SAC and SAN populations are in HWE 
except for HLA-B (HWE = 0.0075) in the SAC and HLA-A in the SAN (HWE = 0.0059) 
(Table 35). Furthermore, the homozygosity test showed that the HLA class-I molecules are 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 124 
 
undergoing statistically significant balancing selection in the SAC but not the SAN (Table 
35). 
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30:02 0.010 
 
0.010 0.052 0.033 0.095 0.043 0.100 0.056 0.053 0.154 0.125 0.238 0.091 0.101 
 









     
0.012 0.014 
 







        
0.003 0.070 
31:06 
    
0.008 
           
32:01 
 









0.010 0.005 0.016 

















   
0.003 0.008 
           
34:02 
 
0.040 0.020 0.023 0.025 0.036 0.057 
  
0.053 0.077 0.021 0.024 0.023 0.035 
 
36:01 
   
0.003 0.008 
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0.063 0.048 0.091 0.035 
 
66:01 
   
0.012 0.008 












     
0.010 
 
68:01 0.020 0.010 0.015 0.033 0.016 0.012 0.057 
 
0.028 0.026 0.038 
 
0.024 0.091 0.033 0.080 
68:02 0.020 
 




0.021 0.095 0.068 0.085 
 
68:27 
   
0.005 0.025 0.012 0.014 






            
74:01 
   
















                 
Alleles‡ 20 16 25 41 30 22 22 8 19 18 13 19 15 18 33 16 
#Combined allele frequency for the Afrikaans and English populations. 
*Combined allele frequency for the Zulu, Xhosa, Tsonga, Swati, South Sotho, Ndebele, Pedi, Venda and Tswana populations.  
‡Total number of alleles in the population. 
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07:02 0.147 0.150 0.149 0.054 0.115 0.063 0.015 
 
0.083 0.053 0.040 0.040 0.071 0.023 0.046 
 
07:05 
   
0.018 0.082 






0.025 0.015 0.100 
 
0.026 
   
0.023 0.015 
 
08:01 0.105 0.160 0.133 0.059 
 
0.113 0.044 0.200 0.083 0.053 0.040 0.020 0.071 0.023 0.064 0.071 
13:01 
   
0.002 0.008 











   
0.006 0.041 
           
14:01 
 












0.021 0.014 0.033 0.025 0.015 
     
0.048 0.023 0.015 
 
14:03 
   
0.002 
            
15:01 0.095 0.080 0.087 0.014 0.008 







0.010 0.005 0.018 




0.005 0.048 0.082 0.100 0.044 0.100 0.083 0.026 
 
0.140 0.095 0.136 0.084 
 
15:05 
   
0.002 
           
0.020 
15:08 
   
0.003 
            
15:10 0.011 
 
0.005 0.035 0.098 0.100 0.088 
 




0.010 0.005 0.009 













0.020 0.010 0.002 
           
0.031 
15:18 
               
0.041 
15:21 
   
0.008 0.008 
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0.010 
15:29 
   
0.002 
            
15:38 
   
0.002 
            






   
0.002 
            
27:01 
    
0.016 




             
27:03 
    
0.008 
           
27:04 
   
0.002 
            
27:05 0.042 0.040 0.041 0.015 
           
0.010 
27:06 
   
0.003 
            




0.024 0.023 0.018 0.020 
35:02 
   
0.002 
            
35:03 
   
0.018 




0.010 0.005 0.014 
            
35:08 0.011 0.010 0.010 0.003 
            
37:01 0.011 0.010 0.010 0.009 
           
0.020 
38:01 0.011 0.020 0.015 0.006 0.008 
           
38:02 
   
0.006 
            
39:01 
   
0.011 
            
39:06 
   
0.002 
            
39:10 










   
0.002 
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40:01 0.021 0.020 0.021 0.018 0.008 0.013 
        
0.003 
 
40:02 0.011 0.010 0.010 0.005 
            
40:04 
    
0.008 








0.010 0.005 0.032 0.033 0.013 0.015 






   
0.011 0.008 
           
42:01 
   
0.021 0.025 0.088 0.118 0.100 0.111 0.053 0.080 0.060 0.119 0.068 0.089 
 
42:02 







0.024 0.045 0.015 
 
42:06 
          
0.040 
   
0.003 
 
44:02 0.042 0.070 0.056 0.017 
            
44:03 0.053 0.090 0.072 0.090 0.098 0.038 0.044 
 




             
44:05 0.011 0.010 0.010 0.003 
            
44:07 





             
45:01 
 
0.010 0.005 0.026 
 
0.013 0.044 0.100 0.028 0.132 0.040 0.080 0.143 0.068 0.064 
 
45:07 
     
0.013 0.015 




   
0.023 0.008 
           
48:01 
   
0.005 






   
0.026 





0.010 0.005 0.005 
           
0.010 
51:01 0.063 0.030 0.046 0.021 0.008 




   
0.010 0.092 
51:06 
   
0.002 
           
0.020 
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0.002 




           
0.082 
52:04 
   
0.002 
            
53:01 









0.030 0.015 0.005 
            
56:01 
               
0.010 
57:01 0.032 0.050 0.041 0.021 0.008 
          
0.102 
57:02 
   
0.006 0.016 0.025 0.044 
 
0.028 




   




0.020 0.048 0.045 0.023 
 





0.005 0.056 0.082 0.100 0.147 
 
0.139 0.079 0.080 0.080 0.024 0.091 0.094 
 
67:01 
    
0.008 
           
81:01 







0.020 0.024 0.045 0.033 
 
82:01 
    
0.008 
           
82:02 
   
0.002 
            
                 
Alleles‡ 29 28 40 67 31 25 24 8 15 20 15 19 18 20 29 23 
#Combined allele frequency for the Afrikaans and English populations. 
*Combined allele frequency for the Zulu, Xhosa, Tsonga, Swati, South Sotho, Ndebele, Pedi, Venda and Tswana populations.  
‡Total number of alleles in the population. 
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01:02 0.029 0.010 0.020 0.015 
           
0.021 










    
0.100 




   
0.054 
 
0.076 0.057 0.100 0.083 0.026 
 
0.120 0.095 0.068 0.071 
 
03:02 





0.026 0.038 0.040 
  
0.015 0.021 
03:03 0.029 0.090 0.059 0.010 
  
0.014 
       
0.003 0.042 
03:04 0.077 0.030 0.054 0.036 0.016 0.063 0.057 
 





             
03:32 
    
0.008 
           
04:01 0.106 0.070 0.088 0.131 0.262 0.127 0.086 
 
0.139 0.158 0.154 0.100 0.095 0.159 0.119 0.042 
04:03 
   
0.011 0.025 
          
0.031 
04:04 
        
0.028 0.026 




   
0.001 









             
05:01 0.038 0.070 0.054 0.017 0.016 
    




06:02 0.058 0.100 0.078 0.167 0.131 0.139 0.171 0.300 0.139 0.105 0.115 0.180 0.143 0.136 0.149 0.177 
06:06 
         
0.026 






             
07:01 0.163 0.180 0.172 0.115 0.041 0.101 0.057 0.100 0.056 0.105 0.115 0.040 0.071 0.068 0.076 0.135 
07:02 0.144 0.130 0.137 0.058 0.131 0.114 0.029 0.100 0.083 0.053 0.038 0.020 0.048 0.045 0.058 0.094 
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0.025 
           
07:04 0.019 
 
0.010 0.027 0.016 0.013 
 
0.100 




07:06 0.029 0.010 0.020 
  
0.013 0.071 
    
0.100 0.024 0.091 0.041 
 
07:10 
    
0.008 
           
07:11 
        
0.028 




      
0.014 




    
0.008 












             
08:01 
 
0.010 0.005 0.032 
 
0.013 
        
0.003 0.042 





















           
0.104 
12:03 0.029 0.020 0.025 0.031 0.049 0.013 0.029 







   
0.002 













   
0.001 





             
15:02 0.029 0.030 0.029 0.020 







   
0.014 0.016 0.051 
   
0.026 




               
0.010 








           
0.010 
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0.010 0.005 0.080 0.082 0.063 0.143 0.100 0.111 0.079 0.154 0.100 0.143 0.136 0.111 
 
18:01 
   














0.020 0.048 0.068 0.033 
 
                 
Alleles‡ 21 22 29 28 20 19 19 8 16 19 12 20 16 13 29 20 
#Combined allele frequency for the Afrikaans and English populations. 
*Combined allele frequency for the Zulu, Xhosa, Tsonga, Swati, South Sotho, Ndebele, Pedi, Venda and Tswana populations.  
‡Total number of alleles in the population. 
Highlighted allele frequencies denote alleles that are present in only one SA population, while allele frequencies in bold are present in two SA population groups. 
 
 
Table 35: Hardy-Weinberg Proportions and selection pressures of the HLA class-I genes in the South African Coloured (SAC) and Khoisan (SAN) 
populations. 
Population 
HLA-A HLA-B HLA-C 
HWE Fnd P-value HWE Fnd P-value HWE Fnd P-value 
SAC 0.0856 -1.6175 0.0005 0.0075 -1.3823 0.0112 0.3679 -1.2822 0.0119 
SAN 0.0059 -0.861 0.1776 0.0988 -0.6126 0.2838 0.3231 -0.2722 0.482 
 
 
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 135 
 
6.3.2 M. tuberculosis vaccine epitope binding by HLA class-I alleles in South 
African populations 
 
Davila et al. identified several class-I alleles that are involved in epitope binding of current 
M. tuberculosis vaccines (Ag85B-ESAT-6, Ag85B-TB10.4, Mtb72f) undergoing various 
phases of clinical trials (Table 36) [484]. 
Table 36: List of HLA class-I alleles and the number of epitopes for each vaccine that they bind. 
[484] 
 Ag85B-ESAT-6 Ag85B-TB10.4 Mtb72f 
A*01:01 6 6 9 
A*02:01 9 10 5 
A*03:01 1 1 1 
A*26:01 8 10 5 
B*07:02 9 11 9 
B*15:01 11 18 7 
B*27:05 1 2 1 
B*40:01 6 8 2 
B*58:01 11 11 4 
 
We analysed the allele frequency for these class-I alleles across the various SA populations 
(Figure 39). Based on these allele frequencies some vaccines may not be effective in certain 
SA populations, while others might be more effective. For example, the A*02:01 allele is the 
only allele present in all SA populations and binds nine epitopes on ESAT-6, ten epitopes on 
TB10.4 and five epitopes on Mtb72f. However, while this allele occurs at a moderate to high 
frequency in the SA white, black and Coloured populations, it is very rare in the Khoisan and 
Natal Tamil populations. We noted that most alleles that bind to the vaccine epitopes occur at 
moderate to high frequencies in the white population but are low to absent in the black, 
Khoisan and Natal Tamil populations. Of particular concern is the A*03:01 allele which is 
predicted to bind to only one epitope of each vaccine subunit, but occurs at moderate to high 
frequencies in the five population groups suggesting that these three vaccines will have poor 
coverage in the SA populations. Finally, none of the current vaccines will have equal efficacy 
across all the SA populations, with the Ag85B-TB10.4 vaccine predicted to have the greatest 
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efficacy in the black, white, Coloured, and Khoisan populations; Ag85B-ESAT-6 only in the 
black and white populations; and MTB72f having the greatest efficacy in the white, Coloured 
and Natal Tamil populations. 
 
Figure 39: Comparison of HLA-A and -B alleles involved in M. tuberculosis vaccine epitope 
binding across South African populations. 
 
6.3.3 HLA class-I haplotype frequencies across South African populations 
 
All pairwise-loci tested for LD in the SAC and SAN populations were shown to be 
significant (Table 37), with stronger LD observed in the SAN population and the C:B loci 
having the strongest LD in both populations. 
Table 37: Pairwise LD estimates of the HLA class-I genes in the South African Coloured (SAC) 
and Khoisan (SAN) populations. 
Population 
A:C C:B A:B 
D' Wn P-value D' Wn P-value D' Wn P-value 
SAC 0.6082 0.3743 <0.001 0.8854 0.6698 <0.001 0.7672 0.4674 <0.001 
SAN 0.7870 0.5670 <0.001 0.9248 0.7279 <0.001 0.8534 0.6297 <0.001 
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The estimated haplotypes for the SAC and SAN populations are listed in Table 38 (haplotype 
frequencies ≥ 0.01) (see Appendix 7 and 8 for list of all SAC and SAN haplotypes, 
respectively). For three-locus haplotypes (A:C:B), the most common haplotype in the SAC 
population was 0101:0701:0801 at a frequency of 0.044, while in the SAN population the 
most common haplotype was 6802:0401:1503 at a frequency of 0.049. Neither of these 
haplotypes was present in the other population. The SAC haplotype however was also the 
most common haplotype in the SA white population at a frequency of 0.104 [463]. In the 
SAC population the most common two-locus haplotypes comprised alleles of the most 
common three-locus haplotype at frequencies of 0.033 (A:C), 0.044 (A:B) and 0.053 (C:B). 
For the SAN population, the most common A:C haplotype was 3201:0401 (0.061), A:B 
haplotype was 6802:1503 (0.049) and C:B haplotype was 0401:4403 (0.090). None of the 
most common SAC haplotypes were found in the SAN population, with only the most 
common C:B haplotype of the SAN being present in the SAC population (f = 0.036), at 
almost one-third of the frequency. With regards to the SA black and white populations 
(haplotypes determined for A:B and C:B only) [463], the most common two-locus SAC 
haplotypes were present in the white population, with the A:B haplotype also being the most 
common in the white population (f = 0.109) and the C:B haplotype present as the second 
most common haplotype (f = 0.119) in the white population. The most common SAC A:B 
haplotype was not present in the black population but the C:B haplotype was the fourth 
highest of the black haplotypes, occurring at a similar frequency (f = 0.042). The most 
common two-locus SAN haplotypes were also present in the black population, albeit at a 
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Table 38: Estimated three- and two-locus haplotypes in the South African Coloured (SAC) and 
Khoisan (SAN) populations. 
SAC SAN 
Haplotype A:C:B Frequency
# No. Haplotype A:C:B Frequency
# No. 
0101:0701:0801 0.044 21 6802:0401:1503 0.049 6 
0301:0602:4701 0.023 11 2901:1203:1303 0.041 5 
3002:0701:0801 0.020 10 0301:0702:0702 0.041 5 
3001:1701:4202 0.017 8 2301:0401:4403 0.033 4 
0101:0602:5701 0.014 7 0301:0602:5802 0.033 4 
2601:1701:4101 0.014 7 3001:0401:1510 0.025 3 
0201:0702:0702 0.014 7 3201:0401:3501 0.025 3 
3002:1601:4501 0.012 6 4301:0401:1510 0.025 3 
2402:0702:0702 0.011 5 2601:0702:0705 0.025 3 
2301:0702:0702 0.010 5 3004:0602:5802 0.025 3 
6601:0602:5802 0.010 5 6827:0401:4403 0.025 3 
3001:1701:4201 0.010 5 6802:0802:1402 0.016 2 
0205:0701:5801 0.010 5 0205:0804:1401 0.016 2 
4301:0401:1510 0.010 5 2402:0401:0702 0.016 2 
7401:0210:1503 0.010 5 2301:1701:4101 0.016 2 
 
  
0202:0701:5702 0.016 2 
 
  
2301:0702:0702 0.016 2 
 
  
2301:0703:0702 0.016 2 
 
  
0202:0702:0705 0.016 2 
 
  
3201:0202:4403 0.016 2 
 
  
2301:0602:5802 0.016 2 
Haplotype A:C Frequency# No. Haplotype A:C Frequency# No. 
0101:0701 0.033 21 3201:0401 0.061 8 
3001:1701 0.030 20 0301:0702 0.049 6 
0301:0602 0.029 19 6802:0401 0.041 5 
0101:0602 0.028 18 0301:0602 0.041 5 
3002:0701 0.019 12 2901:1203 0.041 5 
2402:0401 0.017 11 2301:0602 0.033 4 
2601:1701 0.015 10 0202:0701 0.025 3 
6801:0602 0.014 9 3001:0401 0.025 3 
0301:0701 0.013 9 6827:0401 0.025 3 
4301:0401 0.013 9 2601:0702 0.025 3 
6601:0602 0.012 8 2301:0702 0.025 3 
2402:0702 0.012 8 3004:0602 0.025 3 
3004:0602 0.011 7 4301:0202 0.025 3 
0201:0602 0.011 7 3402:0401 0.025 3 
3201:0210 0.011 7 4301:0401 0.020 3 
2301:0602 0.010 7 4301:0602 0.016 2 
2402:0701 0.010 7 0201:1701 0.016 2 
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2301:0210 0.010 7 6802:0802 0.016 2 
 
  
0205:0804 0.016 2 
 
  
6801:0602 0.016 2 
 
  
2301:1701 0.016 2 
 
  
0202:0702 0.016 2 
 
  
2301:0703 0.016 2 
 
  
3201:1701 0.012 2 
Haplotype A:B Frequency
# No. Haplotype A:B Frequency
# No. 
0101:0801 0.044 24 6802:1503 0.049 6 
0301:4701 0.024 13 0301:0702 0.041 5 
3001:4202 0.018 10 4301:1510 0.041 5 
3002:0801 0.018 10 2301:0702 0.041 5 
3201:4403 0.017 9 2901:1303 0.041 5 
0101:5701 0.017 9 0301:5802 0.033 4 
2402:0702 0.016 8 2601:0705 0.033 4 
0201:0702 0.014 8 2301:5802 0.025 3 
7401:1503 0.013 7 3201:4403 0.025 3 
2301:0702 0.011 6 3004:5802 0.025 3 
0205:5801 0.011 6 3001:1510 0.025 3 
0201:1302 0.011 6 6827:4403 0.025 3 
2601:4101 0.011 6 3201:3501 0.025 3 
4301:4403 0.010 5 3402:4403 0.025 3 
 
  
7401:3501 0.016 2 
 
  
6802:1402 0.016 2 
 
  
0205:1401 0.016 2 
 
  
2402:0702 0.016 2 
 
  
2301:4101 0.016 2 
 
  
0202:0705 0.016 2 
 
  
0202:5702 0.016 2 
 
  
2301:1510 0.016 2 
Haplotype C:B Frequency
# No. Haplotype C:B Frequency
# No. 
0701:0801 0.053 32 0401:4403 0.090 11 
0602:5802 0.048 29 0602:5802 0.082 10 
0702:0702 0.038 23 0401:1510 0.074 9 
0401:4403 0.036 21 0702:0702 0.066 8 
0210:1503 0.030 18 0702:0705 0.066 8 
0401:3501 0.028 17 0401:1503 0.057 7 
1701:4101 0.028 17 1203:1303 0.041 5 
0701:4403 0.027 16 0401:3501 0.041 5 
0602:4701 0.022 13 1701:4101 0.033 4 
0602:1302 0.022 13 0804:1401 0.033 4 
1701:4202 0.022 13 1701:4201 0.025 3 
1701:4201 0.020 12 0802:1402 0.025 3 
0704:1801 0.018 11 0602:5801 0.016 2 
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0401:1510 0.017 10 0202:2701 0.016 2 
0602:5701 0.017 10 1505:1801 0.016 2 
0801:1502 0.017 10 0701:5702 0.016 2 
0210:4403 0.015 9 0703:0702 0.016 2 
1601:4501 0.015 9 0704:0705 0.016 2 
0602:5801 0.015 9 0302:5801 0.016 2 
0401:3505 0.013 8 
   0501:4402 0.013 8 
   1402:5101 0.013 8 
   0701:5801 0.012 7 
   1202:5201 0.012 7 
   1502:4006 0.012 7 
   0210:0702 0.012 7 
   0304:4001 0.012 7 
   1801:1503 0.012 7 
   1701:4102 0.012 7 
   0401:3503 0.010 6 
   0802:1401 0.010 6 
   0602:4501 0.010 6 
   
#Haplotype frequencies > 0.01 are listed. 
Highlighted haplotypes denote haplotypes present in both SAC and SAN populations. 
 
6.3.4 KIR genotype/haplotype frequencies in three South African 
population groups 
 
KIR data for the SA San and Xhosa populations were obtained from the online database, 
AFND. In total, 62 KIR genotypes were present in the SA populations, 1 of which was an AA 
haplotype. Of the 62 KIR genotypes, 50 were found in the SAC, 25 in the San and 16 in the 
Xhosa population (Table 39). Furthermore, the AA haplotype (Genotype ID 1) was the most 
common genotype in the SAC (0.20) and San (0.17) populations, and one of the most 
common genotypes in the Xhosa population, with several genotypes occurring at a frequency 
of 0.120 including AA 1, Bx 5, Bx 20, Bx 21, and Bx 112. 
As per the online KIR database, AFND, 7 of the genotypes (bold or highlighted in Table 39) 
were identified to belong to a “unique population”. However, with the addition of the SAC 
KIR data this no longer holds true for 5 of these “unique population” genotypes (bold in 
Table 39). The remaining 2 unique population genotypes belong to the SA Xhosa (Bx 170) 
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and the SA San (Bx 235). Finally, a genotype not previously identified in AFND was found 
to be present in 3 individuals of the SAC population. 
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AA 1                                 62 (0.200) 16 (0.174) 6 (0.120)  
Bx 2                                 20 (0.060) 
  
 
Bx 3                                 15 (0.040) 
  
 
Bx 4                                 31 (0.090) 4 (0.043) 
 
 
Bx 5                                 18 (0.050) 4 (0.043) 6 (0.120)  
Bx 6                                 17 (0.050) 
  
 
Bx 7                                 8 (0.020) 
  
 
Bx 8                                 4 (0.010) 
  
 
Bx 9                                 11 (0.030) 2(0.022) 
 
 
Bx 10                                 1 (0.003) 
 
1 (0.020)  
Bx 11                                 2 (0.010) 
  
 
Bx 12                                 2 (0.010) 
  
 
Bx 13                                 4 (0.010) 
  
 
Bx 14                                 1 (0.003) 
  
 
Bx 15                                 1 (0.003) 
  
 





Bx 20                                 1 (0.003) 1 (0.011) 6 (0.120)  
Bx 21                                 35 (0.100) 13 (0.141) 6 (0.120)  





Bx 24                                 2 (0.010) 
  
 
Bx 27                                 2 (0.010) 1 (0.011) 
 
 
Bx 28                                 1 (0.003) 
  
 





Bx 32                                 6 (0.020) 1 (0.011) 4 (0.080)  
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Bx 35                                 3 (0.010) 2 (0.022) 1 (0.020)  





Bx 48                                 1 (0.003) 
 
1 (0.020)  
Bx 68                                 2 (0.010) 
  
 
Bx 70                                 1 (0.003) 
  
 
Bx 71                                 8 (0.020) 6(0.065) 4 (0.080)  
Bx 72                                 3 (0.010) 
  
 
Bx 73                                 10 (0.030) 
 
2 (0.040)  
Bx 74                                 1 (0.003) 
  
 





Bx 77                                 
  
1 (0.020)  
Bx 79                                 1 (0.003) 
  
 
Bx 80                                 2 (0.010) 
  
 
Bx 81                                 2 (0.010) 
  
 
Bx 90                                 1 (0.003) 
  
 
Bx 91                                 2 (0.010) 1 (0.011) 
 
 





Bx 93                                 1 (0.003) 
  
 
Bx 106                                 2 (0.010) 3 (0.033) 1 (0.020)  
Bx 112                                 11 (0.030) 9 (0.098) 6 (0.120)  
Bx 113                                 1 (0.003) 
  
 
Bx 118                                 4 (0.010) 
  
 





Bx 166                                 1 (0.003) 
  
 
Bx 170                                 
  
1 (0.020) SA Xhosa 
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Bx 175                                 1 (0.003) 
  
USA Cal. Afr. Am. 
Bx 178                                 1 (0.003) 
  
Comoros Mixed 
Bx 191                                 
  
1 (0.020)  





Bx 228                                 21 (0.060) 10 (0.109) 3 (0.060)  










Bx 237                                 2 (0.010) 1 (0.011) 
 
SA San 
Bx 238                                 1 (0.003) 1 (0.011) 
 
SA San 
Bx 272                                 1 (0.003) 
  
 
Bx 401                                 2 (0.010) 
  
 
Bx 467                                 1 (0.003) 
  
Iran Northern 
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6.3.5 Population structure of the South African Coloured (SAC) and Khoisan 
(SAN) populations 
 
The STRUCTURE analysis of the SAC and SAN populations with their potential ancestral 
populations showed K = 6 as the best approximation for the ancestral genetic contribution to 
the SAC and SAN populations (Figure 40), when accounting for LD between SNP markers 
included in the study. In the SAC population, four ancestral populations were identified as 
major contributors, including Bantu (non-Khoisan Africans), San (Khoisan Africans), French 
(European) and Cambodian (Asian) (Table 40). For the SAN population, European (French) 
and Bantu contribution was noted, with Asian (Cambodian) to a lesser extent. In both the 
SAC and SAN populations, a very small genetic contribution was noted from North 
(Mozabite) and East (Hadza) African populations. 
 
Figure 40: STRUCTURE plot for South African Coloured (SAC_CPT) and Khoisan (SAN_SA) 
populations with K=6. 
 
 
Table 40: Mean genetic contribution of ancestral populations to the South Coloured (SAC) and 
Khoisan (SAN) populations. 
 European Bantu Mozabite Cambodian San Hadza 
SAC 22.5 32.8 1.4 11.8 31.2 0.3 
SAN 11.0 13.0 0.9 2.5 72.5 0.1 
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6.3.6 Genetic contribution to the MHC and LRC regions of the SAC 
population 
 
To determine the genetic contribution to the MHC and LRC regions of the SAC population 
(healthy controls) we used the LAMP-LD program, with San, European and Bantu ancestral 
populations. San individuals with San ancestry ≥ 75%, based on admixture proportions 
assigned in STRUCTURE analysis, were included to reduce the genetic “noise” of other 
ancestral populations. 
Both the MHC (Figure 41) and LRC (Figure 42) regions of the SAC population were shown 
to have the following profile: European>Bantu>San. For the MHC region, ~42% was of 
European origin, ~38% of Bantu origin and ~25% of San origin. To determine the average 
ancestry of the HLA-C gene, the same ancestral contribution was noted as in the MHC 
region, with an average European contribution of ~50%, average Bantu contribution of 
~36.5% and an average San contribution of ~13.5%, showing a greater European contribution 
for this gene. This “fine-scaling” approach can be used to identify genes which are more 
specific to a given ancestral population, as definite European and Bantu peaks are present in 
Figure 41 A. A similar genetic contribution was noted for the LRC region (Figure 42). 
6.3.7 Genetic relation of South African populations with regards to their 
HLA class-I composition 
 
To plot the genetic relationship of South African populations we used PCO analysis using the 
allele frequencies of the HLA class-I alleles (Figure 43). For this analysis we included the 
SAC TB cases to determine their genetic relationship relative to the SAC healthy controls. 
We plotted axis 1 and 2 of the PCO analysis, which accounted for more than 50% of the 
variance. The PCO plot shows clear separation of the SA white, black and Natal Tamil 
populations, with the white and black populations forming clusters on opposite ends of the 
graph. The SAC population was centred at the origin of the plot, with the Khoisan population 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 147 
 
clustering with the SA black populations. Interestingly, the SAC TB cases were found to 
cluster closer to the Khoisan and black SA populations than the SAC healthy controls and 

































Figure 41: Ancestral contributions to the SAC population for the MHC region on chromosome 
6. A: the proportion of each ancestral population in the genetic composition of the MHC region in the SAC, 
where the blue line = San ancestry, green = Bantu ancestry, and red = European ancestry. B: the average 












Stellenbosch University  http://scholar.sun.ac.za































Figure 42: Ancestral contributions to the SAC population for the LRC region on chromosome 9. 
A: the proportion of each ancestral population in the genetic composition of the LRC region in the SAC, where 
the blue line = San ancestry, green = Bantu ancestry, and red = European ancestry. B: the average ancestral 




Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 149 
 
 





The HLA class-I and KIR genes are among the most polymorphic loci in the human genome, 
with their extensive diversity facilitating the role of these genes in various biological 
processes [450,485]. These processes include disease (infectious, autoimmune, cancers), 
reproduction and organ transplantation [234]. The diversity of allele, gene and haplotype 
frequencies of these molecules have also been shown to differ between populations of 
different geographic regions [227,451,454]. Studies to date have shown a clear correlation 
between certain diseases and ethnicities. In this regard, understanding the HLA and KIR 
background of various populations would be highly informative, and facilitate in 
understanding the genetic aetiology of disease, creating vaccines with greater efficacy for 
specific populations, and promoting efficient organ transplantation. This work is especially 
important in countries such as South Africa, which has a wide diversity with regards to the 
various ethnic groups which make up the South African nation. 
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In this study we compared the allele frequencies of the HLA class-I genes across the main 
South African population groups, with the aim of understanding the diversity of the class-I 
alleles within the population and to determine the genetic contribution to the SAC population, 
a highly admixed population, with regards to these genes. Also, given that the HLA genes 
play an important role in host immunity, we were interested in whether marked differences 
were present between SAC TB cases and healthy controls with regards to the class-I allele 
composition.  
In Chapter 4 we highlighted several associations between HLA class-I alleles (and other 
genes of the MHC) and susceptibility to TB in the SAC population. A recent study by our 
group using genome-wide data identified a relationship between TB risk and genetic 
ancestry, where SAC TB cases were found to have a greater proportion of African ancestry 
than healthy controls (58% vs. 51%) [321]. Furthermore, San ancestry was found to be 
associated with an increased risk for TB, while European and Asian ancestry was found to be 
protective. Here we presented data showing that the genetic composition of MHC and LRC in 
SAC healthy controls is predominantly of European descent with a lower San genotype 
contribution, and that the SAC TB cases are more closely related to the San and black 
Africans, than the SAC healthy controls. This casts some light on the genetic aetiology of 
susceptibility to infectious diseases. In the case of TB, it is postulated that European 
populations, through selection events against alleles that predisposed to TB during the 
scourge of the “White Plague” in 17
th
 century Europe [12], are today less susceptible to TB 
compared to individuals of African ancestry. While TB may have been present in Africa 
before the Out-of-Africa migration, the disease never reached epidemic proportions given the 
rural lifestyles of African tribes, thus limiting the chance of selection events against disease 
causing alleles. 
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Several studies have speculated on the role of host genetics in vaccine efficacy [486]. It is 
currently estimated that between 44% and 78% of the variation in antibody responses to 
vaccines is genetic in origin, with the HLAs playing a definitive role in explaining these 
varied responses at the population level [487–489]. These HLA molecules are involved in the 
presentation of antigens from various pathogens and are highly polymorphic, creating a major 
challenge for the design of efficacious vaccines against infectious diseases. To date, HLA-
associated vaccine failure has been reported for several vaccines; including hepatitis B, 
measles and influenza [490–493]. There are currently three TB vaccines at various phases of 
clinical trials that have shown promising results in their test populations [494–502]. To 
evaluate the efficacy of these vaccines in high TB burden countries, Davila et al. evaluated 
the binding of vaccine epitopes to HLA class-I and class-II alleles [484]. Their findings 
suggested that the Mtb72f vaccine offered less protection globally when compared to the 
Ag85B-ESAT-6 and AG85B-TB10.4 vaccines based on the number of HLA alleles found at 
a high frequency within these TB endemic populations but with low affinity for the vaccine 
epitopes. The results presented here from the SA populations confirm that conclusion. 
Vaccine efficacy has also been shown to be determined by the genetics of the challenging M. 
tuberculosis strain, where BCG vaccinated mice were shown to be less protected when 
challenged with Beijing strains than with the laboratory strain H37Rv [406,503]. 
With regards to KIR genotype profiles across the SA population, data was only publicly 
available for two additional populations, San and Xhosa, limiting the analysis we were able to 
do with this family of genes. Of the three SA populations, the SAC were the most diverse 
with respect to number of genotype profiles present, followed by the San and then the Xhosa 
populations. Furthermore, the Xhosa population had no single major KIR profile, with all 
three populations having the AA haplotype as the most common, in line with findings across 
populations of different ethnicities globally [504–508]. Only two BB haplotypes (absent for 
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all four haplotype A genes: 2DL1, 2DL3, 2DS4, 3DL1) were present in the SA populations, 
with Bx 74 present in one SAC individual and Bx 194 in one San individual, with the 
remaining 59 genotype profiles being AB haplotypes. B haplotypes have been shown to 
effect a stronger immune response through their ability to effectively activate NK/T cells in 
response to pathogens, while A haplotypes provide a stronger tolerance to self and are thus 
important in autoimmune diseases [509]. Thus having a greater proportion of AB haplotypes 
suggests some form of balancing selection with regards to the KIR genes. 
Understanding of the genetic contribution of the ancestral populations to the SAC can aid us 
in identifying the genetic causes of disease given that the ancestral populations of the SAC 
have markedly dissimilar rates of TB infection and disease. This is especially important given 
the high burden of this disease among SAC individuals, highlighting the need to identify 
these risk factors, which could be done using admixture mapping [510–514]. Finally, the 
HLA data provided in this study will have useful biomedical applications, including 
understanding the role of HLAs in infectious diseases, vaccine development and 
hematopoietic stem-cell transplantation in SA populations. 
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TB remains a global health issue, even though several advances in the field of biomedical 
research have been achieved, including the discovery and development of chemotherapeutic 
agents, vaccines, and faster diagnosis. TB is a complex disease with host, pathogen and 
environmental factors contributing to the development of active TB disease. 
The work presented in this thesis highlights the role of host genetics in the progression to TB 
disease. Here we investigated the role of genes belonging to the MHC (chromosome 6) and 
the LRC (chromosome 19) in susceptibility to TB in the highly admixed SAC population. 
Both complexes house genes that play an important role in the host immune response. 
In the MHC region we focussed our attention on the HLA class-I genes, comprised of HLA-
A, -B and -C. These genes are known to be important modulators of the host immune 
response, and are involved in antigen processing and presentation, amongst other important 
biological processes. This gene family is the most polymorphic in the human genome, with 
thousands of variants identified to date. This extreme variability is thought to have arisen in 
response to the large number of pathogenic antigens to which humans are exposed. 
In the LRC region we predominantly focused on the KIR gene family. The KIRs comprise 
sixteen genes, of which fourteen are functional. The KIR genes are also classified based on 
function, activating or inhibitory, where activating KIRs induce T and NK cell activation in 
response to pathogens and inhibitory KIRs promote tolerance to self.  
The HLA class-I molecules are also known ligands for certain KIR genes, with some studies 
showing co-evolution between the two gene families, even though they reside on different 
chromosomes. 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 154 
 
While most studies to date have focussed on the role of KIRs and HLAs in viral diseases, 
there is a growing amount of data to support their importance in susceptibility to bacterial 
diseases as well. In this regard, NK cells secrete α-defensins and CD8
+
 T cells produce 
granulysin and perforin, mediating programmed cell death of infected cells 
In this thesis the following observations were made: 
1. Susceptibility to TB 
 KIRs are involved in susceptibility to TB, where an overexpression of aKIRs (≥5) and 
specifically the presence of KIR3DS1, was shown to protect against the development 
of active TB disease. This is in line with the current understanding of KIRs in 
infectious diseases, where aKIRs result in a stronger immune response. 
 Two KIR gene profiles which had fewer than 5 aKIRs and an absence of KIR3DS1 
were found to increase the risk of developing TB. 
 Specific HLA class-I alleles altered susceptibility to TB, with some alleles showing 
risk for (ORs ranging between 1.89 and 4.27) and others protection against (ORs 
ranging between 0.16 and 0.44) developing TB. 
 No statistically significant associations were observed between the KIR-HLA 
compound genotypes and TB susceptibility. However, the true 3DS1 ligand has yet to 
be identified. 
 Several loci in the MHC and LRC were found to alter susceptibility to TB in the SAC 
and the Gambian populations, although with very few SNPs common to the two 
populations. This however is in part due to QC analysis, where SNPs in one 
population failed QC in the other. Genes found to be associated in both populations 
include MDC1, BTNL2, HLA-DOA, C6orf10, and the intergenic region between HLA-
C and WASF5P. In the SAC population only, HLA-DOB, TAP2, LILRA5, LILRP2, 
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NCR1/NLRP7 and the intergenic region between LAIR1/TTYH1 were found to be 
associated with TB, while there were no genes associated in The Gambia that were 
not also associated in the SAC. To data, case-control association studies for TB have 
only been done for the BTNL2 and TAP2 genes. This work therefore presents novel 
gene candidates to be investigated for susceptibility to TB. 
 Alleles and SNPs of the HLA-C gene were associated with susceptibility to TB. This 
gene was recently identified as a risk factor for leprosy, caused by M. leprae, and 
could thus be an important gene for susceptibility to mycobacterial disease. 
2. Susceptibility to TB disease caused by specific M. tuberculosis strains 
 Alleles of the HLA class-I genes were shown to not only be involved in susceptibility 
to TB but disease caused by specific M. tuberculosis strains as well. 
 The Beijing strain was observed to occur more frequently in individuals with multiple 
disease episodes (P < 0.001). 
 The B*27 allele was associated with having fewer TB disease episodes (OR = 0.21) 
and with protection against having disease caused by the Beijing strain (OR = 0.35). 
This allele is found in individuals who are able to control their HIV infections without 
any ARV treatment and in individuals with slow HIV/AIDS disease progression. 
 Additional associations were also observed between class-I alleles, genotypes and 
haplotypes and disease caused by the Beijing, LAM, LCC and Quebec strains. 
 Sub-lineage 7 is the most prevalent Beijing strain causing disease in the Western 
Cape, where the A*30:02 allele was only present in TB cases with disease caused by 
sub-lineage 7 and the A*02:02 allele was shown to protect (OR = 0.04) against 
disease caused by sub-lineage 7. 
 We also observed instances of apparent co-evolution between host and pathogen, 
where a class-I allele more commonly found in white populations was associated with 
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strains belonging to the Euro-American lineage and vice-versa for East Asian human 
populations and strains. However, given the complexity of the disease and the number 
of genes involved this effect was not seen for all the associations tested. 
 This work emphasizes the importance of considering both host and pathogen 
genotypes in the understanding of disease development. By incorporating both 
genotypes we may be able to overcome the genetic heterogeneity associated with TB 
disease. 
3. Influence of ancestral genetic contributions to the development of TB disease in the SAC 
populations 
 Using HLA alleles and KIR gene profiles we noted that the SAC population is the 
most diverse SA population, as would be expected considering its admixture. 
 HLA class-I alleles have been shown to bind several epitopes of the TB vaccines, 
Ag85B-ESAT-6, Ag85B-TB10.4, Mtb72f. Coverage of these class-I alleles was 
shown to be low to moderate in the SA black, San and Natal Tamil populations while 
having the greatest efficacy in the SA white population. Based on the class-I allele 
distribution across the SA populations, none of these vaccines would be equally 
efficacious across all SA populations. 
 We show that while the SAC population may have a greater proportion of San 
ancestry according to genome-wide SNP data, the MHC and LRC regions of the SAC 
are predominantly of European ancestry, followed by Bantu and then San. When 
analysing the genetic relationship between SAC healthy controls and TB cases with 
other SA populations, we see that the TB cases cluster more closely with the San 
population. A recent study by our group showed that San ancestry is in fact a risk 
factor for developing TB, supporting the findings presented here. 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 157 
 
 Certain diseases show a preference for ancestry, occurring more frequently in 
individuals belonging to certain populations group. The same is true for TB disease, 
where individuals of European ancestry seem to have a lower risk for developing TB, 
with the converse seen in individuals of African descent. 
7.2 Limitations and Future work 
 
While the work presented in this thesis has been done to the best of our ability, it does have 
several limitations, which should be addressed in future experiments. 
i. Sample size: Given the extreme variability of the class-I alleles and the number of KIR 
genes, the sample size of 760 individuals may have been sufficient for the purposes of 
this study but limited the analysis that could be done. This is especially true for the HLA 
and M. tuberculosis strain association study where several strains are causing disease in 
our population. To account for this we re-classified our class-I alleles into supertypes to 
reduce the number of variables and increase the number of individuals per HLA type. It is 
also important to note that typing of the class-I alleles and KIR genes are extremely 
complex and expensive, and samples that failed typing at a locus (more than twice) were 
not “called” at that specific locus. However, with regards to class-I allele population 
diversity, our sample size was quite large compared with what is currently presented in 
AFND. The KIR3DP1 gene was not typed in the SAC population. This pseudogene is 
considered a “framework” gene and should be present in all individuals, which was true 
for the other “framework” genes in the SAC. 
ii. Correcting for multiple testing: There are different schools of thought with regards to 
multiple testing in genetic association studies, as some researchers deem it necessary 
while others do not. While we do not oppose correcting for multiple testing, we have the 
view that no appropriate method currently exists. Bonferroni correction is only applicable 
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when all the tests are independent, which is not the case for the HLA alleles or for the M. 
tuberculosis strains. Specifically in the case of the HLA genes which are known to be in 
LD with each other, correcting by Bonferroni would result in markedly overcorrecting for 
the false-positive rates and result in a reduction in power. Bonferroni correction has also 
been shown to increase the likelihood of type II errors, which is no less false than type 1 
errors, resulting in truly important differences being deemed non-significant. The 
Bayesian method on the other hand requires the grouping of variants into clusters with 
different prior probabilities of affecting the outcome, which is not currently possible for 
all variants.  
iii. Correcting for ancestry: Earlier studies showed no stratification in the SAC population 
between cases and controls. However, the recently published study of Chimusa et al. 
[201] showed that the population is in fact stratified, and that San ancestry is a risk factor 
for developing TB. Our group is therefore developing a set of ancestry informative 
markers (AIMS), which will be used to correct for ancestry. 
iv. Latent TB infection: The incidence of latent TB (healthy controls who have positive TST 
skin test) is known to be high in the Ravensmead/Uitsig communities. The case-control 
study conducted here therefore investigated the host genetic factors involved in 
progression to active TB disease, which may also be associated with primary disease. 
v. Validation of associated variants: While several associations were identified in this thesis 
between loci of the MHC and LRC with susceptibility to TB and disease caused by 
specific M. tuberculosis strains, the biological and functional relevance of these loci were 
not investigated. For the KIRs, we propose to investigate the differences in cytolytic 




 NK cells. We will also study 
the KIR gene profile of M. tuberculosis infected CD56
dim/bright
 cells with regards to the 
number of aKIRs present. We propose to design biological models to investigate the 
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specificity of host genotypes with specific M. tuberculosis strain types. With regards to 
the genes identified using the genome-wide SNP chip data, these genes should be 
sequenced in the SAC population to identify relevant SNPs to be tested in an additional 
sample set of the SAC and/or other populations. 
vi. Future approaches: Due to the enormous technical advancements achieved over the last 
several years in DNA sequencing technologies, NGS is now possible, allowing the whole 
human genome to be sequenced within weeks. This approach also allows for the 
identification of both common and rare variants. Using these technologies to study 
extreme forms of TB disease (such as tuberculous meningitis, TBM) could yield novel 
and interesting findings with regards to disease susceptibility. Admixture mapping could 
also serve as an approach for the identification of novel TB susceptibility genes. This 
approach allows for the identification of susceptibility loci in a population which is 
comprised of at least two populations, where one population is known to have a greater 
predisposition to TB disease, and this is particularly relevant for the SAC population, 
which has a complex 5-way admixture. The necessary computational algorithms will 
therefore have to be developed before admixture mapping studies can be done. 
7.3 Conclusion 
 
There is a difference in the rates that diverse populations are infected with tuberculosis and 
progress to disease, thus studying the genetic aetiology of TB disease in admixed populations 
is useful in the identification of disease-causing alleles which may be regarded as 
representative of the variety in the global population. The SAC population is therefore well-
suited to this purpose with known genetic contributions from European, Black African, 
Khoisan and Asian ethnicities. Using HLA class-I data we show that SAC TB cases are more 
closely related to the Khoisan (and Black African) populations than the SAC healthy controls. 
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Furthermore, that the MHC and LRC regions in SAC healthy controls are predominantly of 
European ancestry. We therefore highlight a clear role for ancestry in the development of 
active TB disease in the SAC population. With regards to TB vaccines, we show that three 
vaccines currently undergoing clinical trials may have poor efficacy in SA populations, 
except in the white population, based on HLA allele frequencies which bind to the vaccine 
epitopes. Similar findings were observed in other populations from countries with a high TB 
burden. Future vaccine designs should thus take HLA allele frequencies into account, if we 
are to design TB vaccines which are effective where they are needed most. 
Studies to date have classified M. tuberculosis strains based on their geographical origin, with 
epidemiological studies showing genomic differences between the various strains. Using 
HLA class-I alleles, which are also known to differ across geographical populations, we show 
that co-evolution events occur between human and M. tuberculosis subtypes, and it seems 
likely that the previous geographical differences noted were in fact due to the differences in 
HLA alleles between populations, which we have now identified. However, given the 
complexity of HLA biology, these correlations did not hold true for all associations tested. 
Also, taking bacterial genotype into consideration may reduce the genetic heterogeneity 
associated with disease susceptibility studies. 
In conclusion, we highlight the importance of the KIR and HLA genes in TB disease, vaccine 
development and host-strain interaction.  
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Appendix 1: Estimated HLA class-I haplotypes in the SAC population. 
Haplotypes TB Case (f) Control (f) P-value OR (95% CI) 
A*0101-B*0801-C*0701 0.044 0.027 
 
1 
A*0301-B*4701-C*0602 0.023 0.007 0.3140 0.48 (0.12-1.98) 
A*3001-B*4201-C*1701 0.010 0.019 0.0720 3.35 (0.90-12.45) 
A*3002-B*0801-C*0701 0.020 0.012 0.9320 1.06 (0.28-3.96) 
A*3004-B*5802-C*0602 0.010 0.019 0.2200 2.42 (0.59-9.96) 
A*0201-B*0702-C*0702 0.014 0.014 0.7540 1.23 (0.34-4.39) 
A*4301-B*1503-C*1801 0.008 0.016 0.0750 3.90 (0.87-17.39) 
A*3001-B*4202-C*1701 0.017 0.006 0.1820 0.29 (0.05-1.77) 
A*3002-B*4501-C*1601 0.012 0.008 0.9670 1.03 (0.23-4.55) 
A*6601-B*5802-C*0602 0.010 0.010 0.6260 1.44 (0.33-6.21) 
A*0301-B*0702-C*0702 0.002 0.010 
  A*4301-B*1510-C*0401 0.010 0.008 
  A*3201-B*4403-C*0210 0.008 0.010 
  A*0201-B*1302-C*0602 0.010 0.008 
  A*0101-B*5701-C*0602 0.014 0.000 
  A*2407-B*3505-C*0401 0.004 0.012 
  A*2901-B*1801-C*0704 0.008 0.008 
  A*3402-B*4403-C*0401 0.008 0.008 
  A*6801-B*5802-C*0602 0.004 0.012 
  A*7401-B*1503-C*0210 0.010 0.006 
  A*2601-B*4101-C*1701 0.014 0.002 
  A*2402-B*0702-C*0702 0.011 0.004 
  A*0123-B*5801-C*0602 0.004 0.010 
  A*0202-B*5703-C*0701 0.004 0.010 
  A*0205-B*5801-C*0701 0.010 0.004 
  A*0301-B*1501-C*0304 0.006 0.008 
  A*6802-B*0702-C*0702 0.004 0.009 
  A*1101-B*3501-C*0401 0.008 0.006 
  A*3002-B*5802-C*0602 0.000 0.012 
  A*3001-B*1503-C*0210 0.004 0.010 
  A*0205-B*1401-C*0804 0.006 0.002 
  A*6802-B*1510-C*0304 0.004 0.008 
  A*2402-B*4006-C*1502 0.000 0.008 
  A*2301-B*5802-C*0602 0.005 0.008 
  A*2301-B*4101-C*1701 0.004 0.006 
  A*2301-B*1510-C*1601 0.006 0.004 
  A*3001-B*1302-C*0602 0.008 0.000 
  A*3303-B*4403-C*0701 0.008 0.000 
  A*3201-B*0702-C*0210 0.004 0.006 
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Haplotypes TB Case (f) Control (f) P-value OR (95% CI) 
A*6801-B*5801-C*0602 0.006 0.000 
  A*0201-B*1503-C*0210 0.007 0.002 
  A*2301-B*0702-C*0702 0.010 0.004 
  A*0101-B*4403-C*1601 0.000 0.008 
  A*0101-B*8101-C*1801 0.004 0.000 
  A*0201-B*1801-C*0701 0.002 0.006 
  A*0201-B*4501-C*1601 0.000 0.008 
  A*0301-B*4001-C*0304 0.000 0.006 
  A*0301-B*4501-C*0602 0.004 0.004 
  A*1101-B*0705-C*0702 0.005 0.004 
  A*1101-B*1513-C*0801 0.006 0.002 
  A*1101-B*5201-C*1202 0.004 0.004 
  A*2402-B*3501-C*0401 0.000 0.004 
  A*2402-B*3505-C*0401 0.006 0.000 
  A*2402-B*4403-C*0401 0.000 0.006 
  A*2901-B*1503-C*0401 0.000 0.008 
  A*3002-B*1402-C*0802 0.002 0.006 
  A*3002-B*5703-C*1801 0.000 0.008 
  A*3004-B*3924-C*0701 0.002 0.006 
  A*3303-B*5801-C*0302 0.004 0.004 
  A*7401-B*1502-C*0801 0.006 0.002 
  A*2301-B*4403-C*0401 0.004 0.004 
  A*0301-B*2705-C*0202 0.002 0.006 
  A*1101-B*1302-C*0602 0.004 0.002 
  A*6802-B*4101-C*1701 0.000 0.000 
  A*0201-B*1503-C*1801 0.000 0.006 
  A*0201-B*5101-C*1601 0.000 0.002 
  A*0202-B*5301-C*0401 0.000 0.006 
  A*0214-B*4403-C*0401 0.006 0.000 
  A*0301-B*1801-C*0701 0.000 0.006 
  A*0301-B*4006-C*1502 0.006 0.000 
  A*0301-B*5601-C*0401 0.000 0.006 
  A*0301-B*5802-C*0602 0.000 0.006 
  A*2301-B*1402-C*0802 0.002 0.004 
  A*2402-B*1801-C*0701 0.002 0.002 
  A*2402-B*4001-C*0304 0.002 0.004 
  A*2402-B*4006-C*1202 0.006 0.000 
  A*2402-B*5201-C*1202 0.002 0.004 
  A*2501-B*1801-C*1203 0.004 0.002 
  A*2601-B*0705-C*0702 0.003 0.000 
  A*2601-B*5802-C*0602 0.000 0.004 
  A*2901-B*0705-C*1505 0.006 0.000 
  A*2902-B*4403-C*0701 0.004 0.000 
  A*3001-B*8101-C*0401 0.000 0.006 
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Haplotypes TB Case (f) Control (f) P-value OR (95% CI) 
A*3002-B*5702-C*1801 0.000 0.006 
  A*3004-B*3910-C*1505 0.000 0.004 
  A*3004-B*4102-C*1701 0.006 0.000 
  A*3201-B*0702-C*0102 0.004 0.002 
  A*3301-B*4201-C*1701 0.002 0.004 
  A*3402-B*5802-C*1801 0.004 0.002 
  A*3601-B*5301-C*0401 0.000 0.004 
  A*4301-B*1501-C*0401 0.000 0.004 
  A*6802-B*1401-C*0802 0.000 0.004 
  A*6802-B*1402-C*0802 0.006 0.000 
  A*6802-B*1510-C*0804 0.002 0.004 
  A*6802-B*5802-C*0602 0.002 0.004 
  A*6827-B*4101-C*1701 0.000 0.006 
  A*7401-B*3501-C*0401 0.004 0.002 
  A*2301-B*1503-C*0210 0.000 0.002 
  A*3004-B*1510-C*0401 0.006 0.000 
  A*1101-B*1502-C*0801 0.000 0.002 
  A*1101-B*4006-C*1502 0.004 0.000 
  A*2402-B*1502-C*0801 0.004 0.002 
  A*3002-B*4201-C*1701 0.004 0.000 
  A*0201-B*3501-C*0401 0.000 0.002 
  A*3001-B*5802-C*0602 0.004 0.002 
  A*3002-B*1503-C*0210 0.002 0.000 
  A*0101-B*1503-C*0401 0.000 0.004 
  A*0101-B*5703-C*0701 0.000 0.004 
  A*0101-B*5801-C*0302 0.000 0.002 
  A*0123-B*5802-C*0602 0.000 0.002 
  A*0201-B*1401-C*0802 0.006 0.000 
  A*0201-B*1501-C*0303 0.000 0.002 
  A*0201-B*1501-C*0401 0.004 0.000 
  A*0201-B*3801-C*1203 0.000 0.002 
  A*0201-B*4001-C*0304 0.006 0.000 
  A*0201-B*4101-C*0701 0.002 0.002 
  A*0201-B*4101-C*1701 0.006 0.000 
  A*0201-B*4202-C*1701 0.002 0.000 
  A*0201-B*4403-C*0701 0.002 0.000 
  A*0201-B*4405-C*0202 0.004 0.000 
  A*0201-B*5201-C*1202 0.004 0.000 
  A*0203-B*3503-C*1505 0.000 0.000 
  A*0205-B*1402-C*0804 0.002 0.000 
  A*0206-B*3701-C*0602 0.002 0.002 
  A*0211-B*3503-C*0401 0.004 0.000 
  A*0211-B*5701-C*0602 0.002 0.000 
  A*0301-B*1303-C*0602 0.002 0.002 
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Haplotypes TB Case (f) Control (f) P-value OR (95% CI) 
A*0301-B*1503-C*0701 0.002 0.000 
  A*0301-B*4403-C*0701 0.002 0.002 
  A*0301-B*5801-C*0302 0.000 0.004 
  A*1101-B*0702-C*0702 0.002 0.002 
  A*1101-B*1801-C*0704 0.002 0.002 
  A*1101-B*4001-C*1203 0.002 0.000 
  A*1101-B*4002-C*1502 0.000 0.004 
  A*1101-B*4006-C*0303 0.000 0.000 
  A*1101-B*4403-C*0701 0.000 0.002 
  A*1101-B*5101-C*0401 0.000 0.004 
  A*1101-B*5101-C*1402 0.000 0.002 
  A*1101-B*5501-C*0303 0.000 0.004 
  A*2301-B*0801-C*0304 0.000 0.002 
  A*2301-B*3901-C*0210 0.004 0.000 
  A*2301-B*3910-C*1505 0.002 0.002 
  A*2301-B*4403-C*0210 0.000 0.004 
  A*2301-B*4403-C*0303 0.002 0.002 
  A*2301-B*4403-C*0304 0.002 0.002 
  A*2402-B*1401-C*0802 0.000 0.002 
  A*2402-B*1521-C*0403 0.000 0.004 
  A*2402-B*3502-C*0401 0.002 0.002 
  A*2402-B*4501-C*1601 0.002 0.002 
  A*2402-B*5501-C*0102 0.004 0.000 
  A*2402-B*5802-C*0602 0.004 0.000 
  A*2407-B*1502-C*0801 0.002 0.002 
  A*2407-B*2706-C*0702 0.000 0.004 
  A*2601-B*2705-C*0102 0.004 0.000 
  A*2601-B*5802-C*0401 0.000 0.004 
  A*2612-B*4101-C*0701 0.000 0.000 
  A*2901-B*0705-C*0401 0.000 0.002 
  A*2901-B*4403-C*0210 0.002 0.002 
  A*2902-B*1801-C*0704 0.000 0.002 
  A*2902-B*4403-C*1601 0.002 0.002 
  A*3001-B*4501-C*1601 0.000 0.004 
  A*3002-B*1801-C*0704 0.004 0.000 
  A*3004-B*1401-C*0802 0.002 0.000 
  A*3004-B*4101-C*1701 0.000 0.004 
  A*3004-B*5101-C*1601 0.002 0.002 
  A*3101-B*5101-C*1402 0.004 0.000 
  A*3101-B*5801-C*1203 0.004 0.000 
  A*3201-B*1502-C*0801 0.000 0.004 
  A*3201-B*3801-C*1203 0.004 0.000 
  A*3201-B*4403-C*0202 0.004 0.000 
  A*3201-B*5801-C*0202 0.002 0.002 
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Haplotypes TB Case (f) Control (f) P-value OR (95% CI) 
A*3301-B*5301-C*0401 0.000 0.002 
  A*3402-B*1503-C*0210 0.002 0.000 
  A*3402-B*4403-C*0701 0.004 0.000 
  A*4301-B*1402-C*0804 0.002 0.000 
  A*4301-B*2705-C*0210 0.000 0.004 
  A*4301-B*3501-C*0401 0.000 0.000 
  A*4301-B*5301-C*0804 0.000 0.000 
  A*6801-B*2705-C*0202 0.000 0.004 
  A*6801-B*4001-C*0304 0.002 0.000 
  A*6801-B*4402-C*0501 0.004 0.000 
  A*6802-B*4403-C*0401 0.004 0.000 
  A*6802-B*4501-C*0602 0.002 0.000 
  A*6827-B*4403-C*0401 0.004 0.000 
  A*7401-B*5802-C*0602 0.004 0.000 
  A*8001-B*1801-C*0202 0.000 0.000 
  A*2301-B*0702-C*0210 0.004 0.000 
  A*0205-B*5802-C*0602 0.000 0.002 
  A*3004-B*5801-C*0602 0.002 0.002 
  A*2301-B*4501-C*0602 0.002 0.000 
  A*6801-B*1503-C*1801 0.000 0.004 
  A*2402-B*2705-C*0202 0.002 0.000 
  A*2601-B*0702-C*0702 0.000 0.002 
  A*3001-B*0702-C*0210 0.000 0.000 
  A*7401-B*0801-C*0701 0.000 0.000 
  A*3004-B*4403-C*0401 0.003 0.000 
  A*0101-B*5802-C*0602 0.004 0.000 
  A*0101-B*4402-C*0501 0.000 0.000 
  A*2402-B*0801-C*0701 0.000 0.002 
  A*3002-B*4202-C*1701 0.002 0.000 
  A*0101-B*0702-C*0701 0.000 0.002 
  A*0201-B*1513-C*0801 0.000 0.002 
  A*2402-B*4201-C*1701 0.000 0.000 
  A*3001-B*0702-C*0702 0.000 0.002 
  A*3201-B*0801-C*0210 0.000 0.000 
  A*0101-B*0702-C*0702 0.000 0.000 
  A*0101-B*1501-C*0304 0.000 0.002 
  A*0101-B*1503-C*0210 0.000 0.002 
  A*0101-B*3501-C*0401 0.002 0.000 
  A*0101-B*3701-C*1701 0.000 0.000 
  A*0101-B*5101-C*1602 0.000 0.002 
  A*0101-B*5701-C*1204 0.000 0.000 
  A*0101-B*5801-C*0701 0.000 0.000 
  A*0123-B*1503-C*0401 0.002 0.000 
  A*0123-B*2705-C*0202 0.000 0.002 
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Haplotypes TB Case (f) Control (f) P-value OR (95% CI) 
A*0123-B*4701-C*0602 0.000 0.000 
  A*0201-B*1513-C*1701 0.000 0.000 
  A*0201-B*1801-C*0704 0.002 0.000 
  A*0201-B*1801-C*1203 0.000 0.000 
  A*0201-B*3502-C*0401 0.000 0.002 
  A*0201-B*3502-C*0602 0.000 0.000 
  A*0201-B*3503-C*0401 0.000 0.000 
  A*0201-B*3508-C*0202 0.000 0.000 
  A*0201-B*3910-C*1203 0.000 0.002 
  A*0201-B*4402-C*0501 0.002 0.000 
  A*0201-B*5101-C*1402 0.004 0.002 
  A*0201-B*5301-C*0304 0.002 0.000 
  A*0201-B*5801-C*0302 0.000 0.002 
  A*0201-B*5801-C*0701 0.000 0.000 
  A*0202-B*1503-C*0210 0.000 0.002 
  A*0202-B*1516-C*1402 0.002 0.000 
  A*0202-B*4701-C*0602 0.000 0.002 
  A*0202-B*5801-C*0602 0.002 0.000 
  A*0203-B*1301-C*0403 0.000 0.002 
  A*0203-B*1502-C*0801 0.000 0.002 
  A*0203-B*1801-C*0704 0.002 0.000 
  A*0203-B*3501-C*0602 0.000 0.000 
  A*0203-B*3802-C*0702 0.002 0.000 
  A*0203-B*3901-C*0702 0.002 0.000 
  A*0203-B*4001-C*0702 0.000 0.002 
  A*0205-B*0801-C*0210 0.000 0.002 
  A*0205-B*1510-C*0304 0.000 0.002 
  A*0205-B*1510-C*0704 0.000 0.000 
  A*0205-B*2705-C*0210 0.000 0.002 
  A*0205-B*4201-C*1701 0.000 0.000 
  A*0205-B*4403-C*1801 0.000 0.000 
  A*0205-B*4701-C*0602 0.000 0.002 
  A*0205-B*5101-C*0210 0.000 0.002 
  A*0207-B*4601-C*0302 0.000 0.002 
  A*0211-B*1508-C*0102 0.000 0.002 
  A*0211-B*1801-C*0701 0.000 0.002 
  A*0211-B*2704-C*1202 0.002 0.000 
  A*0211-B*2705-C*0501 0.000 0.000 
  A*0211-B*2706-C*0304 0.000 0.002 
  A*0211-B*3701-C*0602 0.000 0.000 
  A*0211-B*4001-C*0303 0.000 0.000 
  A*0211-B*4006-C*1502 0.002 0.000 
  A*0211-B*5201-C*1202 0.000 0.004 
  A*0214-B*4403-C*0404 0.000 0.000 
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Haplotypes TB Case (f) Control (f) P-value OR (95% CI) 
A*0290-B*0801-C*0702 0.000 0.000 
  A*0301-B*0702-C*0210 0.002 0.000 
  A*0301-B*0801-C*0602 0.002 0.000 
  A*0301-B*0801-C*0702 0.000 0.004 
  A*0301-B*1502-C*0801 0.002 0.000 
  A*0301-B*1503-C*0210 0.002 0.000 
  A*0301-B*1505-C*0303 0.000 0.000 
  A*0301-B*1510-C*0401 0.000 0.002 
  A*0301-B*2705-C*0210 0.000 0.002 
  A*0301-B*3501-C*0401 0.002 0.000 
  A*0301-B*3501-C*0501 0.000 0.000 
  A*0301-B*3508-C*0401 0.000 0.002 
  A*0301-B*4001-C*1203 0.000 0.000 
  A*0301-B*4403-C*0210 0.000 0.002 
  A*0301-B*5001-C*0602 0.000 0.002 
  A*0301-B*5701-C*0602 0.002 0.000 
  A*1101-B*1538-C*0303 0.002 0.000 
  A*1101-B*1801-C*1202 0.002 0.000 
  A*1101-B*3503-C*0401 0.000 0.004 
  A*1101-B*3503-C*1203 0.002 0.000 
  A*1101-B*3503-C*1602 0.002 0.000 
  A*1101-B*3915-C*0401 0.000 0.002 
  A*1101-B*4002-C*0202 0.000 0.002 
  A*1101-B*4402-C*0501 0.000 0.000 
  A*1101-B*4701-C*0602 0.000 0.002 
  A*1101-B*5101-C*1502 0.000 0.002 
  A*1101-B*5101-C*1601 0.000 0.002 
  A*1101-B*8101-C*1801 0.000 0.002 
  A*2301-B*0801-C*0210 0.000 0.002 
  A*2301-B*1516-C*1402 0.000 0.000 
  A*2301-B*1801-C*0704 0.000 0.002 
  A*2301-B*1801-C*1502 0.000 0.000 
  A*2301-B*2705-C*0401 0.000 0.000 
  A*2301-B*3543-C*1601 0.000 0.002 
  A*2301-B*3906-C*0702 0.000 0.000 
  A*2301-B*3910-C*1203 0.000 0.002 
  A*2301-B*4102-C*1701 0.000 0.000 
  A*2301-B*4402-C*0202 0.000 0.002 
  A*2301-B*5001-C*0602 0.000 0.002 
  A*2301-B*5301-C*0202 0.000 0.000 
  A*2301-B*5301-C*0401 0.000 0.002 
  A*2301-B*5703-C*0202 0.000 0.000 
  A*2301-B*8101-C*0404 0.000 0.002 
  A*2301-B*8202-C*0302 0.002 0.000 
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Haplotypes TB Case (f) Control (f) P-value OR (95% CI) 
A*2402-B*1401-C*0804 0.000 0.006 
  A*2402-B*1501-C*0102 0.000 0.002 
  A*2402-B*1501-C*0303 0.000 0.002 
  A*2402-B*1501-C*0304 0.000 0.002 
  A*2402-B*1502-C*0403 0.000 0.000 
  A*2402-B*1531-C*0403 0.000 0.002 
  A*2402-B*4002-C*1502 0.002 0.000 
  A*2402-B*4011-C*0102 0.000 0.002 
  A*2402-B*4403-C*0210 0.000 0.000 
  A*2402-B*4403-C*1601 0.000 0.002 
  A*2402-B*5001-C*0602 0.002 0.000 
  A*2402-B*5101-C*0701 0.000 0.000 
  A*2402-B*5101-C*1502 0.000 0.002 
  A*2402-B*5201-C*0701 0.002 0.000 
  A*2402-B*5702-C*0501 0.000 0.000 
  A*2402-B*8101-C*1801 0.000 0.000 
  A*2403-B*1801-C*0701 0.000 0.000 
  A*2405-B*4501-C*1601 0.000 0.000 
  A*2407-B*0801-C*0701 0.002 0.000 
  A*2407-B*0801-C*0702 0.000 0.002 
  A*2407-B*1501-C*0202 0.000 0.002 
  A*2407-B*1501-C*0702 0.000 0.002 
  A*2407-B*4801-C*0801 0.000 0.000 
  A*2407-B*5201-C*1202 0.000 0.000 
  A*2417-B*4804-C*0102 0.000 0.002 
  A*2501-B*1503-C*1801 0.002 0.000 
  A*2501-B*1521-C*0403 0.000 0.000 
  A*2501-B*3901-C*1203 0.000 0.000 
  A*2501-B*3901-C*1502 0.000 0.000 
  A*2501-B*4101-C*1701 0.002 0.000 
  A*2601-B*1516-C*1402 0.000 0.000 
  A*2601-B*1517-C*0602 0.000 0.000 
  A*2601-B*3501-C*1701 0.000 0.000 
  A*2601-B*3508-C*0202 0.002 0.000 
  A*2601-B*3801-C*1203 0.002 0.000 
  A*2601-B*4002-C*0202 0.002 0.000 
  A*2601-B*4011-C*1203 0.000 0.000 
  A*2601-B*4102-C*0801 0.000 0.000 
  A*2601-B*4901-C*0701 0.002 0.000 
  A*2601-B*5501-C*0303 0.000 0.002 
  A*2601-B*5702-C*0701 0.002 0.000 
  A*2601-B*8101-C*0401 0.002 0.000 
  A*2612-B*3701-C*0602 0.002 0.000 
  A*2901-B*1303-C*1203 0.002 0.000 
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Haplotypes TB Case (f) Control (f) P-value OR (95% CI) 
A*2901-B*4101-C*1701 0.002 0.000 
  A*2901-B*4403-C*0701 0.002 0.000 
  A*2901-B*4403-C*0802 0.000 0.002 
  A*2901-B*5108-C*1602 0.002 0.000 
  A*2902-B*1503-C*0210 0.000 0.000 
  A*2902-B*1510-C*0401 0.002 0.000 
  A*2902-B*3701-C*0602 0.000 0.000 
  A*2902-B*4202-C*1701 0.002 0.000 
  A*2902-B*4501-C*0602 0.002 0.000 
  A*2902-B*5801-C*0602 0.000 0.000 
  A*2911-B*5801-C*0302 0.002 0.000 
  A*3001-B*0705-C*0702 0.000 0.002 
  A*3001-B*0801-C*0702 0.000 0.002 
  A*3001-B*1516-C*1601 0.000 0.002 
  A*3001-B*1801-C*0701 0.000 0.002 
  A*3001-B*5101-C*1402 0.002 0.000 
  A*3001-B*5301-C*0401 0.002 0.000 
  A*3001-B*5801-C*0102 0.000 0.002 
  A*3001-B*5801-C*0602 0.000 0.004 
  A*3002-B*0702-C*0702 0.000 0.002 
  A*3002-B*0801-C*0702 0.002 0.000 
  A*3002-B*1510-C*0702 0.000 0.000 
  A*3002-B*4403-C*1602 0.000 0.000 
  A*3002-B*5001-C*0701 0.000 0.002 
  A*3002-B*5201-C*0602 0.002 0.000 
  A*3002-B*5802-C*1204 0.002 0.000 
  A*3004-B*2705-C*1203 0.000 0.002 
  A*3004-B*4403-C*0210 0.002 0.000 
  A*3004-B*4501-C*1601 0.002 0.000 
  A*3004-B*4901-C*0401 0.000 0.000 
  A*3009-B*1402-C*0802 0.000 0.002 
  A*3101-B*0702-C*0702 0.000 0.002 
  A*3101-B*1401-C*0804 0.000 0.002 
  A*3101-B*1503-C*0210 0.000 0.000 
  A*3101-B*4001-C*0304 0.000 0.002 
  A*3101-B*5101-C*1502 0.002 0.000 
  A*3101-B*5101-C*1602 0.002 0.000 
  A*3201-B*0702-C*0702 0.000 0.002 
  A*3201-B*1302-C*0602 0.002 0.000 
  A*3201-B*1503-C*1801 0.002 0.000 
  A*3201-B*1510-C*0401 0.000 0.002 
  A*3201-B*1801-C*0701 0.002 0.000 
  A*3201-B*2705-C*0202 0.000 0.002 
  A*3201-B*3501-C*0210 0.000 0.002 
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Haplotypes TB Case (f) Control (f) P-value OR (95% CI) 
A*3201-B*3901-C*1203 0.002 0.000 
  A*3201-B*4402-C*0202 0.000 0.000 
  A*3201-B*5802-C*0602 0.002 0.000 
  A*3301-B*8101-C*0403 0.002 0.000 
  A*3303-B*1513-C*0801 0.002 0.000 
  A*3303-B*1801-C*0704 0.000 0.002 
  A*3303-B*3503-C*0401 0.002 0.000 
  A*3303-B*3701-C*0302 0.000 0.002 
  A*3303-B*4403-C*0401 0.000 0.000 
  A*3303-B*8101-C*0804 0.000 0.002 
  A*3303-B*8101-C*1801 0.000 0.002 
  A*3401-B*1521-C*0403 0.002 0.000 
  A*3401-B*5701-C*0403 0.002 0.000 
  A*3402-B*3503-C*0701 0.000 0.000 
  A*3402-B*3901-C*1203 0.000 0.000 
  A*3402-B*4201-C*1701 0.000 0.002 
  A*3402-B*4801-C*0801 0.002 0.000 
  A*3402-B*5703-C*1801 0.002 0.000 
  A*3601-B*1801-C*0704 0.000 0.002 
  A*3601-B*4201-C*1700 0.000 0.002 
  A*3601-B*5301-C*0407 0.000 0.002 
  A*4301-B*0705-C*0702 0.000 0.002 
  A*4301-B*1401-C*0804 0.000 0.002 
  A*4301-B*1801-C*0704 0.000 0.002 
  A*4301-B*1801-C*0802 0.000 0.000 
  A*4301-B*3504-C*1402 0.000 0.000 
  A*4301-B*3701-C*0602 0.002 0.000 
  A*4301-B*4403-C*0804 0.004 0.000 
  A*6601-B*4102-C*1701 0.000 0.002 
  A*6601-B*4701-C*0602 0.002 0.000 
  A*6602-B*4201-C*1701 0.000 0.002 
  A*6801-B*0801-C*0401 0.000 0.000 
  A*6801-B*1402-C*0804 0.002 0.000 
  A*6801-B*1501-C*0303 0.002 0.000 
  A*6801-B*1510-C*0602 0.000 0.002 
  A*6801-B*4006-C*0202 0.000 0.000 
  A*6801-B*5601-C*0102 0.000 0.002 
  A*6801-B*8202-C*0302 0.000 0.002 
  A*6802-B*0705-C*0702 0.000 0.002 
  A*6802-B*1517-C*0702 0.002 0.000 
  A*6802-B*1801-C*0501 0.000 0.002 
  A*6802-B*4901-C*0304 0.000 0.000 
  A*6802-B*5702-C*1801 0.002 0.000 
  A*6802-B*5703-C*1801 0.000 0.002 
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Haplotypes TB Case (f) Control (f) P-value OR (95% CI) 
A*6802-B*5801-C*0701 0.000 0.002 
  A*6827-B*0705-C*0702 0.000 0.002 
  A*6827-B*1510-C*0401 0.000 0.002 
  A*6901-B*1401-C*1203 0.002 0.000 
  A*7401-B*5703-C*0701 0.002 0.000 
  A*7403-B*3910-C*1203 0.000 0.000 
  A*8001-B*0801-C*0701 0.000 0.002 
  A*2402-B*4402-C*0501 0.002 0.000 
  A*7401-B*4201-C*1701 0.002 0.000 
  A*3004-B*1503-C*1801 0.000 0.000 
  A*0205-B*5801-C*0602 0.000 0.002 
  A*0205-B*4501-C*0602 0.000 0.002 
  A*0101-B*4006-C*1502 0.000 0.000 
  A*2301-B*1516-C*1601 0.002 0.000 
  A*2601-B*4011-C*1502 0.000 0.000 
  A*2601-B*4102-C*1701 0.000 0.002 
  A*6827-B*4403-C*0210 0.000 0.000 
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Appendix 2: Case-control association data for SNPs of the MHC and susceptibility to TB in the 
SAC population. 
SNP BP P-value 
rs9295873 30414235 0.6036 
rs9461607 30414574 0.4953 
rs2844731 30416985 0.5387 
rs9295878 30417149 0.4198 
rs9295881 30417459 0.3361 
rs9295888 30422481 0.1477 
rs17411480 30423117 0.4797 
rs2516675 30430520 0.4767 
rs2516670 30434999 0.4578 
rs3094694 30451904 0.8751 
rs2157605 30454076 0.6817 
rs2516662 30475415 0.6012 
rs2844720 30475717 0.4673 
rs996589 30477235 0.8972 
rs996588 30477256 0.6326 
rs2844718 30477276 0.635 
rs1058318 30512163 0.3879 
rs4713337 30529475 0.4837 
rs3888778 30529622 0.341 
rs1264432 30562021 0.5953 
rs2239515 30577966 0.4631 
rs2239516 30578048 0.6132 
rs2252745 30579315 0.3036 
rs2270172 30592414 0.4414 
rs6904236 30596135 0.5718 
rs9262138 30627867 0.259 
rs3130000 30628082 0.1639 
rs7749235 30635593 0.3205 
rs1075496 30658239 0.5404 
rs7565 30668159 0.02 
rs2253802 30684686 0.2924 
rs1061397 30692539 0.1541 
rs8233 30692965 0.4163 
rs3095329 30693816 0.4471 
rs3094127 30697447 0.4933 
rs2394401 30724430 0.9344 
rs3095340 30726939 0.4981 
rs3094122 30728360 0.6259 
rs3094121 30730960 0.7246 
rs3132605 30739972 0.9601 
rs3130666 30740160 0.2157 
rs4248148 30742134 0.1821 
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SNP BP P-value 
rs10947091 30747216 0.7685 
rs12527415 30754540 0.9768 
rs11758688 30758348 0.8836 
rs3131043 30758466 0.9658 
rs3131050 30760025 0.8497 
rs3131060 30763291 0.8487 
rs6930444 30763632 0.7386 
rs12660883 30764420 0.9912 
rs10947096 30765895 0.9715 
rs4587207 30766945 0.8684 
rs4483030 30767129 0.9049 
rs4713370 30767538 0.876 
rs4248149 30767627 0.9432 
rs2394403 30767869 0.8085 
rs9380192 30772344 0.9015 
rs3094123 30772378 0.9999 
rs4713376 30773314 0.9647 
rs9380197 30778203 0.9616 
rs4713382 30787175 0.822 
rs12195469 30789608 0.9783 
rs12215119 30795328 0.7542 
rs9368644 30797083 0.9825 
rs1264344 30800577 0.3695 
rs3130649 30803254 0.9945 
rs3095350 30817866 0.6505 
rs3095345 30822413 0.9875 
rs6924600 30857542 0.5259 
rs6457282 30857988 0.689 
rs9295931 30869714 0.3906 
rs2074508 30876438 0.4119 
rs3218815 30878769 0.4119 
rs2074512 30878919 0.4086 
rs3218831 30882431 0.7036 
rs1264303 30882513 0.7428 
rs7738138 30887344 0.6342 
rs753725 30890871 0.1291 
rs4711247 30895680 0.2058 
rs3131785 30901895 0.07636 
rs3131784 30903948 0.06278 
rs3132581 30913458 0.1937 
rs3757340 30921882 0.1673 
rs2532921 30922570 0.3275 
rs2530710 30940387 0.4291 
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rs2530709 30940569 0.3189 
rs2517446 30940945 0.2302 
rs2844678 30950050 0.05639 
rs3873342 30957766 0.2154 
rs2517411 30960267 0.1124 
rs2844673 30961926 0.1119 
rs2252925 30966282 0.1169 
rs2252926 30966304 0.2112 
rs2530690 30967202 0.2152 
rs436376 30972390 0.1914 
rs2256514 30972471 0.1674 
rs1634717 30972589 0.06625 
rs1634718 30972865 0.3504 
rs2523915 30973358 0.313 
rs1632854 30975649 0.1141 
rs12528087 30980603 0.4369 
rs9262494 30986504 0.6399 
rs6933349 31002013 0.8006 
rs4713423 31002301 0.7567 
rs2517538 31013541 0.8691 
rs2523865 31018448 0.3048 
rs4713429 31021017 0.4765 
rs9262615 31021161 0.9523 
rs3873352 31022113 0.3298 
rs9262635 31025479 0.3878 
rs2517524 31025713 0.9584 
rs9262636 31025848 0.4344 
rs2517510 31030122 0.6826 
rs2523841 31030283 0.1009 
rs2523840 31030425 0.1081 
rs2246330 31041493 0.637 
rs2523883 31042070 0.6372 
rs2517489 31042306 0.5638 
rs2523881 31042608 0.527 
rs2523880 31042769 0.7538 
rs2535318 31051388 0.6992 
rs2517471 31052098 0.693 
rs2535315 31052127 0.4939 
rs2535306 31053867 0.765 
rs3130955 31054511 0.9241 
rs4947296 31058178 0.6794 
rs3130544 31058340 0.3569 
rs9263597 31071547 0.2915 
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rs2233969 31080432 0.9009 
rs1265052 31080471 0.5487 
rs2233967 31080828 0.46 
rs1265048 31081409 0.961 
rs3130975 31081838 0.9679 
rs3130981 31083813 0.6858 
rs3095324 31087133 0.4093 
rs3130991 31087354 0.3184 
rs3095314 31089631 0.487 
rs9263702 31094195 0.27 
rs9263715 31095801 0.9641 
rs9263716 31095816 0.8866 
rs3130558 31097183 0.5122 
rs3131009 31098832 0.466 
rs13200022 31098957 0.7195 
rs4959053 31099577 0.8794 
rs3130564 31101674 0.8075 
rs3130575 31113106 0.8811 
rs1265074 31113214 0.1583 
rs2240066 31114335 0.05253 
rs2240063 31114745 0.514 
rs6929434 31127947 0.3985 
rs2073724 31129707 0.9998 
rs9263794 31130019 0.2648 
rs2073723 31130078 0.8814 
rs2106074 31133509 0.885 
rs9501063 31133894 0.05352 
rs3757349 31134532 0.1119 
rs9263800 31134599 0.1167 
rs9263804 31135706 0.9132 
rs3130501 31136453 0.9909 
rs3132524 31136714 0.7066 
rs887466 31143511 0.015 
rs887465 31143652 0.6356 
rs1265181 31155785 0.3218 
rs9405015 31155803 0.3234 
rs3095238 31161210 0.8455 
rs6899874 31162328 0.0623 
rs9295961 31167498 0.6482 
rs2894180 31172655 0.6501 
rs4516988 31176602 0.8851 
rs3130953 31177094 0.2768 
rs3130952 31177915 0.6575 
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rs3130944 31196671 0.4728 
rs6908994 31198709 0.14 
rs3130713 31205617 0.2912 
rs3130531 31206616 0.6334 
rs2394894 31206920 0.6041 
rs2394895 31206979 0.7013 
rs3095250 31208340 0.6168 
rs3130532 31208453 0.9577 
rs3130534 31209045 0.9733 
rs3134762 31210866 0.7996 
rs3899471 31215037 0.137 
rs2248880 31233510 0.7097 
rs2524078 31242649 0.3765 
rs2844615 31242959 0.3971 
rs3132486 31243170 0.988 
rs6906846 31245736 0.9901 
rs2524067 31245821 0.2183 
rs7382297 31247067 0.9878 
rs3873375 31251360 0.05755 
rs2394963 31251462 0.09572 
rs2524051 31255500 0.1247 
rs9357123 31262869 0.06869 
rs3905495 31265539 0.106 
rs2524115 31265554 0.05889 
rs2524095 31266117 0.3739 
rs16899203 31266335 0.01068 
rs16899205 31266361 0.259 
rs16899207 31266387 0.2253 
rs2524089 31266522 0.5927 
rs2394967 31269129 0.3249 
rs9366778 31269173 0.2095 
rs3873385 31269308 0.00389 
rs4523128 31269382 0.3239 
rs9295970 31269522 0.643 
rs396038 31272980 0.03372 
rs1634788 31277686 0.08547 
rs9295984 31317697 0.1358 
rs4394275 31318177 0.3214 
rs9378249 31327701 0.8636 
rs2596477 31327723 0.8823 
rs2523575 31328826 0.4061 
rs2523544 31333562 0.6894 
rs7761068 31333939 0.5427 
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rs2523537 31335707 0.6888 
rs2156874 31335976 0.293 
rs2523536 31336000 0.2481 
rs2523535 31336250 0.5601 
rs2523534 31336349 0.4926 
rs9266406 31336418 0.08878 
rs9266409 31336568 0.08988 
rs2523533 31336649 0.8093 
rs2853986 31338844 0.6577 
rs2263311 31340807 0.329 
rs5025315 31343604 0.5595 
rs6910516 31343827 0.08878 
rs5022119 31343862 0.9247 
rs2523638 31344273 0.2108 
rs3997982 31344294 0.9287 
rs2596571 31348022 0.5438 
rs2523485 31351035 0.8945 
rs3016013 31351242 0.1735 
rs3099848 31351442 0.1223 
rs9266774 31352880 0.07883 
rs2596565 31353329 0.6114 
rs9266775 31353417 0.118 
rs4081552 31353689 0.1238 
rs2596517 31360095 0.8195 
rs16899524 31362310 0.3652 
rs2523467 31362930 0.02942 
rs1063635 31379931 0.8802 
rs3094584 31383848 0.08021 
rs9295990 31386019 0.6356 
rs2848716 31387967 0.4912 
rs2394999 31400935 0.728 
rs2596464 31412961 0.708 
rs16899646 31416920 0.9938 
rs2596457 31418022 0.2388 
rs2516460 31418700 0.9543 
rs3131622 31420500 0.2921 
rs2523691 31420687 0.5212 
rs3131621 31425499 0.06414 
rs2844507 31436581 0.2206 
rs2244579 31436639 0.2021 
rs2395031 31437305 0.6645 
rs3828886 31440552 0.2155 
rs2248373 31446546 0.8379 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 211 
 
SNP BP P-value 
rs2248459 31446710 0.9974 
rs2248462 31446796 0.7415 
rs2248617 31448533 0.8238 
rs3749946 31448862 0.7975 
rs3099844 31448976 0.4796 
rs2523650 31449022 0.9086 
rs2904776 31449081 0.7635 
rs2516422 31449269 0.9693 
rs9267247 31455834 0.5987 
rs2395034 31460143 0.8042 
rs3093953 31474688 0.1793 
rs3095229 31480272 0.8575 
rs3131631 31484683 0.09665 
rs2516486 31494202 0.3431 
rs2734573 31494738 0.2911 
rs3115537 31497835 0.102 
rs3093978 31498497 0.119 
rs2516478 31498737 0.3186 
rs2071593 31512799 0.2316 
rs3219183 31516363 0.4004 
rs1799964 31542308 0.09936 
rs1052248 31556581 0.8932 
rs9348876 31575276 0.6704 
rs2857697 31585219 0.6962 
rs2736177 31586094 0.06362 
rs2736172 31590898 0.8702 
rs1046089 31602967 0.8873 
rs2255741 31605167 0.3262 
rs760293 31611777 0.2835 
rs2077102 31611840 0.07282 
rs3130048 31613739 0.1466 
rs2844463 31615167 0.3223 
rs805301 31618121 0.7349 
rs805300 31618567 0.8348 
rs805297 31622606 0.5608 
rs707921 31625541 0.8428 
rs2242655 31627449 0.06931 
rs707974 31629499 0.4607 
rs805268 31638178 0.3786 
rs2142234 31639129 0.08409 
rs805267 31639757 0.809 
rs707918 31654732 0.9098 
rs376510 31688200 0.6211 
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rs805292 31690009 0.1255 
rs707915 31710968 0.6371 
rs3130484 31715882 0.7656 
rs2299851 31718602 0.5782 
rs3131379 31721033 0.7737 
rs707939 31726688 0.9224 
rs707937 31731014 0.7095 
rs2075800 31777946 0.4428 
rs2763979 31794592 0.4805 
rs11965547 31836151 0.02436 
rs486416 31856070 0.6172 
rs9267673 31883679 0.726 
rs644045 31883957 0.9607 
rs638383 31908224 0.9976 
rs17201431 31916013 0.132 
rs541862 31916951 0.4906 
rs2072633 31919578 0.9232 
rs550513 31920687 0.7109 
rs9501161 31924327 0.632 
rs406936 31933161 0.7754 
rs492899 31933518 0.7967 
rs3130287 32050544 0.1447 
rs1150753 32059867 0.9605 
rs17421624 32066177 0.3083 
rs9296009 32114515 0.2864 
rs3130284 32140487 0.4117 
rs408359 32141883 0.01733 
rs204990 32161430 0.6932 
rs204989 32161852 0.6917 
rs2071278 32165444 0.8547 
rs2071286 32179896 0.1084 
rs3131294 32180146 0.6586 
rs206015 32182759 0.05069 
rs379464 32186348 0.7052 
rs8192590 32187783 0.06873 
rs415929 32189032 0.7696 
rs391755 32192436 0.8166 
rs377763 32199144 0.9385 
rs3134926 32200147 0.246 
rs9267954 32213052 0.8984 
rs3115576 32216850 0.6155 
rs6936204 32217092 0.8592 
rs9267971 32217185 0.4315 
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rs3130311 32217367 0.4907 
rs4959090 32219962 0.3456 
rs7767325 32233886 0.7761 
rs3132928 32234015 0.9873 
rs1559873 32243129 0.6479 
rs17577123 32257547 0.1685 
rs544358 32273158 0.496 
rs574710 32288190 0.6201 
rs539703 32288462 0.5369 
rs12524063 32297310 0.0328 
rs926591 32305690 0.5942 
rs3129900 32305979 0.2104 
rs9368716 32306090 0.292 
rs4959093 32313097 0.4735 
rs910050 32315654 0.1594 
rs910049 32315727 0.1816 
rs9268302 32324817 0.04579 
rs6907322 32324945 0.04633 
rs2894249 32325835 0.2249 
rs3129932 32336127 0.256 
rs3129933 32336161 0.1943 
rs3129934 32336187 0.2703 
rs9268402 32341353 0.2803 
rs9391858 32341398 0.8614 
rs9268403 32341473 0.5897 
rs9268418 32343686 0.5443 
rs9268429 32345052 0.4657 
rs12528797 32345086 0.2436 
rs2894254 32345689 0.4959 
rs17423649 32357133 0.9921 
rs17495612 32359431 0.6603 
rs3129953 32361821 0.1351 
rs2076533 32363527 0.6322 
rs2076530 32363816 0.5666 
rs9268480 32363844 0.7054 
rs10947261 32373232 0.2919 
rs3806156 32373698 0.2471 
rs3763307 32374622 0.5548 
rs3763308 32374640 0.04921 
rs9268541 32384527 0.321 
rs3135378 32385099 0.09041 
rs3135377 32385399 0.7478 
rs3135376 32385470 0.1437 
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rs2395161 32387752 0.09418 
rs2395167 32388308 0.1305 
rs2213580 32388574 0.1071 
rs3135366 32388709 0.153 
rs9268560 32389512 0.3665 
rs3135363 32389648 0.5561 
rs6929953 32391988 0.8769 
rs3135342 32396615 0.339 
rs5000563 32404135 0.4129 
rs3129872 32407153 0.4908 
rs9268645 32408527 0.4042 
rs3129877 32408597 0.4229 
rs3135393 32408842 0.5563 
rs3135392 32409242 0.7649 
rs3177928 32412435 0.5336 
rs7194 32412480 0.41 
rs1051336 32412592 0.1082 
rs9268831 32427748 0.6271 
rs9268856 32429719 0.6104 
rs9268858 32429758 0.582 
rs9268861 32429894 0.2601 
rs7766843 32430729 0.4406 
rs7746922 32430975 0.492 
rs9268877 32431147 0.3399 
rs9268878 32431292 0.5458 
rs4999342 32448098 0.09428 
rs9269186 32448416 0.2994 
rs7749092 32449050 0.273 
rs9270986 32574060 0.1427 
rs615672 32574171 0.9452 
rs502055 32579003 0.7084 
rs4530903 32581889 0.03306 
rs3129768 32595083 0.1942 
rs9272219 32602269 0.08728 
rs9272346 32604372 0.05842 
rs9272723 32609427 0.01838 
rs9273363 32626272 0.8022 
rs9275134 32650612 0.4053 
rs2856688 32654640 0.3974 
rs7775228 32658079 0.5058 
rs9469220 32658310 0.06163 
rs6457617 32663851 0.05736 
rs6457620 32663999 0.08211 
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rs2647015 32664093 0.9352 
rs2647046 32668336 0.01531 
rs2858308 32670000 0.7424 
rs9275418 32670244 0.126 
rs9275523 32674994 0.2319 
rs9275572 32678999 0.02784 
rs3916765 32685550 0.8807 
rs9275765 32689324 0.8982 
rs9275772 32689503 0.991 
rs9461799 32689529 0.4024 
rs9275793 32690027 0.825 
rs2859090 32700833 0.2262 
rs9276299 32703108 0.8717 
rs2227127 32711782 0.7148 
rs9276429 32712104 0.5248 
rs9276431 32712247 0.509 
rs9276432 32712384 0.5985 
rs2239800 32713267 0.6953 
rs4398729 32713854 0.4328 
rs9276435 32713867 0.3185 
rs9276440 32714783 0.5293 
rs9276448 32715629 0.9438 
rs5014418 32719381 0.8542 
rs7768538 32729821 0.54 
rs7453920 32730012 0.5506 
rs2051549 32730086 0.5873 
rs6902723 32731960 0.2584 
rs6903130 32732210 0.3917 
rs6919798 32732890 0.1425 
rs9296044 32736144 0.0702 
rs2857212 32740411 0.2426 
rs17429127 32751614 0.9088 
rs719654 32752139 0.6425 
rs2857173 32754920 0.5131 
rs9276712 32759252 0.5108 
rs2621384 32759273 0.4371 
rs2857161 32759297 0.3714 
rs2621383 32759335 0.2557 
rs2621382 32760445 0.03074 
rs2157082 32760714 0.02454 
rs2857154 32762616 0.07957 
rs2857136 32775686 0.02923 
rs2857129 32776623 0.02638 
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rs2621330 32781524 0.9965 
rs16870880 32782018 0.4698 
rs17501267 32782149 0.08595 
rs2071474 32782582 0.7209 
rs1894407 32787036 0.03338 
rs9784858 32787175 0.00052 
rs17220136 32787337 0.292 
rs10484565 32795032 0.006188 
rs241438 32797620 0.5657 
rs1800454 32800412 0.9518 
rs241429 32803840 0.5765 
rs241428 32804070 0.9963 
rs241427 32804414 0.6475 
rs4711312 32814659 0.9844 
rs16871026 32815488 0.6443 
rs12529313 32817130 0.1428 
rs20547 32826233 0.9774 
rs9276832 32832400 0.2015 
rs17508331 32865338 0.5371 
rs241403 32866992 0.8123 
rs3101942 32870057 0.02009 
rs241400 32871536 0.7167 
rs151719 32903900 0.1523 
rs17583852 32912588 0.727 
rs1050391 32917857 0.5832 
rs11539216 32917980 0.9404 
rs17840186 32938199 0.7526 
rs188245 32955976 0.3596 
rs3129305 32959180 0.5848 
rs3128947 32965062 0.04371 
rs176248 32965942 0.1441 
rs12216336 32967741 0.7453 
rs2894311 32968339 0.652 
rs12191230 32968598 0.5002 
rs2395301 32968693 0.6302 
rs12192713 32968856 0.6291 
rs12199692 32968929 0.8014 
rs3130602 32972207 0.49 
rs1044429 32972642 0.5288 
rs592625 32972690 0.5404 
rs3129304 32973743 0.01344 
rs3129303 32973878 0.02381 
rs3129302 32974343 0.8332 
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rs399604 32975014 0.734 
rs365066 32975257 0.7159 
rs6920363 32976572 0.624 
rs429916 32978587 0.006727 
rs3763341 32979020 0.3825 
rs4713603 32979609 0.7235 
rs4713604 32979770 0.738 
rs6936620 32984451 0.8453 
rs2116264 32984788 0.6778 
rs1367731 32985199 0.06103 
rs3135196 32997577 0.7869 
rs439852 33005208 0.3466 
rs3130578 33018310 0.7386 
rs446853 33018377 0.6468 
rs3130179 33018459 0.6629 
rs9296069 33018957 0.3901 
rs440841 33019643 0.4485 
rs3128952 33019973 0.3019 
rs3128955 33021192 0.105 
rs3130588 33022062 0.1494 
rs9277183 33023370 0.07969 
rs3097669 33023792 0.8848 
rs9277194 33023894 0.1185 
rs9277196 33023946 0.06182 
rs367645 33024499 0.2686 
rs376877 33024606 0.8947 
rs3077 33033022 0.2771 
rs9348904 33040835 0.4117 
rs9296073 33042551 0.4115 
rs2856816 33045500 0.3997 
rs3135021 33045558 0.1291 
rs1431403 33047031 0.363 
rs9277542 33055247 0.7851 
rs3128963 33055780 0.7701 
rs3128965 33055899 0.2825 
rs3128966 33055946 0.2859 
rs3117229 33056069 0.9605 
rs2068204 33058718 0.7694 
rs2179920 33058874 0.3897 
rs7763822 33060428 0.675 
rs2295120 33060769 0.9052 
rs6928954 33060822 0.9904 
rs7764491 33060840 0.8764 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 218 
 
SNP BP P-value 
rs3117242 33069893 0.4431 
rs3128921 33070749 0.1283 
rs3128923 33071322 0.2015 
rs3117230 33075635 0.4181 
rs3128930 33075666 0.06315 
rs872956 33076090 0.5477 
rs6937034 33079766 0.3845 
rs6937061 33079812 0.2897 
rs3117039 33085851 0.9656 
rs3130233 33095176 0.1202 
rs3117016 33095516 0.8745 
rs3116996 33097964 0.8527 
rs2395351 33100427 0.07865 
rs3129249 33109556 0.3109 
rs3129248 33109658 0.5797 
rs1003979 33114171 0.9161 
rs2071025 33143756 0.171 
rs16868943 33147727 0.3719 
rs7382464 33150268 0.5083 
rs2744537 33162215 0.982 
rs6531 33163451 0.9761 
rs213208 33178010 0.1208 
rs461338 33218180 0.6999 
rs462618 33222163 0.7015 
rs455567 33252115 0.01496 
rs3130267 33306794 0.0979 
rs3130014 33312308 0.006388 
rs211455 33328518 0.355 
rs211453 33330131 0.8324 
rs2747476 33351251 0.03223 
rs211457 33365640 0.7896 
rs10807124 33404064 0.4107 
rs411136 33408542 0.332 
rs3119021 33429952 0.1739 
rs4713630 33472941 0.8254 
rs7747216 33476718 0.9783 
rs4713633 33477140 0.8533 
rs9461864 33481469 0.1049 
rs6924409 33491057 0.3475 
rs435945 33496632 0.4013 
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Appendix 3: Case-control association data for SNPs of the MHC and susceptibility to TB in the 
Gambian population. 
SNP BP P 
rs9295873 30414235 0.01715 
rs9461607 30414574 0.01598 
rs9295878 30417149 0.03265 
rs9295881 30417459 0.03524 
rs9295888 30422481 0.01531 
rs17411480 30423117 0.02082 
rs2516675 30430520 0.2919 
rs3094694 30451904 0.6241 
rs2516662 30475415 0.155 
rs2844720 30475717 0.1489 
rs996589 30477235 0.1045 
rs996588 30477256 0.1303 
rs2844718 30477276 0.1529 
rs1058318 30512163 0.2938 
rs3888778 30529622 0.9468 
rs1264432 30562021 0.1531 
rs2239515 30577966 0.788 
rs2239516 30578048 0.9027 
rs2252745 30579315 0.2342 
rs2270172 30592414 0.7494 
rs6904236 30596135 0.9303 
rs7749235 30635593 0.3922 
rs1075496 30658239 0.3686 
rs7565 30668159 0.03813 
rs2253802 30684686 0.7804 
rs1061397 30692539 0.451 
rs3095329 30693816 0.8645 
rs3094127 30697447 0.8943 
rs3095340 30726939 0.04012 
rs3094122 30728360 0.07552 
rs3094121 30730960 0.01613 
rs3132605 30739972 0.287 
rs3130666 30740160 0.6585 
rs4248148 30742134 0.5774 
rs10947091 30747216 0.7013 
rs12527415 30754540 0.9016 
rs11758688 30758348 0.8756 
rs3131043 30758466 0.7473 
rs3131050 30760025 0.4471 
rs3131060 30763291 0.1419 
rs6930444 30763632 0.3567 
rs12660883 30764420 0.1977 
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SNP BP P 
rs4483030 30767129 0.6078 
rs4713370 30767538 0.7522 
rs4248149 30767627 0.5641 
rs2394403 30767869 0.7065 
rs9380192 30772344 0.8768 
rs3094123 30772378 0.08761 
rs9380197 30778203 0.9863 
rs4713382 30787175 0.6146 
rs12195469 30789608 0.8795 
rs9368644 30797083 0.5089 
rs1264344 30800577 0.5154 
rs3130649 30803254 0.4852 
rs3095350 30817866 0.8291 
rs3095345 30822413 0.5024 
rs6924600 30857542 0.5952 
rs6457282 30857988 0.5205 
rs9295931 30869714 0.5631 
rs3218815 30878769 0.5909 
rs2074512 30878919 0.6249 
rs3218831 30882431 0.5914 
rs1264303 30882513 0.6663 
rs7738138 30887344 0.9545 
rs753725 30890871 0.6344 
rs4711247 30895680 0.9168 
rs3131785 30901895 0.694 
rs3131784 30903948 0.6152 
rs3132581 30913458 0.468 
rs3757340 30921882 0.9544 
rs2532921 30922570 0.8278 
rs2530709 30940569 0.9424 
rs2517446 30940945 0.1988 
rs2844678 30950050 0.3471 
rs3873342 30957766 0.1709 
rs2517411 30960267 0.1933 
rs2844673 30961926 0.1873 
rs2252925 30966282 0.1769 
rs2252926 30966304 0.1769 
rs2530690 30967202 0.1605 
rs436376 30972390 0.2616 
rs2256514 30972471 0.2768 
rs1634717 30972589 0.399 
rs1634718 30972865 0.8649 
rs2523915 30973358 0.3011 
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SNP BP P 
rs1632854 30975649 0.4254 
rs12528087 30980603 0.4571 
rs9262494 30986504 0.04041 
rs6933349 31002013 0.1028 
rs4713423 31002301 0.3363 
rs2517538 31013541 0.5386 
rs2523865 31018448 0.6542 
rs4713429 31021017 0.07422 
rs9262615 31021161 0.227 
rs3873352 31022113 0.1461 
rs9262635 31025479 0.3823 
rs2517524 31025713 0.8625 
rs9262636 31025848 0.801 
rs2517510 31030122 0.2573 
rs2517509 31030224 0.3867 
rs2523841 31030283 0.2935 
rs2523840 31030425 0.2777 
rs2246330 31041493 0.2987 
rs2523883 31042070 0.3744 
rs2517489 31042306 0.3551 
rs2523881 31042608 0.2209 
rs2523880 31042769 0.08358 
rs2535318 31051388 0.3369 
rs2517471 31052098 0.2544 
rs2535306 31053867 0.2012 
rs3130955 31054511 0.03187 
rs4947296 31058178 0.2578 
rs9263597 31071547 0.1204 
rs2233969 31080432 0.2045 
rs1265052 31080471 0.03058 
rs2233967 31080828 0.1508 
rs1265048 31081409 0.441 
rs3130975 31081838 0.5878 
rs3130981 31083813 0.5189 
rs3095324 31087133 0.222 
rs3130991 31087354 0.6298 
rs9263702 31094195 0.7123 
rs9263715 31095801 0.4983 
rs9263716 31095816 0.6996 
rs3130558 31097183 0.627 
rs13200022 31098957 0.1739 
rs3130564 31101674 0.5653 
rs3130575 31113106 0.5689 
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SNP BP P 
rs2240063 31114745 0.4132 
rs2073724 31129707 0.7323 
rs9263794 31130019 0.7275 
rs2073723 31130078 0.9836 
rs2106074 31133509 0.9299 
rs9501063 31133894 0.3311 
rs9263804 31135706 0.893 
rs3130501 31136453 0.9693 
rs3132524 31136714 0.9665 
rs887466 31143511 0.1856 
rs887465 31143652 0.431 
rs1265181 31155785 0.4279 
rs9405015 31155803 0.8653 
rs3095238 31161210 0.0923 
rs6899874 31162328 0.8643 
rs2894180 31172655 0.8479 
rs4516988 31176602 0.3682 
rs3130953 31177094 0.3781 
rs3130952 31177915 0.2782 
rs3130944 31196671 0.3306 
rs6908994 31198709 0.8518 
rs3130713 31205617 0.5957 
rs3130531 31206616 0.7699 
rs2394894 31206920 0.6001 
rs2394895 31206979 0.813 
rs3095250 31208340 0.805 
rs3130532 31208453 0.3702 
rs3130534 31209045 0.5552 
rs3134762 31210866 0.5696 
rs2248880 31233510 0.5016 
rs2844615 31242959 0.0645 
rs3132486 31243170 0.01522 
rs6906846 31245736 0.1253 
rs2524067 31245821 0.5796 
rs7382297 31247067 0.5342 
rs3873375 31251360 0.1391 
rs2394963 31251462 0.1385 
rs2524051 31255500 0.1746 
rs9357123 31262869 0.678 
rs3905495 31265539 0.08736 
rs2524115 31265554 0.2753 
rs2524095 31266117 0.673 
rs16899203 31266335 0.1131 
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SNP BP P 
rs16899205 31266361 0.2028 
rs16899207 31266387 0.1977 
rs2524089 31266522 0.6372 
rs2394967 31269129 0.009868 
rs9366778 31269173 0.1591 
rs3873385 31269308 0.7045 
rs4523128 31269382 0.009868 
rs9295970 31269522 0.4119 
rs396038 31272980 0.04522 
rs1634788 31277686 0.8802 
rs9295984 31317697 0.02184 
rs4394275 31318177 0.2785 
rs2596477 31327723 0.1919 
rs2523575 31328826 0.03751 
rs7761068 31333939 0.2699 
rs2523536 31336000 0.5772 
rs2523535 31336250 0.4 
rs2523534 31336349 0.3204 
rs9266406 31336418 0.931 
rs9266409 31336568 0.9449 
rs2853986 31338844 0.2364 
rs2263311 31340807 0.1556 
rs5025315 31343604 0.5591 
rs6910516 31343827 0.923 
rs5022119 31343862 0.4096 
rs2523638 31344273 0.9715 
rs3997982 31344294 0.9019 
rs2596571 31348022 0.2738 
rs2523485 31351035 0.6325 
rs3016013 31351242 0.8619 
rs3099848 31351442 0.7379 
rs9266774 31352880 0.7861 
rs9266775 31353417 0.9114 
rs4081552 31353689 0.05837 
rs2596517 31360095 0.8988 
rs2523467 31362930 0.1644 
rs1063635 31379931 0.1101 
rs3094584 31383848 0.826 
rs9295990 31386019 0.8876 
rs2848716 31387967 0.06023 
rs2596464 31412961 0.8151 
rs16899646 31416920 0.07342 
rs2596457 31418022 0.8312 
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SNP BP P 
rs2516460 31418700 0.4882 
rs3131622 31420500 0.5679 
rs2523691 31420687 0.8269 
rs3131621 31425499 0.3466 
rs2244579 31436639 0.2741 
rs3828886 31440552 0.9794 
rs2248373 31446546 0.742 
rs2248459 31446710 0.3938 
rs2248462 31446796 0.4807 
rs2248617 31448533 0.3264 
rs3749946 31448862 0.1884 
rs3099844 31448976 0.2362 
rs2523650 31449022 0.7775 
rs2904776 31449081 0.5739 
rs2516422 31449269 0.7039 
rs9267247 31455834 0.9751 
rs2395034 31460143 0.4589 
rs3093953 31474688 0.5186 
rs3095229 31480272 0.9406 
rs3131631 31484683 0.7859 
rs2516486 31494202 0.4115 
rs2734573 31494738 0.3233 
rs2516478 31498737 0.1827 
rs2071593 31512799 0.3937 
rs3219183 31516363 0.8083 
rs1799964 31542308 0.9851 
rs1052248 31556581 0.563 
rs9348876 31575276 0.291 
rs1046089 31602967 0.4838 
rs2255741 31605167 0.2338 
rs760293 31611777 0.3366 
rs2077102 31611840 0.6137 
rs3130048 31613739 0.431 
rs805301 31618121 0.2716 
rs805300 31618567 0.3211 
rs805297 31622606 0.04136 
rs707921 31625541 0.2808 
rs2242655 31627449 0.9678 
rs805268 31638178 0.2646 
rs2142234 31639129 0.4521 
rs805267 31639757 0.3053 
rs707918 31654732 0.246 
rs376510 31688200 0.4031 
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rs805292 31690009 0.9611 
rs707915 31710968 0.1102 
rs3130484 31715882 0.003021 
rs3131379 31721033 0.01695 
rs707939 31726688 0.07131 
rs707937 31731014 0.9677 
rs2075800 31777946 0.2485 
rs2763979 31794592 0.2987 
rs11965547 31836151 0.8259 
rs486416 31856070 0.5663 
rs9267673 31883679 0.1956 
rs644045 31883957 0.7352 
rs17201431 31916013 0.03477 
rs541862 31916951 0.9088 
rs4151655 31916985 0.98 
rs2072633 31919578 0.3878 
rs550513 31920687 0.4537 
rs9501161 31924327 0.08682 
rs17421624 32066177 0.03488 
rs9296009 32114515 0.3628 
rs3130284 32140487 0.6437 
rs408359 32141883 0.9174 
rs204990 32161430 0.4938 
rs204989 32161852 0.5816 
rs2071286 32179896 0.08019 
rs206015 32182759 0.4373 
rs379464 32186348 0.9374 
rs415929 32189032 0.9399 
rs391755 32192436 0.05613 
rs377763 32199144 0.1815 
rs3134926 32200147 0.01232 
rs9267954 32213052 0.01162 
rs6936204 32217092 0.7895 
rs3130311 32217367 0.3805 
rs7767325 32233886 0.7027 
rs3132928 32234015 0.7447 
rs1559873 32243129 0.04344 
rs544358 32273158 0.6685 
rs574710 32288190 0.6832 
rs539703 32288462 0.6253 
rs12524063 32297310 0.2091 
rs926591 32305690 0.7647 
rs3129900 32305979 0.09735 
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SNP BP P 
rs9368716 32306090 0.115 
rs4959093 32313097 0.7647 
rs910050 32315654 0.7048 
rs910049 32315727 0.8637 
rs9268302 32324817 0.2387 
rs2894249 32325835 0.9117 
rs3129932 32336127 0.8625 
rs3129933 32336161 0.06492 
rs3129934 32336187 0.08916 
rs9268402 32341353 0.3448 
rs9391858 32341398 0.5548 
rs9268403 32341473 0.7258 
rs9268418 32343686 0.8535 
rs9268429 32345052 0.7959 
rs12528797 32345086 0.04564 
rs17423649 32357133 0.6838 
rs17495612 32359431 0.5983 
rs3129953 32361821 0.7681 
rs2076533 32363527 0.9517 
rs2076530 32363816 0.9651 
rs9268480 32363844 0.7261 
rs10947261 32373232 0.9937 
rs3806156 32373698 0.8811 
rs3763307 32374622 0.8078 
rs3763308 32374640 0.9756 
rs9268541 32384527 0.4874 
rs3135378 32385099 0.1178 
rs3135377 32385399 0.187 
rs3135376 32385470 0.01751 
rs17606006 32386788 0.9801 
rs2395161 32387752 0.03753 
rs2395167 32388308 0.1387 
rs2213580 32388574 0.1098 
rs3135366 32388709 0.07436 
rs9268560 32389512 0.3606 
rs3135363 32389648 0.2137 
rs3135342 32396615 0.5247 
rs5000563 32404135 0.7534 
rs3129872 32407153 0.7878 
rs9268645 32408527 0.8784 
rs3129877 32408597 0.5108 
rs3135393 32408842 0.1682 
rs3135392 32409242 0.5633 
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rs3177928 32412435 0.7847 
rs7194 32412480 0.8557 
rs1051336 32412592 0.1406 
rs9268831 32427748 0.9552 
rs9268856 32429719 0.7996 
rs9268858 32429758 0.1601 
rs9268861 32429894 0.08604 
rs7766843 32430729 0.971 
rs7746922 32430975 0.9852 
rs9268877 32431147 0.2399 
rs9268878 32431292 0.8992 
rs9269186 32448416 0.7594 
rs9270986 32574060 0.7495 
rs615672 32574171 0.4521 
rs502055 32579003 0.1573 
rs4530903 32581889 0.1506 
rs9272219 32602269 0.553 
rs9272346 32604372 0.7828 
rs9273363 32626272 0.6706 
rs9275134 32650612 0.4521 
rs2856688 32654640 0.5694 
rs7775228 32658079 0.7718 
rs9469220 32658310 0.1885 
rs6457617 32663851 0.2411 
rs6457620 32663999 0.2343 
rs2647046 32668336 0.1173 
rs2858308 32670000 0.8739 
rs9275418 32670244 0.5264 
rs9275523 32674994 0.6173 
rs9275572 32678999 0.1153 
rs3957146 32681530 0.5961 
rs9275765 32689324 0.3202 
rs9275772 32689503 0.2984 
rs9461799 32689529 0.07227 
rs9275793 32690027 0.2984 
rs2859090 32700833 0.1814 
rs9276299 32703108 0.4666 
rs2227127 32711782 0.1387 
rs9276429 32712104 0.7588 
rs9276431 32712247 0.7588 
rs9276432 32712384 0.7441 
rs2239800 32713267 0.9656 
rs9276435 32713867 0.5292 
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rs9276440 32714783 0.7228 
rs9276448 32715629 0.8744 
rs5014418 32719381 0.5688 
rs6933763 32722852 0.6806 
rs7768538 32729821 0.4407 
rs7453920 32730012 0.4912 
rs2051549 32730086 0.2993 
rs6902723 32731960 0.7563 
rs6903130 32732210 0.8684 
rs6919798 32732890 0.5707 
rs9296044 32736144 0.9729 
rs2857212 32740411 0.7722 
rs17429127 32751614 0.4825 
rs719654 32752139 0.5049 
rs2857173 32754920 0.7305 
rs2621384 32759273 0.5299 
rs2857161 32759297 0.5316 
rs2621383 32759335 0.6117 
rs2621382 32760445 0.5248 
rs2157082 32760714 0.5971 
rs2857154 32762616 0.451 
rs2857136 32775686 0.4706 
rs2857129 32776623 0.4597 
rs2621330 32781524 0.1963 
rs16870880 32782018 0.03148 
rs17501267 32782149 0.05929 
rs2071474 32782582 0.5139 
rs1894407 32787036 0.527 
rs9784858 32787175 0.9155 
rs17220136 32787337 0.04364 
rs10484565 32795032 0.03439 
rs241438 32797620 0.06224 
rs1800454 32800412 0.5128 
rs241428 32804070 0.9908 
rs241427 32804414 0.7371 
rs16871026 32815488 0.3107 
rs12529313 32817130 0.884 
rs9276832 32832400 0.3651 
rs17508331 32865338 0.1302 
rs3101942 32870057 0.4552 
rs151719 32903900 0.4648 
rs1050391 32917857 0.2759 
rs17840186 32938199 0.1983 
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rs3129305 32959180 0.5697 
rs12216336 32967741 0.008655 
rs12191230 32968598 0.08506 
rs2395301 32968693 0.00938 
rs12192713 32968856 0.06951 
rs12199692 32968929 0.006147 
rs3130602 32972207 0.989 
rs1044429 32972642 0.7939 
rs592625 32972690 0.3613 
rs3129304 32973743 0.1447 
rs3129303 32973878 0.03502 
rs3129302 32974343 0.05632 
rs399604 32975014 0.2786 
rs365066 32975257 0.4343 
rs6920363 32976572 0.4978 
rs429916 32978587 0.7663 
rs3763341 32979020 0.3325 
rs4713603 32979609 0.0866 
rs4713604 32979770 0.1124 
rs6936620 32984451 0.01574 
rs1367731 32985199 0.873 
rs3135196 32997577 0.03287 
rs439852 33005208 0.9668 
rs3130578 33018310 0.5479 
rs446853 33018377 0.8673 
rs3130179 33018459 0.267 
rs440841 33019643 0.4204 
rs3128952 33019973 0.643 
rs3128955 33021192 0.7623 
rs3130588 33022062 0.5 
rs9277183 33023370 0.7871 
rs9277196 33023946 0.5142 
rs367645 33024499 0.7382 
rs376877 33024606 0.4512 
rs3077 33033022 0.03535 
rs9348904 33040835 0.02864 
rs9296073 33042551 0.8642 
rs2856816 33045500 0.1271 
rs3135021 33045558 0.01214 
rs1431403 33047031 0.04383 
rs9277542 33055247 0.1013 
rs3128963 33055780 0.1142 
rs3128965 33055899 0.2289 
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rs3128966 33055946 0.3769 
rs3117229 33056069 0.4829 
rs2068204 33058718 0.3203 
rs2179920 33058874 0.1281 
rs7763822 33060428 0.7883 
rs2295120 33060769 0.6539 
rs6928954 33060822 0.2209 
rs7764491 33060840 0.8577 
rs3117242 33069893 0.1362 
rs3128921 33070749 0.08612 
rs3128923 33071322 0.1927 
rs3117230 33075635 0.1038 
rs3128930 33075666 0.2743 
rs872956 33076090 0.2187 
rs6937034 33079766 0.7163 
rs6937061 33079812 0.9539 
rs3117039 33085851 0.7787 
rs3130233 33095176 0.4937 
rs3117016 33095516 0.4448 
rs3116996 33097964 0.5533 
rs2395351 33100427 0.1834 
rs3129248 33109658 0.08252 
rs1003979 33114171 0.1069 
rs2071025 33143756 0.5483 
rs7382464 33150268 0.3025 
rs2744537 33162215 0.8923 
rs213208 33178010 0.6032 
rs461338 33218180 0.8763 
rs462618 33222163 0.6918 
rs455567 33252115 0.7657 
rs3130267 33306794 0.5218 
rs3130014 33312308 0.9642 
rs211455 33328518 0.7014 
rs211453 33330131 0.6603 
rs411136 33408542 0.8164 
rs4713630 33472941 0.7608 
rs7747216 33476718 0.7654 
rs4713633 33477140 0.7078 
rs9461864 33481469 0.3635 
 
 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 231 
 
Appendix 4: Case-control association data for SNPs of the LHC and susceptibility to TB in the 
SAC population. 
SNP  BP P 
rs10416258 54795939 0.8707 
rs1761450 54818035 0.003 
rs3848611 54828870 0.7023 
rs10419832 54849399 0.9454 
rs8102662 54851228 0.5511 
rs4356595 54852504 0.9258 
rs8109349 54902385 0.009 
rs10425451 54952513 0.1791 
rs3813148 54965860 0.7681 
rs11672056 54988060 0.186 
rs41514951 54990042 0.568 
rs6509880 55017416 0.5067 
rs4806518 55017594 0.611 
rs2363059 55026398 0.7315 
rs6509883 55030376 0.1636 
rs1469335 55042628 0.7261 
rs1000321 55046487 0.7934 
rs7257192 55055754 0.2152 
rs7246707 55060274 0.5932 
rs2555685 55067465 0.4063 
rs2555687 55067854 0.3215 
rs16985743 55069964 0.1122 
rs10402506 55074470 0.5063 
rs12459217 55081592 0.3534 
rs2363864 55121186 0.9022 
rs10411879 55123305 0.3701 
rs8105809 55123464 0.09875 
rs1077598 55138402 0.5695 
rs10418733 55158851 0.118 
rs10419191 55159164 0.2585 
rs4806798 55166721 0.3686 
rs1749311 55173497 0.8025 
rs11574597 55182696 0.3939 
rs7258577 55186255 0.8576 
rs1654660 55195187 0.2528 
rs1749295 55200042 0.2566 
rs1749296 55200398 0.2363 
rs11084367 55213281 0.07268 
rs8104498 55214795 0.035 
rs11672983 55383051 0.7163 
rs775850 55429258 0.5173 
rs17699476 55432460 0.08915 
Stellenbosch University  http://scholar.sun.ac.za
P a g e  | 232 
 
SNP  BP P 
rs775859 55433596 0.4028 
rs16986092 55433696 0.01 
rs2365582 55436017 0.4978 
rs269940 55440357 0.4461 
rs269957 55445174 0.898 
rs17699561 55447612 0.3537 
rs4806626 55447840 0.6712 
rs703473 55458816 0.1464 
rs9941465 55459156 0.9736 
rs8102561 55488150 0.6743 
rs4306647 55494157 0.2901 
rs10412915 55494740 0.5615 
rs1654502 55505208 0.2371 
rs12981732 55524375 0.5248 
rs1654416 55530035 0.2919 
rs11084382 55535434 0.3095 
rs11668169 55535482 0.1839 
rs11672026 55535515 0.4261 
rs1654419 55535881 0.2862 
rs1654420 55536206 0.4482 
rs17836542 55549386 0.7529 
rs1671214 55552823 0.683 
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Appendix 5: Case-control association data for SNPs of the LHC and susceptibility to TB in the 
Gambian population. 
SNP BP P 
rs10416258 54795939 0.1752 
rs741584 54815093 0.9519 
rs3848611 54828870 0.2314 
rs8102662 54851228 0.4184 
rs4356595 54852504 0.3746 
rs10425451 54952513 0.2998 
rs3813148 54965860 0.4551 
rs41514951 54990042 0.4476 
rs6509880 55017416 0.009 
rs4806518 55017594 0.3904 
rs2363059 55026398 0.7239 
rs7257192 55055754 0.4073 
rs7246707 55060274 0.6533 
rs2555685 55067465 0.002 
rs2555687 55067854 0.009 
rs16985743 55069964 0.019 
rs12461246 55081245 0.3378 
rs12459217 55081592 0.1139 
rs2363864 55121186 0.3861 
rs10411879 55123305 0.05725 
rs8105809 55123464 0.7696 
rs1077598 55138402 0.4847 
rs10418733 55158851 0.8736 
rs10419191 55159164 0.8261 
rs4806798 55166721 0.8671 
rs11574597 55182696 0.3401 
rs7258577 55186255 0.7587 
rs1654660 55195187 0.1773 
rs1749295 55200042 0.3823 
rs1749296 55200398 0.2804 
rs4420651 55207053 0.3665 
rs8104498 55214795 0.6298 
rs11672983 55383051 0.5622 
rs8102504 55393722 0.08525 
rs775850 55429258 0.8907 
rs775859 55433596 0.8892 
rs2365582 55436017 0.6956 
rs269940 55440357 0.5553 
rs269957 55445174 0.9469 
rs703473 55458816 0.4796 
rs8102561 55488150 0.5056 
rs10412915 55494740 0.391 
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rs1654502 55505208 0.4935 
rs1654416 55530035 0.9329 
rs11084382 55535434 0.6711 
rs11668169 55535482 0.2462 
rs11672026 55535515 0.6499 
rs1654419 55535881 0.7475 
rs1654420 55536206 0.7874 
rs1671214 55552823 0.3863 
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M A J O R A R T I C L E
Associations Between Human Leukocyte Antigen
Class I Variants and theMycobacterium
tuberculosis Subtypes Causing Disease
Muneeb Salie,1 Lize van der Merwe,1,2,3 Marlo Möller,1 Michelle Daya,1 Gian D. van der Spuy,1 Paul D. van Helden,1
Maureen P. Martin,4,5 Xiao-jiang Gao,4,5 Robin M. Warren,1 Mary Carrington,4,5 and Eileen G. Hoal1
1MRC Centre for Molecular and Cellular Biology and the DST/NRF Centre of Excellence for Biomedical TB Research, Division of Molecular Biology and
Human Genetics, Stellenbosch University, Tygerberg, 2MRC Biostatistics Unit, Medical Research Council, Tygerberg, and 3Department of Statistics,
University of Western Cape, Bellville, South Africa; 4Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, Inc,
Frederick National Laboratory for Cancer Research, Frederick, Maryland; and 5Ragon Institute of Massachusetts General Hospital, Massachusetts
Institute of Technology, and Harvard University, Cambridge
Background. The development of active tuberculosis disease has been shown to be multifactorial. Interactions
between host and bacterial genotype may influence disease outcome, with some studies indicating the adaptation of
M. tuberculosis strains to specific human populations. Here we investigate the role of the human leukocyte antigen
(HLA) class I genes in this biological process.
Methods. Three hundred patients with tuberculosis from South Africa were typed for their HLA class I alleles
by direct sequencing. Mycobacterium tuberculosis genotype classification was done by IS6110 restriction fragment
length polymorphism genotyping and spoligotyping.
Results. We showed that Beijing strain occurred more frequently in individuals with multiple disease episodes
(P < .001) with the HLA-B27 allele lowering the odds of having an additional episode (odds ratio, 0.21; P = .006). As-
sociations were also identified for specific HLA types and disease caused by the Beijing, LAM, LCC, and Quebec
strains. HLA types were also associated with disease caused by strains from the Euro-American or East Asian lineag-
es, and the frequencies of these alleles in their sympatric human populations identified potential coevolutionary
events between host and pathogen.
Conclusions. This is the first report of the association of human HLA types andM. tuberculosis strain genotype,
highlighting that both host and pathogen genetics need to be taken into consideration when studying tuberculosis
disease development.
Keywords. Mycobacterium tuberculosis; tuberculosis; human leukocyte antigens; host–pathogen; coadaptation;
susceptibility.
The human leukocyte antigen (HLA) class I molecules
are involved in various biological processes and play an
essential role in immunity [1]. These molecules act as
multisite receptors; including peptides for antigen pre-
sentation, αβ T-cell receptors, and CD8 for cytotoxic
T-cell response stimulation. The HLAs represent an
unsurpassed example of polymorphism with thousands
of SNPs identified to date [2]. This extreme diversity is
believed to have occurred by selection events, allowing
for the identification of peptide antigens from various
pathogens and stimulation of an effective immune re-
sponse by upregulation of the Th1 pathway [3]. HLA
data for various populations demonstrate significant
differences in allele frequencies between different
geographical populations, with some HLA alleles
completely absent from certain populations [4, 5]. The
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HLA genes were the first to be associated with susceptibility to
tuberculosis, and many different HLA alleles have been associ-
ated in different populations [6].
The present-day population structure of several pathogens,
including Mycobacterium leprae and Mycobacterium tuberculo-
sis, can be attributed to ancient human migrations [7, 8]. Such
long-standing host–pathogen interactions could lead to adap-
tive genetic changes in both the host and pathogen populations
[9]. Evidence of this can be seen from studies that have shown
that M. tuberculosis lineages have adapted to specific human
populations [9–11] and the selection of strains from a distinct
sublineage by a human population in a defined geographical
setting [12]. In cosmopolitan settings, the association between
particular M. tuberculosis complex (MTBC) lineages and their
human hosts have remained even though some degree of
intermingling of the different human populations has occurred
[9–11].
Mycobacterium tuberculosis strains of the Beijing lineage are
probably the most well characterized and are associated with
increased virulence and transmission [13]. They are the most
dominant strain lineage globally and have been reported in
many Asian countries, and are emerging as the dominant strain
in several other countries, including South Africa [14], Argentina,
Cuba, Malawi, Vietnam, countries of the former Soviet Union,
and parts of Western Europe [15]. Different M. tuberculosis
strains induce different patterns of host immune response [16] as
well as resulting in different disease phenotypes [17]. Beijing
strains are also thought to be able to evade the protective effect
of the BCG vaccine [18] and have evolved properties that allow
them to cause disease more frequently than non-Beijing strains
[19]. This could be due to their ability to modulate the host
immunity toward a Th2 instead of a Th1 response or their inhibi-
tion of TNF-α release as demonstrated in activated THP-1
macrophages [20].
Within the Cape Town metropolis in South Africa, disease
caused by the Beijing strains was found to be rising exponen-
tially over a decade whereas disease caused by non-Beijing
strains has remained constant [14]. Furthermore, Hanekom
et al showed that the Beijing sublineage 7 strains were able to
transmit and cause disease more frequently than strains from
sublineages 2–6 in urban and rural populations of the Western
Cape [12]. It appears that this is due to an evolutionary selec-
tion in local populations for this sublineage instead of a
founder effect.
In this study, we investigate the relationship between HLA
class I molecules and disease by specific M. tuberculosis lineag-
es, specifically those lineages occurring in the Western Cape,
South Africa. We show that HLA class I variants are associated
with several strains in our study cohort and that taking host
and pathogen genetic factors into consideration is necessary for
further understanding of the tuberculosis disease burden.
MATERIALS ANDMETHODS
Ethics Statement
Human blood and sputum samples were obtained with written
informed consent for DNA extraction or culture and with ap-
proval from the Health Research Ethics Committee of Stellen-
bosch University, South Africa (project registration numbers
95/072 and 2003/022/N).
Study Participants and Genotyping
Participants for this study were recruited from suburbs in Cape
Town, South Africa, where the incidence of tuberculosis was
high (1005 per 100 000 in 2007) [21] and the prevalence of
human immunodeficiency virus (HIV) was low [22]. These in-
dividuals belong to the South African Coloured (SAC) popula-
tion, a highly admixed population [23]. Three hundred patients
with bacteriologically confirmed pulmonary tuberculosis were
included in this study (mean age, 34.8 ± 12.6 years, 53% males).
All participants were HIV negative and unrelated.
The HLA class I genes were genotyped by direct sequencing.
In brief, locus-specific primers flanking exons 2 and 3 were
used to amplify the HLA-A, -B and -C loci. The purified poly-
merase chain reaction products were then sequenced using
exon-specific primers and a BigDye Terminator version 3.1
cycle sequencing kit (Applied Biosystems) on the ABI-3130XL
DNA analyzer. Sequence traces were analyzed using the Assign
SBT 3.5.1 software (Conexio Genomics). HLA class I supertype
classification was done as described by Sidney et al for HLA-A
and HLA-B [24]. HLA-C alleles were defined based on their
KIR2DL1 and KIR2DL2 binding [25] as previously done by Ba-
lamurugan et al [26]. Individuals who had alleles (4-digit) that
could not be classified into a supertype were identified as “un-
defined.” HLA class I allele frequency data for white and East
Asian populations were obtained from the online Allele Fre-
quency Net Database (AFND; www.allelefrequencies.net) [27]
(see Supplementary Data for lists of countries).
Bacterial Isolates and Genotyping
Sputum samples were collected for culture at diagnosis from all
new and retreatment tuberculosis patients who attended
primary healthcare clinics and who were resident in an epide-
miological field site in Cape Town, South Africa, during the
period January 1993 to December 2004.
Mycobacterium tuberculosis isolates were classified by cultur-
ing the sputum on mycobacteria growth indicator tube and/or
Löwenstein-Jensen media, and isolates were classified by
IS6110 restriction fragment length polymorphism genotyping
and spoligotyping using internationally standardized protocols
[14]. Strains were identified according to distinct IS6110
banding patterns using Gelcompar II (Applied Maths) and
were subsequently grouped into evolutionary clades that were
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classified based on their spoligotype signatures. Strains having
<6 IS6110 bands (low-copy clade) comprise a single lineage as
defined by IS6110 and were therefore regarded as a single clade.
Sublineages of the Beijing clade were identified as previously
described [12]. Mycobacterium tuberculosis lineages were in-
ferred as members of the East Asian or Euro-American MTBC
lineages [9].
Statistical Analysis
Logistic regression models were used to analyze the likelihood of
tuberculosis cases having a specific strain, compared to having
any other strain, because they enable us to adjust for other vari-
ables by including them in the models as covariates. All results
were corrected for age and sex in this way. All P values, odds
ratios (ORs), and their confidence intervals (CIs) were derived
from these models. Genetic association with the susceptibility to
different strains was tested using each of the following as predic-
tors in the models: genotypes, additive allelic effect, and additive
haplotypes. The haplotypes were inferred, with their probabilities
of being correct, and haplotypes were used as predictors in logis-
tic regression models, with their probabilities as weights as previ-
ously described [28].We tested for Hardy-Weinberg equilibrium
(HWE) using the exact test [29].
A result or effect was described as significant if P < .05. Bon-
ferroni correction for multiple testing was not used, as this
method is considered to be overly conservative when several
genetic associations are tested in the same group of individuals
[30], resulting in the potential rejection of important findings.
Bonferroni correction might also be inappropriate in a situation
such as this where there is a priori evidence that the genes are
associated with tuberculosis [31], whereas Bayesian methods
for correction rely on knowledge of prior probability of involve-
ment, which is currently unknown for most genetic variants
[32]. Current methods for multiple testing are only applicable
if all tests are independent, which is not the case in this study,
and therefore no appropriate method is available. All analyses
were done in R (freely available from www.r-project.org) using
functions from base R and R packages genetics and haplo.stats.
RESULTS
Host Genotype and Multiplicity of Infections
MTBC lineage, strain, and sublineage frequencies in this study
cohort are listed in Table 1. Most of the tuberculosis patients
(90%) had only 1 episode of disease with infection caused by 1
strain, but 27 (9%) and 3 individuals (1%) had disease episodes
caused by 2 and 3 different strains, respectively. Of the 30 indi-
viduals with >1 disease episode, 19 (63%) had 1 infection with
the Beijing strain, and other episodes with another strain,
whereas 37% of those with a non-Beijing strain had an addi-
tional episode with another strain. Figure 1 shows that of the 70
individuals with a Beijing strain, 19 (27%) had >1 episode with
different strains. Of the 19 individuals who had ≥2 infections
of which 1 was Beijing, Beijing was the first infection in 6 cases,
and a subsequent infection in 13 cases. Having the HLA-B*27
allele was found to be significantly associated (OR, 0.21 [95%
CI, .03–.68], P = .006) with having fewer strains.
Relationship Between Host and Bacterial Genotype in
Tuberculosis Disease
All genotype distributions were in HWE. The allele, genotype,
and haplotype distributions for HLA-A, -B, and -C were signifi-
cantly associated with the genotype of theM. tuberculosis strain
causing disease in the host. The Beijing strain was significantly
associated with each class of variation of the HLA class I genes,
with the A*01, B*08, and C2 alleles increasing the odds of
having disease with a Beijing strain (Table 2) with ORs ranging
between 1.58 and 2.32, while conversely, each B*27 and C1
Table 1. Mycobacterium tuberculosis Strain Frequencies in the South African Coloured Population of the Western Cape










Beijing Sublineage 2–6 0.26
Beijing Sublineage 7 0.74
Other 0.11
Abbreviation: MTBC,M. tuberculosis complex.
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allele lowered the odds of having disease with a Beijing strain
(ORs, 0.35 and 0.60, respectively). Disease with a Beijing strain
was also influenced by HLA-B and HLA-C genotypes, as well as
3 class I haplotypes (Table 3). However, due to the small sample
sizes and the resulting large CIs, these results are imprecise.
Tuberculosis caused by LAM genotype strains was found to
be significantly associated with the A*03 allele (Table 2), where
each additional allele increased the risk with an OR of 1.65.
Two HLA-A genotypes were also associated with a LAM infec-
tion (Table 3). For the LCC strain (Table 2), each B*44 allele in-
creased the risk of disease (OR, 2.07) whereas the presence of
the B*07 allele lowered the chances of disease (OR, 0.49). The
odds of disease with a Quebec strain (Table 2) was increased by
the presence of the B*58 allele (OR, 2.69).
As Beijing sublineage 7 is the most frequent sublineage in
the Western Cape but not the rest of South Africa, we tested
whether this could be attributed to the HLAs in the human
host. We identified 2 significant associations: where the
A*30:02 allele occurred only in individuals with tuberculosis
due to a Beijing sublineage 7 strain (P = .02) and is thus a po-
tential risk factor, and with A*02:02 having a protective role
against disease with Beijing sublineage 7 strain (OR, 0.04 [95%
CI, .0–.51], P = .012). However, it should be noted that these
Beijing sublineage 7 results are preliminary due to the small
number of individuals (53 individuals with a sublineage 7 in-
fection and 19 individuals with a sublineage 2–6 infection) that
could be included in this analysis.
Relationship BetweenM. tuberculosis Phylogenetic Lineages
and HLA Class I Allele Frequencies in Specific Geographical
Populations
Table 4 contains a summary of associations between MTBC
lineages and HLA types in the SAC population, as well as the
bacterial “footprint” of these MTBC lineages in various regions
Figure 1. Presence of Beijing strain in individuals according to number of infections. Individuals with a Beijing strain of infection were more likely to
have subsequent infections (P < .001). Of the 19 individuals who had ≥2 disease episodes, 1 of which was Beijing, Beijing was the first infection in 6 indi-
viduals, and a subsequent infection in 13 individuals.
Table 2. Significant Associations Only, of HLA Class I Alleles
and Mycobacterium tuberculosis Lineages in the South African
Coloured Population of the Western Cape
HLA Allele Frequency (No.) Strain P Valuea OR (95% CI)b
A*01 0.33 (167) Beijing .031 1.58 (1.04–2.40)
A*03 0.24 (120) LAM .022 1.65 (1.08–2.54)
B*07 0.25 (123) LCC .019 0.49 (.25–.89)
B*08 0.06 (31) Beijing .045 2.32 (1.02–5.13)
B*27 0.17 (84) Beijing .002 0.35 (.16–.68)
B*44 0.23 (114) LCC .007 2.07 (1.22–3.52)
B*58 0.17 (86) Quebec .001 2.69 (1.27–5.75)
C1 0.45 (243) Beijing .011 0.60 (.40–.89)
C2 0.32 (171) Beijing <.001 2.03 (1.35–3.08)
Abbreviations: CI, confidence interval; HLA, human leukocyte antigen; OR,
odds ratio.
a P value adjusted for age and sex. P values in bold are statistically significant.
b Odds of having a specific lineage, vs any other lineage, for each extra HLA
allele carried.
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globally. Mycobacterium tuberculosis strains in our study group
were separated into members of Euro-American or East Asian,
the 2 MTBC lineages most prevalent in the Western Cape.
HLA class I allele frequencies of the ancestral populations were
derived from AFND. In our SAC sample set there were 199 in-
dividuals with an Euro-American MTBC strain only, 57 with
an East Asian MTBC strain only, 18 with strains from both
MTBCs, and 26 with neither. Several significant associations
were identified, with the following alleles associated with both
MTBC member strains: A*23:01, B*14:01, B*14:02, and
C*16:01. The A*23:01 and C*16:01 alleles were found to be less
prevalent in those individuals with disease caused by a Euro-
American MTBC strain, while increasing the risk of having
disease caused by an East Asian MTBC strain. However, the
HLA allele frequencies in the white and East Asian human pop-
ulations do not correlate with this, as these alleles were found to
be more prevalent in white populations than in East Asian
populations. The opposite effect was seen for the B*14:01 and
B*14:02 alleles, with all individuals carrying these alleles having
a Euro-American MTBC strain. In this instance, the HLA pop-
ulation data for B*14:02 was in line with this finding as the
allele occurs more frequently in white populations than in East
Asian populations.
Individuals with disease caused by Euro-American MTBC
strains were less likely to have the C*08:01 allele and more
likely to have the A*74:01 and B*58:02 alleles. At the population
level, alleles A*74:01 and B*58:02 occurred at the same frequen-
cy in both human populations, whereas allele C*08:01 was
found at an extremely low frequency in the white population
and at a very high frequency in the East Asian population,
providing an inconsistent correlation between risk in the popu-
lation of specific strains and frequency of HLA alleles.
Statistically significant associations with disease caused by
East Asian MTBC strains were seen for the B*07:05 and
B*35:01 alleles, with the former increasing the risk of having
this strain and the latter reducing the chance (to zero in this
study). These findings largely concur with the population data
where the B*07:05 allele is found more frequently in East Asian
populations than in white populations and the B*35:01 allele
occurs more frequently in white populations than in East Asian
populations.
DISCUSSION
We report for the first time a number of associations between
human HLA class I types and specific M. tuberculosis strains.
The role of the coevolution of host and pathogen in disease de-
velopment has been difficult to study in humans, with most of
the proof of concept to date provided by studies of pathogen
[9–12] and animal models [33].We postulated a natural experi-
ment in coevolution taking place in the Cape Town area, which
has experienced a multiplicity of human visitors and their my-
cobacterial strains over the past 350 years. The resident popula-
tion is extremely diverse [23], with inputs from Khoisan, Bantu,
European, and Asian people and could therefore be assumed to
have HLA types from all these ancestral populations. The M.
tuberculosis strains present can be expected to have experienced
intense competition and the incidence of tuberculosis is one of
the highest in the world (1005 per 100 000 in 2007 [21]),
thereby enabling us to investigate correlations between bacterial
strain and HLA type in adequate numbers of patients. In this
study we identified associations between HLA class I gene vari-
ants with certain strain genotypes, excluding Haarlem,
Haarlem-like, and CAS1 strains, which occurred at very low
frequencies within our study cohort. The strongest associations
were identified for disease with Beijing genotype strains, which
was found to be associated with several alleles, genotypes, and
haplotypes of the HLA class I genes in the SAC population.
Specific allelic associations were also identified for the LAM,
LCC, and Quebec genotype strains. We showed that the Beijing
genotype strains occurred more frequently in individuals with
Table 3. Significant Associations Only, of HLA Class I Genotypes
and Haplotypes WithMycobacterium tuberculosis Lineages in the
South African Coloured Population of the Western Cape
Lineage HLA Factor Frequency
(No.)
P
Valuea OR (95% CI)bGenotype
LAM A*01/A*01c 0.13 (33) .036 1
A*01/A*02 0.11 (27) 3.89 (1.37–11.04)
A*03/
Undefined
0.03 (8) 6.33 (1.19–33.67)
Beijing B*07/B*07c 0.06 (15) .001 1
B*07/B*08 0.04 (10) 19.6
B*07/B*44 0.09 (23) 10.4
B*08/B*62 0.01 (3) 25.4
Beijing C1/C1c 0.23 (62) <.001 1
C1/C2 0.24 (65) 3.61 (1.39–9.33)
C2/C2 0.12 (32) 4.39 (1.49–12.97)
C2/Undefined 0.16 (42) 4.46 (1.62–12.29)
Haplotype
Beijing A*01-B*58-C1c 0.07 (30) <.001 1
A*01-B*08-C2 0.05 (20) 7.8 (1.2–50.0)
A*02-B*07-C2 0.05 (24) 8.3 (1.5–45.6)
A*01-B*44-
Undefined
0.03 (17) 7.6 (1.2 50.30)
Abbreviations: CI, confidence interval; HLA, human leukocyte antigen; OR,
odds ratio.
a P value for genotype and haplotype models, adjusted for age and sex. P
values in bold are statistically significant.
b Odds of having a specific lineage and genotype or haplotype, vs any other
lineage, compared to the reference genotype/haplotype (OR = 1). The 95% CI
could not be calculated for HLA-B genotypes due to their very low frequencies
in patients whose infections were not Beijing.
c Reference genotypes/haplotype—the most common (having the highest
frequency, so assumed to be the wild type) homozygous genotype and
haplotype in the study population.
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multiple disease episodes (P < .001) compared to infections by
non–Beijing genotype strains.
The B*27 supertype reduced the odds of having multiple
disease episodes, as well as having a Beijing strain. This super-
type allele is found frequently in individuals who are able to
control their HIV infections without any antiretroviral treat-
ment and slow disease progression [34]. This is thought to be
due to an increased CD8 T-cell response in individuals with
this allele and induction of the apoptotic pathway through the
increased presence of cytotoxic proteins [35]. The B*27 super-
type has not previously been shown to be associated with sus-
ceptibility to tuberculosis [6].
Even though CD4+ T cells (HLA class II restricted) represent
the predominant immune response mechanism against M. tu-
berculosis infection [36], there is growing evidence that suggests
an important role for CD8+ T cells (HLA class I restricted) in
protection against M. tuberculosis infection [37, 38]. Studies in
animals and humans have shown that M. tuberculosis is
capable of stimulating MHC class I restricted CD8+ T cells and
the involvement of several different pathways for class I presen-
tation of mycobacterial antigens via cross-presentation [39],
where HLA class I recognition of mycobacterial antigens in-
cludes ESAT-6 (HLA-B*52), 19 kDa lipoprotein (HLA-
A*02:01), and Ag85B (HLA-A*02:01) [37, 40, 41]. CD8+ T cells
also have direct microbicidal activity and kill M. tuberculosis
through the expression of granulysin and perforin [42]. HLA
class I alleles have been associated with leprosy susceptibility
[43], providing further support for the role of class I genes in
immunity against mycobacterial infections. It is, however,
possible that the strong LD between genes within the MHC
complex [44] could mean that the associations found here
reflect the involvement of the class II genes, which remain to be
genotyped in this population.
To date, variants in the TLR2 [45], IRGM [46], and SLC11A1
[47] genes have shown a correlation between human and bacte-
rial genotype. Variants in SLC11A1 and TLR2 were found to be
associated with an increased risk of having tuberculosis with a
Beijing strain in Asian populations, whereas in Ghana, the
IRGM polymorphism was found to protect against disease
caused by the Euro-American lineage. The phenotype of tuber-
culosis disease may be affected by the bacterial strain, as strains
of the Euro-American lineage appear to be less likely to cause
extrapulmonary disease [45], whereas strains of the Beijing and
S genotypes were associated with an increased risk of extra-
thoracic disease [48]. In Vietnam, the relapse rate was signifi-
cantly increased in tuberculosis cases caused by Beijing strains,
and this probably contributes to the successful spread of this
strain family [49]. It is therefore evident that the outcome of ex-
posure to M. tuberculosis depends on both the human and bac-
terial genotypes, and Alter et al [43] speculated that genetic
heterogeneity in common infectious diseases could be at least
partially explained by the pathogen strain differences, and
patient strain types should therefore be incorporated into the
analysis to overcome genetic heterogeneity.
Both MTBC lineages and HLA allele frequencies are found
in specific geographical settings; for example, lineages of an
East Asian origin occur more frequently in human populations
from the same region [9]. HLA allele frequencies are hugely
Table 4. Significant Associations Only, Between Mycobacterium tuberculosis Phylogenetic Strains and HLA Class I Alleles in Geo-
graphic Populations
MTBC Phylogenetic Lineages Allele Frequency per Population
Euro-American East Asian
SACa Whiteb East AsianbAllele P Valuec OR (95% CI)d P Valuec OR (95% CI)d
A*23:01 .026 0.43 (.20–.90) .043 2.24 (1.03–4.84) 0.065 0.023 0.008
A*74:01 .016 All are EuroAm .338 0.39 (.02–2.31) 0.016 0.003 0.003
B*07:05 .051 0.23 (.05–1.01) .020 5.66 (1.32–29.02) 0.016 0.003 0.009
B*14:01 .018 All are EuroAm .019 None are East Asian 0.018 0.005 0.008
B*14:02 .024 All are EuroAm .028 None are East Asian 0.016 0.019 0.007
B*35:01 .129 3.93 (.72–75.44) .010 None are East Asian 0.022 0.057 0.039
B*58:02 .001 4.64 (1.73–16.48) .134 0.53 (.20–1.21) 0.087 0.003 0.002
C*08:01 .021 0.20 (.04–.78) .054 3.83 (.97–16.10) 0.017 0.002 0.107
C*16:01 .028 0.35 (.14–.89) .002 4.48 (1.78–11.69) 0.039 0.021 0.005
Abbreviations: CI, confidence interval; EuroAm, European American; HLA, human leukocyte antigen; OR, odds ratio; SAC, South African Coloured.
a Frequency in the SAC population.
b List of countries included and their respective numbers can be found in the Supplementary Data. Frequency data from Allele Frequency Net Database (www.
allelefrequencies.net).
c P value adjusted for age and sex. P Values in bold are statistically significant.
d Odds of having a specificMycobacterium tuberculosis complex (MTBC) phylogenetic lineage, vs the other MTBC phylogenetic lineage.
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dissimilar between different ethnic groups, with certain alleles
completely absent in some populations [4, 5]. We therefore in-
vestigated the frequencies of HLA class I alleles associated with
the Euro-American and East Asian M. tuberculosis lineages, in
their sympatric populations. We postulated that an allele more
frequent in individuals with a Euro-American strain would also
occur more frequently in white populations, whereas an allele
that lowered the risk of having a Euro-American strain infec-
tion would occur at an extremely low frequency or be absent in
white populations. The same rationale would apply to East
AsianM. tuberculosis strains and human populations from East
Asia. However, although results fitting the postulate were found
in several cases, there was no fit in an equivalent number. This
could be explained by the use of allele frequency averages
across a number of populations listed in the databases. The
A*23:01 allele for example, occurs between allele frequencies of
0.075 in the Beijing Han population (AFND), and 0.004 in the
Shijiazhuang Tianjian Han, highlighting the enormous discrep-
ancies between allele frequencies in populations of the same
geographical region. Second, HLA genes are involved in several
biological processes [1] and some could thus be under balancing
selective pressures [3], which could have led to the discrepant
findings. In spite of the limitations of this broad categorization
of populations, we did find several cases where the predominant
MTBC lineage and the HLA class I allele frequency fit the
hypothesis of the coevolution of M. tuberculosis strains with
the HLA class I genes. We now show that specific strains
are associated with HLA types of the host, thus providing a
molecular genetic explanation for the previous observation by
Gagneux et al, who correlated M. tuberculosis strain lineages
with geography [9].
The evolutionary forces on HLA have been extremely
complex [3], including many bacterial and viral infections. We
could thus be seeing the remaining association due to coevolu-
tion with M. tuberculosis and/or other diseases with similar
clinical pathologies. Hershberg et al has postulated an “out-of-
and-back-to-Africa” migration of MTBC that coincided with
the out-of-Africa human migration pattern and the subsequent
global human exploration quests [7]. Considering this hypothe-
sis, the bottleneck events that accompanied the out-of-Africa
migration, and the expansion of disease-causing variants
within the last 5000 years [50], it is quite likely that coevolution
between MTBC and their human hosts could have occurred.
In summary, this study highlights the role of HLA class I
molecules in infection with M. tuberculosis strains and empha-
sizes the importance of considering both host and pathogen ge-
notype in understanding tuberculosis disease development and
vaccine efficacy. Host–pathogen coevolution has significant bi-
omedical and epidemiological implications and by identifying
the genes involved in this interaction, the adaptation mecha-
nisms of host and pathogen can be understood, as well as the
limitations they impose upon each other. It is also likely that
the complexity of HLA types within any given population, and
the possible balancing effects of increased susceptibility to tu-
berculosis vs other pathogens or conditions, will prevent any
simple correlations being seen between the predominant HLA
type in a population and the strain of M. tuberculosis in that
area.
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Appendix 7: Estimated HLA class-I haplotypes in SAC healthy controls. 
Haplotype A:C:B Freq. No. Haplotype A:C Freq. No. Haplotype A:B Freq. No. Haplotype C:B Freq. No. 
0101:0701:0801 0.04364 21.1 0101:0701 0.03255 21.4 0101:0801 0.04386 23.9 0701:0801 0.05348 32 
0301:0602:4701 0.02273 11 3001:1701 0.03023 19.8 0301:4701 0.0239 13 0602:5802 0.04849 29 
3002:0701:0801 0.02041 9.9 0301:0602 0.029 19 3001:4202 0.01838 10 0702:0702 0.03846 23 
3001:1701:4202 0.01653 8 0101:0602 0.02794 18.3 3002:0801 0.01808 9.8 0401:4403 0.03566 21.3 
0101:0602:5701 0.01446 7 3002:0701 0.0185 12.1 3201:4403 0.01654 9 0210:1503 0.02958 17.7 
2601:1701:4101 0.01446 7 2402:0401 0.01675 11 0101:5701 0.01654 9 0401:3501 0.02843 17 
0201:0702:0702 0.01354 6.6 2601:1701 0.01509 9.9 2402:0702 0.0155 8.4 1701:4101 0.02843 17 
3002:1601:4501 0.0124 6 6801:0602 0.0136 8.9 0201:0702 0.01425 7.8 0701:4403 0.02659 15.9 
2402:0702:0702 0.01125 5.4 0301:0701 0.01347 8.8 7401:1503 0.01287 7 0602:4701 0.02174 13 
2301:0702:0702 0.01033 5 4301:0401 0.01324 8.7 2301:0702 0.01148 6.2 0602:1302 0.02174 13 
6601:0602:5802 0.01033 5 6601:0602 0.0122 8 0205:5801 0.01103 6 1701:4202 0.02174 13 
3001:1701:4201 0.01033 5 2402:0702 0.01166 7.6 0201:1302 0.01103 6 1701:4201 0.02007 12 
0205:0701:5801 0.01033 5 3004:0602 0.01129 7.4 2601:4101 0.01083 5.9 0704:1801 0.01839 11 
4301:0401:1510 0.01033 5 0201:0602 0.01083 7.1 4301:4403 0.01 5.4 0401:1510 0.01694 10.1 
7401:0210:1503 0.01033 5 3201:0210 0.01057 6.9 3303:4403 0.00919 5 0602:5701 0.01672 10 
3004:0602:5802 0.0093 4.5 2301:0602 0.0103 6.8 6601:5802 0.00919 5 0801:1502 0.01672 10 
0201:0602:1302 0.00885 4.3 2402:0701 0.01019 6.7 3001:4201 0.00919 5 0210:4403 0.01536 9.2 
3001:0602:1302 0.00826 4 2301:0210 0.01012 6.6 2901:1801 0.00919 5 1601:4501 0.01505 9 
3303:0701:4403 0.00826 4 0201:0702 0.00994 6.5 6802:4101 0.00919 5 0602:5801 0.01505 9 
2901:0704:1801 0.00826 4 3004:0401 0.00979 6.4 3004:5802 0.00902 4.9 0401:3505 0.01338 8 
3402:0401:4403 0.00826 4 3002:1601 0.00957 6.3 3402:4403 0.00862 4.7 0501:4402 0.01338 8 
4301:1801:1503 0.00826 4 1101:0801 0.00941 6.2 3002:4501 0.00862 4.7 1402:5101 0.01254 7.5 
3201:0210:4403 0.00826 4 3001:0602 0.00915 6 4301:1510 0.00838 4.6 0701:5801 0.01171 7 
1101:0401:3501 0.008 3.9 0123:0602 0.00915 6 2301:4403 0.00818 4.4 1202:5201 0.01171 7 
2402:0210:1503 0.00734 3.6 2301:1601 0.00915 6 3002:4403 0.00793 4.3 1502:4006 0.01171 7 
0201:0210:1503 0.00712 3.4 3402:0401 0.00913 6 3101:5101 0.00735 4 0210:0702 0.01171 7 
0301:0304:1501 0.0062 3 0205:0804 0.00903 5.9 2901:0705 0.00735 4 0304:4001 0.01171 7 
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Haplotype A:C:B Freq. No. Haplotype A:C Freq. No. Haplotype A:B Freq. No. Haplotype C:B Freq. No. 
2901:1505:0705 0.0062 3 2301:0702 0.00898 5.9 3001:1302 0.00735 4 1801:1503 0.01171 7 
1101:0801:1513 0.0062 3 0201:1701 0.00896 5.9 3201:0702 0.00735 4 1701:4102 0.01171 7 
0201:0802:1401 0.0062 3 3303:0701 0.00874 5.7 6801:5802 0.00735 4 0401:3503 0.01003 6 
6802:0802:1402 0.0062 3 0201:1203 0.00814 5.3 1101:3501 0.00735 4 0802:1401 0.01003 6 
6801:0602:5801 0.0062 3 2301:0401 0.00791 5.2 4301:1503 0.00735 4 0602:4501 0.01003 6 
7401:0801:1502 0.0062 3 0205:0701 0.00764 5 6802:4501 0.00673 3.7 0304:1510 0.00836 5 
0201:0304:4001 0.0062 3 2402:1202 0.00762 5 2902:4403 0.00555 3 0801:1513 0.00836 5 
0201:1701:4101 0.0062 3 4301:1801 0.00762 5 1101:4006 0.00551 3 0302:5801 0.00836 5 
2301:1601:1510 0.0062 3 3002:1701 0.00757 5 0301:1501 0.00551 3 0702:0705 0.00836 5 
0205:0804:1401 0.0062 3 1101:0401 0.00757 5 0201:1501 0.00551 3 0802:1402 0.00836 5 
3004:0401:1510 0.0062 3 7401:0210 0.00754 4.9 3001:5802 0.00551 3 0602:3701 0.00836 5 
3004:1701:4102 0.0062 3 1101:0702 0.00738 4.8 2402:1502 0.00551 3 0701:1801 0.00834 5 
0214:0401:4403 0.0062 3 0301:0304 0.00725 4.8 2501:1801 0.00551 3 0401:5301 0.00711 4.2 
2402:0401:3505 0.0062 3 7401:0801 0.00723 4.7 6802:1510 0.00551 3 0304:1501 0.00669 4 
0301:1502:4006 0.0062 3 6802:0401 0.00712 4.7 3402:1503 0.00551 3 1505:0705 0.00669 4 
2402:1202:4006 0.0062 3 6802:0802 0.00701 4.6 1101:1513 0.00551 3 1203:3801 0.00669 4 
1101:0602:1302 0.00439 2.1 0202:0602 0.00686 4.5 0201:1401 0.00551 3 0701:5703 0.00669 4 
1101:1502:4006 0.00413 2 0201:0210 0.00641 4.2 6801:5801 0.00551 3 0804:1401 0.00669 4 
0201:0401:1501 0.00413 2 0201:0304 0.00634 4.2 7401:1502 0.00551 3 0202:2705 0.0065 3.9 
3101:1402:5101 0.00413 2 0205:0602 0.0062 4.1 0123:5802 0.00551 3 1601:1510 0.00647 3.9 
3402:1801:5802 0.00413 2 0201:0701 0.00618 4.1 0205:1401 0.00551 3 0401:1503 0.00551 3.3 
0201:1202:5201 0.00413 2 3402:1801 0.0061 4 3004:1510 0.00551 3 0401:1501 0.00502 3 
2407:0401:3505 0.00413 2 3303:0401 0.0061 4 3004:4102 0.00551 3 0403:1521 0.00502 3 
7401:0401:3501 0.00413 2 3201:0202 0.0061 4 2402:3505 0.00551 3 1203:1801 0.00502 3 
3201:0202:4403 0.00413 2 2901:0704 0.0061 4 1101:1801 0.00551 3 1203:4001 0.00502 3 
3001:0210:1503 0.00413 2 2402:0102 0.0061 4 0201:1801 0.00551 3 0804:1402 0.00502 3 
3001:0602:5802 0.00413 2 6802:0702 0.00604 4 3002:5802 0.00525 2.9 1801:8101 0.00502 3 
2301:1701:4101 0.00413 2 7401:0602 0.00599 3.9 2402:4006 0.00499 2.7 1203:3901 0.00502 3 
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Haplotype A:C:B Freq. No. Haplotype A:C Freq. No. Haplotype A:B Freq. No. Haplotype C:B Freq. No. 
2501:1203:1801 0.00413 2 2402:1502 0.00597 3.9 0301:4001 0.00499 2.7 0102:5501 0.00502 3 
3303:0302:5801 0.00413 2 0214:0401 0.00527 3.5 2301:1503 0.00487 2.6 0102:2705 0.00502 3 
3101:1203:5801 0.00413 2 2402:0304 0.00527 3.5 2402:1503 0.00472 2.6 1202:4006 0.00502 3 
6802:0304:1510 0.00413 2 3201:0602 0.00508 3.3 0201:4001 0.00453 2.5 0801:4801 0.00502 3 
2601:0702:0705 0.00413 2 7401:0701 0.00492 3.2 2301:1510 0.00452 2.5 1601:5101 0.00418 2.5 
3201:0102:0702 0.00413 2 2902:0701 0.0049 3.2 6802:5802 0.0043 2.3 0202:4403 0.00353 2.1 
0301:0602:4501 0.00413 2 2501:1203 0.00457 3 3402:4501 0.00425 2.3 0210:2705 0.00353 2.1 
3201:1203:3801 0.00413 2 6802:0304 0.00457 3 3002:4201 0.00424 2.3 0202:1801 0.00334 2 
3402:0701:4403 0.00413 2 4301:0804 0.00457 3 0301:4006 0.0042 2.3 1502:5101 0.00334 2 
0101:1801:8101 0.00413 2 1101:0303 0.00457 3 2301:4101 0.00387 2.1 1801:5802 0.00334 2 
0201:1402:5101 0.00413 2 2902:1601 0.00457 3 2601:0702 0.00387 2.1 0702:3901 0.00334 2 
2301:0210:0702 0.00413 2 6801:0202 0.00457 3 3004:4403 0.00385 2.1 0602:5001 0.00334 2 
3201:0210:0702 0.00413 2 2301:0202 0.00457 3 3301:8101 0.00368 2 1505:3910 0.00334 2 
6801:0602:5802 0.00413 2 1101:1202 0.00457 3 0201:4403 0.00368 2 1203:5801 0.00334 2 
2601:0102:2705 0.00413 2 2301:0302 0.00457 3 0201:5201 0.00368 2 0102:0702 0.00334 2 
2402:0801:1502 0.00413 2 0202:0701 0.00457 3 2407:3505 0.00368 2 0401:8101 0.00334 2 
0123:0602:5801 0.00413 2 0201:0202 0.00457 3 0201:1513 0.00368 2 0303:1501 0.00334 2 
1101:0702:0705 0.00413 2 6827:0401 0.00457 3 4301:3501 0.00368 2 0202:5801 0.00334 2 
3303:0401:4403 0.00413 2 0301:0303 0.00457 3 7401:3501 0.00368 2 0202:4002 0.00334 2 
6802:0401:4403 0.00413 2 3004:1701 0.00433 2.8 0301:0702 0.00368 2 0804:1510 0.00334 2 
3002:1701:4201 0.00413 2 1101:0602 0.00432 2.8 0301:0801 0.00368 2 0501:1510 0.00334 2 
0211:0401:3503 0.00413 2 7401:0704 0.00432 2.8 3001:1503 0.00368 2 0501:1801 0.00334 2 
0202:0701:5703 0.00413 2 2402:0704 0.00418 2.7 3303:5801 0.00368 2 1801:5702 0.00334 2 
0201:0202:4405 0.00413 2 0101:1801 0.00417 2.7 3101:5801 0.00368 2 0202:4405 0.00334 2 
2402:0602:5802 0.00413 2 6802:0602 0.00416 2.7 0211:4006 0.00368 2 0210:3901 0.00334 2 
1101:1202:5201 0.00413 2 2901:1505 0.00416 2.7 2601:0705 0.00368 2 1203:1303 0.00334 2 
2301:0210:3901 0.00413 2 0101:0501 0.00394 2.6 0301:4501 0.00368 2 0304:0801 0.00332 2 
2902:0701:4403 0.00413 2 3002:0802 0.00389 2.6 1101:3503 0.00368 2 1402:1516 0.00251 1.5 
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Haplotype A:C:B Freq. No. Haplotype A:C Freq. No. Haplotype A:B Freq. No. Haplotype C:B Freq. No. 
6801:0501:4402 0.00413 2 3201:1203 0.00381 2.5 3201:3801 0.00368 2 0804:4403 0.00209 1.2 
3002:0704:1801 0.00413 2 2402:0602 0.00373 2.4 7401:5703 0.00368 2 1601:4403 0.00203 1.2 
6827:0401:4403 0.00413 2 2301:0802 0.00373 2.4 0301:1303 0.00368 2 0701:4901 0.00181 1.1 
7401:0602:5802 0.00413 2 0301:0401 0.00355 2.3 0101:8101 0.00368 2 0701:5201 0.00173 1 
0123:0401:5802 0.00413 2 0301:0702 0.00354 2.3 0201:5101 0.00368 2 0602:0801 0.00173 1 
6802:0702:0702 0.00413 2 4301:0602 0.00353 2.3 3004:5101 0.00368 2 0210:1801 0.00169 1 
0101:0602:5802 0.00388 1.9 3004:1505 0.00346 2.3 0203:3802 0.00368 2 0701:1503 0.00169 1 
0201:1203:3901 0.00328 1.6 3002:0702 0.00346 2.3 6802:1402 0.00368 2 0403:8101 0.00167 1 
3201:0602:1302 0.00328 1.6 3002:0704 0.00331 2.2 0301:1503 0.00368 2 1402:5106 0.00167 1 
2301:0602:5802 0.0031 1.5 3001:0401 0.00331 2.2 2402:5501 0.00368 2 0401:1529 0.00167 1 
3004:0401:4403 0.0031 1.5 0301:0210 0.00329 2.2 2601:4901 0.00368 2 0602:1521 0.00167 1 
0201:0401:3501 0.00233 1.1 0301:1701 0.00328 2.2 2601:2705 0.00368 2 0407:1521 0.00167 1 
3301:0403:8101 0.00207 1 0201:0401 0.00325 2.1 0123:5801 0.00368 2 0403:1502 0.00167 1 
4301:0401:1501 0.00207 1 1101:1502 0.00318 2.1 1101:0705 0.00368 2 0702:0801 0.00167 1 
8001:0202:1801 0.00207 1 3101:1402 0.00305 2 3601:5301 0.00368 2 0403:5701 0.00167 1 
3001:0401:5301 0.00207 1 0201:1202 0.00305 2 0301:3501 0.00368 2 0702:1517 0.00167 1 
3303:0801:1513 0.00207 1 3401:0403 0.00305 2 1101:1302 0.00368 2 1202:5204 0.00167 1 
2301:0403:1502 0.00207 1 3001:0210 0.00305 2 0211:3503 0.00368 2 1602:4403 0.00167 1 
0301:0702:0702 0.00207 1 3303:0302 0.00305 2 0101:3701 0.00368 2 0702:3906 0.00167 1 
0301:0304:0801 0.00207 1 3101:1203 0.00305 2 0202:5703 0.00368 2 1602:5108 0.00167 1 
3401:0403:1521 0.00207 1 0203:0801 0.00305 2 1101:1508 0.00368 2 0701:0702 0.00167 1 
3401:0403:5701 0.00207 1 3201:0102 0.00305 2 2901:4403 0.00368 2 0202:4402 0.00167 1 
3002:0702:0801 0.00207 1 0201:1402 0.00305 2 2402:5201 0.00368 2 1602:3503 0.00167 1 
6802:0702:1517 0.00207 1 0203:0702 0.00305 2 0203:3503 0.00368 2 0501:5702 0.00167 1 
2402:0602:5001 0.00207 1 2601:0801 0.00305 2 0201:4101 0.00368 2 0701:5702 0.00167 1 
2301:1505:3910 0.00207 1 2601:0102 0.00305 2 0201:4405 0.00368 2 0702:3802 0.00167 1 
0211:0602:5801 0.00207 1 2601:0304 0.00305 2 2601:5702 0.00368 2 1203:1302 0.00167 1 
3004:0602:5701 0.00207 1 0211:0401 0.00305 2 2301:1402 0.00368 2 0701:3924 0.00167 1 
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Haplotype A:C:B Freq. No. Haplotype A:C Freq. No. Haplotype A:B Freq. No. Haplotype C:B Freq. No. 
0101:1602:4403 0.00207 1 2407:0801 0.00305 2 1101:5201 0.00368 2 0701:4101 0.00167 1 
3002:0302:5801 0.00207 1 6801:0501 0.00305 2 2402:3501 0.00368 2 1801:3505 0.00167 1 
2301:0702:3906 0.00207 1 2601:1203 0.00305 2 2301:3901 0.00368 2 1701:4901 0.00167 1 
2402:0802:1401 0.00207 1 0206:0802 0.00305 2 7401:5802 0.00368 2 1701:3501 0.00167 1 
2901:1602:5108 0.00207 1 6801:1502 0.00305 2 6801:4402 0.00368 2 0304:2706 0.00167 1 
0211:1502:4006 0.00207 1 4301:0704 0.00305 2 0201:4202 0.00368 2 0704:1802 0.00167 1 
0201:0304:5301 0.00207 1 1101:1601 0.00305 2 3002:1801 0.00368 2 1202:1801 0.00167 1 
2901:0401:1510 0.00207 1 2407:0401 0.003 2 0214:4403 0.00368 2 0302:8202 0.00167 1 
3002:0702:0705 0.00207 1 2901:0210 0.00298 2 6827:4403 0.00368 2 0303:4006 0.00167 1 
3201:0602:5802 0.00207 1 0201:0501 0.00281 1.8 2902:1510 0.00364 2 1204:5701 0.00167 1 
2402:1601:4501 0.00207 1 2902:0602 0.00272 1.8 0201:1503 0.00327 1.8 0702:5201 0.00167 1 
6601:0602:4701 0.00207 1 3402:1601 0.00262 1.7 2402:5802 0.00305 1.7 0303:1538 0.00167 1 
0101:0501:4402 0.00207 1 0101:1502 0.00249 1.6 1101:0702 0.0027 1.5 0303:1505 0.00167 1 
3201:0202:4402 0.00207 1 2601:0702 0.00237 1.6 2402:4501 0.00246 1.3 0303:4001 0.00167 1 
3004:0210:4403 0.00207 1 3002:0602 0.00232 1.5 7401:0801 0.0024 1.3 0401:3502 0.00167 1 
1101:1602:3503 0.00207 1 2601:0401 0.0023 1.5 2402:4001 0.00236 1.3 0501:3701 0.00167 1 
3402:0210:1503 0.00207 1 2402:0403 0.00223 1.5 0101:5802 0.0021 1.1 0802:1801 0.00167 1 
2902:0401:1510 0.00207 1 2901:0401 0.00223 1.5 2301:5802 0.00201 1.1 1204:5802 0.00167 1 
4301:0804:1402 0.00207 1 0201:0802 0.00213 1.4 4301:1501 0.00184 1 0202:5301 0.00167 1 
0201:0501:5702 0.00207 1 0101:0401 0.00208 1.4 8001:1801 0.00184 1 1202:2704 0.00167 1 
2402:0701:5801 0.00207 1 7401:0401 0.00203 1.3 3402:5301 0.00184 1 1403:4403 0.00167 1 
3101:0701:1801 0.00207 1 3402:0701 0.00197 1.3 3303:1513 0.00184 1 1601:0705 0.00167 1 
2402:0701:1503 0.00207 1 2901:1701 0.00194 1.3 3401:1521 0.00184 1 1505:3503 0.00167 1 
2402:0701:1801 0.00207 1 0301:0704 0.00192 1.3 0101:4006 0.00184 1 0303:4403 0.00167 1 
0301:0602:5701 0.00207 1 3201:0701 0.00188 1.2 3401:5701 0.00184 1 1801:5703 0.00167 1 
0301:0602:1303 0.00207 1 0301:1203 0.00177 1.2 6802:1517 0.00184 1 0202:1401 0.00167 1 
1101:0303:1501 0.00207 1 2902:1701 0.00171 1.1 2402:5001 0.00184 1 1203:3508 0.00167 1 
3301:1701:4201 0.00207 1 1101:0701 0.00168 1.1 2301:1801 0.00184 1 0802:1403 0.00167 1 
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Haplotype A:C:B Freq. No. Haplotype A:C Freq. No. Haplotype A:B Freq. No. Haplotype C:B Freq. No. 
0202:1402:1516 0.00207 1 3002:0210 0.00168 1.1 2301:3910 0.00184 1 1203:3503 0.00167 1 
0203:0702:3802 0.00207 1 2402:0801 0.00166 1.1 0211:5701 0.00184 1 1602:5101 0.00167 1 
6802:0401:3501 0.00207 1 2301:0304 0.00165 1.1 3004:5801 0.00184 1 1502:4002 0.00167 1 
3004:1601:4501 0.00207 1 6801:0804 0.00164 1.1 0101:5801 0.00184 1 0701:1303 0.00167 1 
2902:0401:4403 0.00207 1 3004:0210 0.00162 1.1 2301:3906 0.00184 1 0602:5201 0.00162 1 
2902:1601:4403 0.00207 1 2901:0701 0.0016 1 2402:1401 0.00184 1 1601:4901 0.00153 0.9 
0301:0102:5501 0.00207 1 2601:0701 0.00159 1 2901:5108 0.00184 1 0804:5301 0.00126 0.8 
3004:0701:3924 0.00207 1 6802:1701 0.00158 1 0201:5301 0.00184 1 1601:1516 0.00084 0.5 
6801:0804:1402 0.00207 1 2407:0701 0.00157 1 3002:1510 0.00184 1 0304:4403 0.00002 0 
2402:1801:5301 0.00207 1 2902:0210 0.00152 1 3201:5802 0.00184 1 
3301:0401:8101 0.00207 1 3004:1601 0.00152 1 3201:5801 0.00184 1 
0301:0801:1502 0.00207 1 3301:0403 0.00152 1 2402:1801 0.00184 1 
2601:0401:4901 0.00207 1 8001:0202 0.00152 1 6601:4701 0.00184 1 
3004:1701:3501 0.00207 1 2402:1701 0.00152 1 0101:4402 0.00184 1 
2902:0602:4501 0.00207 1 2301:1505 0.00152 1 3201:4402 0.00184 1 
2407:0701:0801 0.00207 1 0211:0602 0.00152 1 0101:3503 0.00184 1 
2301:0602:4501 0.00207 1 0101:1602 0.00152 1 0201:3802 0.00184 1 
3201:0202:5801 0.00207 1 3002:0302 0.00152 1 4301:1402 0.00184 1 
0203:0704:1801 0.00207 1 2901:1602 0.00152 1 0301:3503 0.00184 1 
2601:0202:4002 0.00207 1 0211:1502 0.00152 1 0201:5702 0.00184 1 
6801:0304:4001 0.00207 1 2402:1601 0.00152 1 2402:5801 0.00184 1 
0203:0702:3901 0.00207 1 3004:0701 0.00152 1 3101:1801 0.00184 1 
2402:0202:2705 0.00207 1 1101:0210 0.00152 1 0301:5701 0.00184 1 
1101:1202:1801 0.00207 1 3402:1602 0.00152 1 1101:5101 0.00184 1 
2301:0302:8202 0.00207 1 2902:0304 0.00152 1 3301:4201 0.00184 1 
0101:0303:4006 0.00207 1 3101:0210 0.00152 1 2301:1516 0.00184 1 
1101:1204:5701 0.00207 1 1101:1402 0.00152 1 0202:1516 0.00184 1 
0101:0401:3501 0.00207 1 3301:1701 0.00152 1 2612:4101 0.00184 1 
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Haplotype A:C:B Freq. No. Haplotype A:C Freq. No. Haplotype A:B Freq. No. Haplotype C:B Freq. No. 
2402:0501:4402 0.00207 1 3004:0802 0.00152 1 6802:3501 0.00184 1 
3201:0701:1801 0.00207 1 0206:0704 0.00152 1 3004:1402 0.00184 1 
4301:0804:5301 0.00207 1 3301:1801 0.00152 1 3201:3901 0.00184 1 
2501:1801:1503 0.00207 1 3301:0401 0.00152 1 3201:1302 0.00184 1 
2601:0701:4901 0.00207 1 3201:1505 0.00152 1 3004:3924 0.00184 1 
2402:0304:4001 0.00207 1 2403:0701 0.00152 1 6801:1402 0.00184 1 
0201:0701:4403 0.00207 1 2410:1601 0.00152 1 2402:5301 0.00184 1 
0301:0401:3501 0.00207 1 3601:0401 0.00152 1 0301:1502 0.00184 1 
1101:0303:1538 0.00207 1 8001:1203 0.00152 1 3004:3501 0.00184 1 
0211:0303:4001 0.00207 1 2402:0202 0.00152 1 2902:4501 0.00184 1 
0301:0303:1505 0.00207 1 2601:0210 0.00152 1 2407:0801 0.00184 1 
2402:0401:3502 0.00207 1 2601:0403 0.00152 1 0203:1801 0.00184 1 
0101:1701:3501 0.00207 1 6802:0801 0.00152 1 2601:4001 0.00184 1 
0301:0501:3701 0.00207 1 0101:1204 0.00152 1 6801:4002 0.00184 1 
3201:1801:1503 0.00207 1 3402:0801 0.00152 1 0203:3901 0.00184 1 
1101:0702:0702 0.00207 1 2417:0801 0.00152 1 2402:2705 0.00184 1 
2901:0701:4403 0.00207 1 2501:1801 0.00152 1 3001:2705 0.00184 1 
2407:0801:1502 0.00207 1 6801:1202 0.00152 1 2601:4402 0.00184 1 
1101:0802:4403 0.00207 1 3303:1701 0.00152 1 2301:4201 0.00184 1 
4301:0701:1801 0.00207 1 0211:0303 0.00152 1 2301:8202 0.00184 1 
2402:1202:5201 0.00207 1 3201:1801 0.00152 1 0101:3501 0.00184 1 
0201:1204:5802 0.00207 1 3002:1204 0.00152 1 2402:4402 0.00184 1 
3002:0501:4402 0.00207 1 0201:0704 0.00152 1 3402:1801 0.00184 1 
2301:0701:0801 0.00207 1 6802:0804 0.00152 1 2501:5802 0.00184 1 
7401:0202:5301 0.00207 1 0211:1202 0.00152 1 3201:0801 0.00184 1 
0201:0701:1801 0.00207 1 3101:1502 0.00152 1 2417:1502 0.00184 1 
6802:0801:1513 0.00207 1 3002:1505 0.00152 1 0301:4403 0.00184 1 
3002:0602:5201 0.00207 1 2612:0602 0.00152 1 1101:1538 0.00184 1 
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Haplotype A:C:B Freq. No. Haplotype A:C Freq. No. Haplotype A:B Freq. No. Haplotype C:B Freq. No. 
0201:0704:1801 0.00207 1 6802:1801 0.00152 1 0211:1505 0.00184 1 
6802:0804:1510 0.00207 1 2902:0702 0.00152 1 2402:3502 0.00184 1 
0211:0701:2704 0.00207 1 0203:1505 0.00152 1 3101:3910 0.00184 1 
0301:1202:4403 0.00207 1 2501:0704 0.00152 1 3201:1503 0.00184 1 
3101:1502:5101 0.00207 1 6901:0202 0.00152 1 8001:4201 0.00184 1 
2612:0602:3701 0.00207 1 2911:0302 0.00152 1 2407:1502 0.00184 1 
6802:1801:5702 0.00207 1 3303:1402 0.00152 1 0201:4402 0.00184 1 
3402:1601:5101 0.00207 1 0123:0804 0.00152 1 2301:5301 0.00184 1 
2901:1701:4101 0.00207 1 6801:0303 0.00152 1 0201:1301 0.00184 1 
0301:0210:0702 0.00207 1 2301:0804 0.00152 1 3002:5201 0.00184 1 
0101:0702:3701 0.00207 1 2902:0403 0.00152 1 0211:2704 0.00184 1 
2902:0602:0702 0.00207 1 1101:0102 0.00152 1 2612:3701 0.00184 1 
2402:1203:3901 0.00207 1 2501:1701 0.00152 1 3402:3901 0.00184 1 
2501:0401:3501 0.00207 1 3001:1402 0.00152 1 2901:4101 0.00184 1 
2901:0210:4403 0.00207 1 6801:1203 0.00152 1 2902:0702 0.00184 1 
2402:0701:5201 0.00207 1 3101:1602 0.00152 1 2501:3901 0.00184 1 
2407:0801:4801 0.00207 1 4301:0304 0.00152 1 2301:0705 0.00184 1 
3004:1505:3910 0.00207 1 2612:1502 0.00152 1 6827:0705 0.00184 1 
3402:0801:4801 0.00207 1 2901:1203 0.00152 1 2407:3910 0.00184 1 
2601:0210:0702 0.00207 1 4301:1402 0.00152 1 3004:4801 0.00184 1 
3002:0210:1503 0.00207 1 6801:0304 0.00152 1 0201:4801 0.00184 1 
2601:0401:8101 0.00207 1 0202:1402 0.00152 1 3004:1401 0.00184 1 
3002:0802:1402 0.00207 1 4301:0802 0.00152 1 2601:8101 0.00184 1 
6802:1701:4202 0.00207 1 3303:0704 0.00152 1 3002:1402 0.00184 1 
0201:1701:4202 0.00207 1 3004:1203 0.00152 1 0301:2705 0.00184 1 
6802:0602:5802 0.00207 1 3201:0304 0.00152 1 3402:5703 0.00184 1 
6802:0602:4501 0.00207 1 2902:0401 0.00134 0.9 2601:1401 0.00184 1 
0203:1505:3503 0.00207 1 2402:0501 0.00088 0.6 6901:3508 0.00184 1 
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
Haplotype A:C:B Freq. No. Haplotype A:C Freq. No. Haplotype A:B Freq. No. Haplotype C:B Freq. No. 
4301:0401:3501 0.00207 1 0214:0403 0.00082 0.5 3303:5701 0.00184 1 
2301:0304:4403 0.00207 1 2901:0304 0.00082 0.5 0205:1402 0.00184 1 
2301:0303:4403 0.00207 1 0202:0401 0.00076 0.5 3002:4202 0.00184 1 
7401:0701:5703 0.00207 1 0201:1502 0.00056 0.4 2911:5801 0.00184 1 
2501:0704:1801 0.00207 1 3303:1801 0.00041 0.3 0214:1503 0.00184 1 
0201:0202:2705 0.00207 1    0206:3701 0.00184 1 
0301:0701:4101 0.00207 1    2902:4202 0.00184 1 
3402:1801:5703 0.00207 1    2902:1521 0.00184 1 
2601:0202:3508 0.00207 1    6801:4006 0.00184 1 
6901:1203:1401 0.00207 1    6801:5001 0.00184 1 
2301:0401:3503 0.00207 1    2601:3801 0.00184 1 
1101:1601:3503 0.00207 1    0201:3801 0.00184 1 
3004:1203:5101 0.00207 1    0202:5801 0.00184 1 
1101:1203:4001 0.00207 1    2501:4101 0.00184 1 
0205:0804:1402 0.00207 1    3001:5101 0.00184 1 
3002:1701:4202 0.00207 1    0101:3508 0.00184 1 
2911:0302:5801 0.00207 1    0301:4102 0.00184 1 
0206:0602:3701 0.00207 1    4301:3701 0.00184 1 
2402:0804:5501 0.00207 1    2901:1303 0.00184 1 
4301:0102:4403 0.00207 1    6801:1501 0.00184 1 
6801:0303:1501 0.00207 1    2402:4002 0.00184 1 
2902:1701:4202 0.00207 1    2301:3503 0.00184 1 
2902:0403:1521 0.00207 1    3303:5301 0.00184 1 
2301:0202:1801 0.00207 1    6802:4006 0.00184 1 
6801:1502:4006 0.00207 1    7401:4201 0.00128 0.7 
2301:1601:1516 0.00207 1    1101:4001 0.00098 0.5 
2601:1203:3801 0.00207 1 
0202:0602:5801 0.00207 1 
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Haplotype A:C:B Freq. No. Haplotype A:C Freq. No. Haplotype A:B Freq. No. Haplotype C:B Freq. No. 
2501:1701:4101 0.00207 1 
2601:0701:5702 0.00207 1 
3001:1402:5101 0.00207 1 
3004:0802:1401 0.00207 1 
0301:0602:0801 0.00207 1 
3101:1602:5101 0.00207 1 
0301:1203:1801 0.00207 1 
7401:1701:4201 0.00207 1 
0301:1701:4102 0.00207 1 
2402:1203:4001 0.00207 1 
4301:0602:3701 0.00207 1 
2301:0802:1402 0.00207 1 
2402:1502:4002 0.00207 1 
2901:1203:1303 0.00207 1 
3601:0602:5301 0.00207 1 
2402:1203:3801 0.00207 1 
1101:0704:1801 0.00207 1 
2301:0602:1503 0.00207 1 
0301:0210:1503 0.00207 1 
2301:0401:4403 0.00103 0.5 
3201:1203:3901 0.00085 0.4 
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Appendix 8: Estimated HLA class-I haplotypes in SAN individuals. 
Haplotype A:C:B Freq. No. Haplotype A:C Freq. No. Haplotype A:B Freq. No. Haplotype C:B Freq. No. 
6802:0401:1503 0.04918 6 3201:0401 0.06148 7.5 6802:1503 0.04918 6 0401:4403 0.09016 11 
2901:1203:1303 0.04098 5 0301:0702 0.04918 6 0301:0702 0.04098 5 0602:5802 0.08197 10 
0301:0702:0702 0.04098 5 6802:0401 0.04098 5 4301:1510 0.04098 5 0401:1510 0.07377 9 
2301:0401:4403 0.03279 4 0301:0602 0.04098 5 2301:0702 0.04098 5 0702:0702 0.06557 8 
0301:0602:5802 0.03279 4 2901:1203 0.04098 5 2901:1303 0.04098 5 0702:0705 0.06557 8 
3001:0401:1510 0.02459 3 2301:0602 0.03279 4 0301:5802 0.03279 4 0401:1503 0.05738 7 
3201:0401:3501 0.02459 3 0202:0701 0.02459 3 2601:0705 0.03279 4 1203:1303 0.04098 5 
4301:0401:1510 0.02459 3 3001:0401 0.02459 3 2301:5802 0.02459 3 0401:3501 0.04098 5 
2601:0702:0705 0.02459 3 6827:0401 0.02459 3 3201:4403 0.02459 3 1701:4101 0.03279 4 
3004:0602:5802 0.02459 3 2601:0702 0.02459 3 3004:5802 0.02459 3 0804:1401 0.03279 4 
6827:0401:4403 0.02459 3 2301:0702 0.02459 3 3001:1510 0.02459 3 1701:4201 0.02459 3 
6802:0802:1402 0.01639 2 3004:0602 0.02459 3 6827:4403 0.02459 3 0802:1402 0.02459 3 
0205:0804:1401 0.01639 2 4301:0202 0.02459 3 3201:3501 0.02459 3 0602:5801 0.01639 2 
2402:0401:0702 0.01639 2 3402:0401 0.02459 3 3402:4403 0.02459 3 0202:2701 0.01639 2 
2301:1701:4101 0.01639 2 4301:0401 0.02049 2.5 7401:3501 0.01639 2 1505:1801 0.01639 2 
0202:0701:5702 0.01639 2 4301:0602 0.01639 2 6802:1402 0.01639 2 0701:5702 0.01639 2 
2301:0702:0702 0.01639 2 0201:1701 0.01639 2 0205:1401 0.01639 2 0703:0702 0.01639 2 
2301:0703:0702 0.01639 2 6802:0802 0.01639 2 2402:0702 0.01639 2 0704:0705 0.01639 2 
0202:0702:0705 0.01639 2 0205:0804 0.01639 2 2301:4101 0.01639 2 0302:5801 0.01639 2 
3201:0202:4403 0.01639 2 6801:0602 0.01639 2 0202:0705 0.01639 2 0501:1801 0.0082 1 
2301:0602:5802 0.01639 2 2301:1701 0.01639 2 0202:5702 0.01639 2 0501:3501 0.0082 1 
4301:0202:4403 0.0082 1 0202:0702 0.01639 2 2301:1510 0.01639 2 0701:5703 0.0082 1 
3201:0401:4403 0.0082 1 2301:0703 0.01639 2 3002:1801 0.0082 1 0202:4403 0.0082 1 
3002:0501:1801 0.0082 1 3201:1701 0.0123 1.5 3002:1402 0.0082 1 0703:0705 0.0082 1 
7401:0501:3501 0.0082 1 2301:0401 0.0082 1 4301:5801 0.0082 1 0712:0702 0.0082 1 
3002:0602:1402 0.0082 1 3002:0501 0.0082 1 0201:4101 0.0082 1 0202:0702 0.0082 1 
4301:0802:5801 0.0082 1 7401:0501 0.0082 1 0202:5703 0.0082 1 1203:3801 0.0082 1 
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Haplotype A:C:B Freq. No. Haplotype A:C Freq. No. Haplotype A:B Freq. No. Haplotype C:B Freq. No. 
0201:1701:4101 0.0082 1 3002:0802 0.0082 1 0201:4403 0.0082 1 0701:3501 0.0082 1 
0202:0701:5703 0.0082 1 6802:1701 0.0082 1 4301:1401 0.0082 1 0202:1503 0.0082 1 
0201:0804:1401 0.0082 1 0205:0701 0.0082 1 2301:4403 0.0082 1 1701:6701 0.0082 1 
2631:0804:1401 0.0082 1 2631:0804 0.0082 1 3002:0705 0.0082 1 1701:4102 0.0082 1 
3002:0703:0705 0.0082 1 2601:1701 0.0082 1 2601:4101 0.0082 1 0304:4001 0.0082 1 
3402:0712:0702 0.0082 1 2901:1701 0.0082 1 2901:4201 0.0082 1 1701:5101 0.0082 1 
3402:0702:0705 0.0082 1 2402:0202 0.0082 1 4301:2701 0.0082 1 0602:4701 0.0082 1 
2601:1701:4101 0.0082 1 2402:0401 0.0082 1 3002:3801 0.0082 1 1801:1503 0.0082 1 
2901:1701:4201 0.0082 1 3002:1203 0.0082 1 1101:4403 0.0082 1 0602:1302 0.0082 1 
1101:0701:3501 0.0082 1 1101:0401 0.0082 1 3301:3501 0.0082 1 0602:1510 0.0082 1 
3301:0401:4403 0.0082 1 3301:0701 0.0082 1 2407:3501 0.0082 1 1801:1510 0.0082 1 
2407:0702:3501 0.0082 1 2407:0702 0.0082 1 3401:5801 0.0082 1 0403:1301 0.0082 1 
3401:0302:1521 0.0082 1 3401:0302 0.0082 1 6601:1521 0.0082 1 0202:2703 0.0082 1 
6601:0403:5801 0.0082 1 6601:0403 0.0082 1 3301:5801 0.0082 1 0403:1510 0.0082 1 
3301:0202:1503 0.0082 1 3301:0202 0.0082 1 7401:1503 0.0082 1 0804:1402 0.0082 1 
7401:0302:5801 0.0082 1 7401:0302 0.0082 1 0205:0705 0.0082 1 0302:5701 0.0082 1 
0205:0704:0705 0.0082 1 0205:0704 0.0082 1 0301:1501 0.0082 1 0602:8201 0.0082 1 
0301:0304:1501 0.0082 1 0301:0304 0.0082 1 3001:6701 0.0082 1 0304:1501 0.0082 1 
3001:1701:0705 0.0082 1 3001:0702 0.0082 1 3201:0705 0.0082 1 0202:4004 0.0082 1 
3201:0702:6701 0.0082 1 7401:0401 0.0082 1 3201:4102 0.0082 1 0701:5801 0.0082 1 
2301:0332:1510 0.0082 1 2301:0332 0.0082 1 0101:1503 0.0082 1 0710:0702 0.0082 1 
2601:0704:0705 0.0082 1 2601:0704 0.0082 1 3601:1510 0.0082 1 0403:1521 0.0082 1 
0101:0401:1503 0.0082 1 0101:0401 0.0082 1 0225:4001 0.0082 1 0332:1503 0.0082 1 
3601:0401:1510 0.0082 1 3601:0401 0.0082 1 6802:4004 0.0082 1 
   0225:0304:4001 0.0082 1 0225:0304 0.0082 1 0201:0705 0.0082 1 
   6802:0202:4004 0.0082 1 6802:0202 0.0082 1 0301:5101 0.0082 1 
   0201:1701:5101 0.0082 1 0205:0202 0.0082 1 6801:4701 0.0082 1 
   0301:0702:0705 0.0082 1 2301:1505 0.0082 1 3201:1503 0.0082 1 
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Haplotype A:C:B Freq. No. Haplotype A:C Freq. No. Haplotype A:B Freq. No. Haplotype C:B Freq. No. 
6801:0602:4701 0.0082 1 6802:1505 0.0082 1 0205:5801 0.0082 1 
   3201:1801:1503 0.0082 1 2301:1801 0.0082 1 0205:2701 0.0082 1 
   0205:0701:5801 0.0082 1 2488:0403 0.0082 1 0301:1302 0.0082 1 
   0205:0202:1302 0.0082 1 0202:0401 0.0082 1 2301:1801 0.0082 1 
   0301:0602:2701 0.0082 1 2602:0804 0.0082 1 6802:1801 0.0082 1 
   2301:1505:1801 0.0082 1 3004:0401 0.0082 1 2301:5801 0.0082 1 
   6802:1505:1801 0.0082 1 6802:0710 0.0082 1 2488:1301 0.0082 1 
   2301:0602:5801 0.0082 1 0101:0302 0.0082 1 0301:2703 0.0082 1 
   2301:1801:1510 0.0082 1 0201:0804 0.0082 1 0202:1503 0.0082 1 
   2488:0403:1301 0.0082 1 3002:0703 0.0082 1 3106:4201 0.0082 1 
   0301:0202:1510 0.0082 1 0301:0403 0.0082 1 2602:1402 0.0082 1 
   4301:0403:2703 0.0082 1 3106:1701 0.0082 1 3004:1510 0.0082 1 
   4301:0602:1510 0.0082 1 6802:1801 0.0082 1 6802:0702 0.0082 1 
   0202:0401:1503 0.0082 1 2301:0712 0.0082 1 6802:4201 0.0082 1 
   2602:0804:1402 0.0082 1 4301:1701 0.0041 0.5 0101:8201 0.0082 1 
   3004:0401:1510 0.0082 1 
   
6801:5701 0.0082 1 
   6802:0710:0702 0.0082 1 
   
2631:1401 0.0082 1 
   6802:1701:4201 0.0082 1 
   
2301:0705 0.0082 1 
   0101:0602:5701 0.0082 1 
         6801:0302:8201 0.0082 1 
         3002:1203:3801 0.0082 1 
         7401:0401:3501 0.0082 1 
         3201:1701:4102 0.0082 1 
         3106:1701:4201 0.0082 1 
         3402:0602:5802 0.0082 1 
         4301:0401:2701 0.0082 1 
          
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
